JP6585158B2 - ヤヌスキナーゼの阻害に有用なピロロ［２，３−ｄ］ピリミジン誘導体 - Google Patents

Info

Publication number

JP6585158B2

JP6585158B2 JP2017507009A JP2017507009A JP6585158B2 JP 6585158 B2 JP6585158 B2 JP 6585158B2 JP 2017507009 A JP2017507009 A JP 2017507009A JP 2017507009 A JP2017507009 A JP 2017507009A JP 6585158 B2 JP6585158 B2 JP 6585158B2

Authority

JP

Japan

Prior art keywords

methyl

pyrrolo

cyclobutyl

cis

pyrimidin

Prior art date

2014-08-12

Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)

Expired - Fee Related

Links

• Espacenet
• Global Dossier
• Discuss

• 108010024121 Janus Kinases Proteins 0.000 title description 18
• 102000015617 Janus Kinases Human genes 0.000 title description 17
• 150000004943 pyrrolo[2,3-d]pyrimidines Chemical class 0.000 title description 5
• 230000005764 inhibitory process Effects 0.000 title description 4
• 150000001875 compounds Chemical class 0.000 claims description 276
• -1 {cis-3- [methyl (7H-pyrrolo [2,3-d] pyrimidin-4-yl) amino] cyclobutyl} methyl Chemical group 0.000 claims description 192
• 239000000203 mixture Substances 0.000 claims description 138
• 150000003839 salts Chemical class 0.000 claims description 79
• 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 78
• 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims description 76
• 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 51
• 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 39
• 238000011282 treatment Methods 0.000 claims description 34
• 208000035475 disorder Diseases 0.000 claims description 33
• 150000001412 amines Chemical class 0.000 claims description 28
• 125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 claims description 24
• 201000011240 Frontotemporal dementia Diseases 0.000 claims description 15
• 206010020751 Hypersensitivity Diseases 0.000 claims description 15
• 201000008937 atopic dermatitis Diseases 0.000 claims description 15
• 208000006673 asthma Diseases 0.000 claims description 14
• 241000283073 Equus caballus Species 0.000 claims description 12
• 206010028980 Neoplasm Diseases 0.000 claims description 12
• 208000006011 Stroke Diseases 0.000 claims description 12
• 208000026935 allergic disease Diseases 0.000 claims description 12
• 230000000926 neurological effect Effects 0.000 claims description 12
• 208000024827 Alzheimer disease Diseases 0.000 claims description 11
• 208000023504 respiratory system disease Diseases 0.000 claims description 11
• 206010012438 Dermatitis atopic Diseases 0.000 claims description 10
• 206010015037 epilepsy Diseases 0.000 claims description 10
• 208000018737 Parkinson disease Diseases 0.000 claims description 9
• 206010052779 Transplant rejections Diseases 0.000 claims description 9
• 230000001154 acute effect Effects 0.000 claims description 9
• 208000010668 atopic eczema Diseases 0.000 claims description 9
• 210000003169 central nervous system Anatomy 0.000 claims description 9
• 206010014599 encephalitis Diseases 0.000 claims description 9
• 201000006417 multiple sclerosis Diseases 0.000 claims description 9
• 230000007815 allergy Effects 0.000 claims description 8
• 201000011510 cancer Diseases 0.000 claims description 8
• 210000000056 organ Anatomy 0.000 claims description 8
• NJEZHAMMPIETMR-BJHJDKERSA-N CN([C@H]1C[C@H](C1)CS(=O)(=O)N1CC(C1)C#N)C=1C2=C(N=CN=1)NC=C2 Chemical compound CN([C@H]1C[C@H](C1)CS(=O)(=O)N1CC(C1)C#N)C=1C2=C(N=CN=1)NC=C2 NJEZHAMMPIETMR-BJHJDKERSA-N 0.000 claims description 7
• 208000003251 Pruritus Diseases 0.000 claims description 7
• 201000004681 Psoriasis Diseases 0.000 claims description 7
• 150000001408 amides Chemical class 0.000 claims description 7
• 230000001363 autoimmune Effects 0.000 claims description 7
• 230000001404 mediated effect Effects 0.000 claims description 7
• 230000002265 prevention Effects 0.000 claims description 7
• OYRRZWATULMEPF-UHFFFAOYSA-N pyrimidin-4-amine Chemical class NC1=CC=NC=N1 OYRRZWATULMEPF-UHFFFAOYSA-N 0.000 claims description 7
• QSCPXSMHOGRYJB-BETUJISGSA-N CC1(CN(C1)S(=O)(=O)C[C@@H]1C[C@@H](C1)N(C=1C2=C(N=CN=1)NC=C2)C)C#N Chemical compound CC1(CN(C1)S(=O)(=O)C[C@@H]1C[C@@H](C1)N(C=1C2=C(N=CN=1)NC=C2)C)C#N QSCPXSMHOGRYJB-BETUJISGSA-N 0.000 claims description 6
• 208000000609 Pick Disease of the Brain Diseases 0.000 claims description 6
• 230000004770 neurodegeneration Effects 0.000 claims description 6
• 208000031261 Acute myeloid leukaemia Diseases 0.000 claims description 5
• 208000003174 Brain Neoplasms Diseases 0.000 claims description 5
• 206010009900 Colitis ulcerative Diseases 0.000 claims description 5
• 208000011231 Crohn disease Diseases 0.000 claims description 5
• 201000004624 Dermatitis Diseases 0.000 claims description 5
• 206010012434 Dermatitis allergic Diseases 0.000 claims description 5
• 208000003556 Dry Eye Syndromes Diseases 0.000 claims description 5
• 206010013774 Dry eye Diseases 0.000 claims description 5
• 208000022559 Inflammatory bowel disease Diseases 0.000 claims description 5
• 208000033776 Myeloid Acute Leukemia Diseases 0.000 claims description 5
• 241000721454 Pemphigus Species 0.000 claims description 5
• 206010035226 Plasma cell myeloma Diseases 0.000 claims description 5
• 208000021386 Sjogren Syndrome Diseases 0.000 claims description 5
• 208000029052 T-cell acute lymphoblastic leukemia Diseases 0.000 claims description 5
• 201000006704 Ulcerative Colitis Diseases 0.000 claims description 5
• 206010002026 amyotrophic lateral sclerosis Diseases 0.000 claims description 5
• 230000001684 chronic effect Effects 0.000 claims description 5
• 208000014674 injury Diseases 0.000 claims description 5
• 206010025135 lupus erythematosus Diseases 0.000 claims description 5
• 206010039073 rheumatoid arthritis Diseases 0.000 claims description 5
• 208000000884 Airway Obstruction Diseases 0.000 claims description 4
• 208000019901 Anxiety disease Diseases 0.000 claims description 4
• 206010003571 Astrocytoma Diseases 0.000 claims description 4
• 208000014644 Brain disease Diseases 0.000 claims description 4
• QKNYDTOQCBKYND-ZSZSROOQSA-N CN([C@H]1C[C@H](C1)CS(=O)(=O)[C@@H]1C[C@H](C1)C#N)C=1C2=C(N=CN=1)NC=C2 Chemical compound CN([C@H]1C[C@H](C1)CS(=O)(=O)[C@@H]1C[C@H](C1)C#N)C=1C2=C(N=CN=1)NC=C2 QKNYDTOQCBKYND-ZSZSROOQSA-N 0.000 claims description 4
• 206010006895 Cachexia Diseases 0.000 claims description 4
• 208000002249 Diabetes Complications Diseases 0.000 claims description 4
• 206010014561 Emphysema Diseases 0.000 claims description 4
• 208000032274 Encephalopathy Diseases 0.000 claims description 4
• 208000034578 Multiple myelomas Diseases 0.000 claims description 4
• 201000002481 Myositis Diseases 0.000 claims description 4
• 206010061902 Pancreatic neoplasm Diseases 0.000 claims description 4
• 206010039710 Scleroderma Diseases 0.000 claims description 4
• 206010040070 Septic Shock Diseases 0.000 claims description 4
• 208000028552 Treatment-Resistant Depressive disease Diseases 0.000 claims description 4
• 206010067584 Type 1 diabetes mellitus Diseases 0.000 claims description 4
• 206010047115 Vasculitis Diseases 0.000 claims description 4
• 230000036506 anxiety Effects 0.000 claims description 4
• 230000002612 cardiopulmonary effect Effects 0.000 claims description 4
• GFBLFDSCAKHHGX-UHFFFAOYSA-N cyclobutanecarbonitrile Chemical compound N#CC1CCC1 GFBLFDSCAKHHGX-UHFFFAOYSA-N 0.000 claims description 4
• 230000004064 dysfunction Effects 0.000 claims description 4
• 208000005017 glioblastoma Diseases 0.000 claims description 4
• 230000009610 hypersensitivity Effects 0.000 claims description 4
• 208000032839 leukemia Diseases 0.000 claims description 4
• 206010025482 malaise Diseases 0.000 claims description 4
• 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims description 4
• 201000008383 nephritis Diseases 0.000 claims description 4
• 230000000414 obstructive effect Effects 0.000 claims description 4
• 208000008443 pancreatic carcinoma Diseases 0.000 claims description 4
• 208000028173 post-traumatic stress disease Diseases 0.000 claims description 4
• 230000001823 pruritic effect Effects 0.000 claims description 4
• 230000000306 recurrent effect Effects 0.000 claims description 4
• 201000000980 schizophrenia Diseases 0.000 claims description 4
• 230000036303 septic shock Effects 0.000 claims description 4
• 208000020431 spinal cord injury Diseases 0.000 claims description 4
• 230000008733 trauma Effects 0.000 claims description 4
• 208000009746 Adult T-Cell Leukemia-Lymphoma Diseases 0.000 claims description 3
• 208000016683 Adult T-cell leukemia/lymphoma Diseases 0.000 claims description 3
• 208000020925 Bipolar disease Diseases 0.000 claims description 3
• 206010012655 Diabetic complications Diseases 0.000 claims description 3
• 206010018338 Glioma Diseases 0.000 claims description 3
• 208000031671 Large B-Cell Diffuse Lymphoma Diseases 0.000 claims description 3
• 208000012902 Nervous system disease Diseases 0.000 claims description 3
• 201000010133 Oligodendroglioma Diseases 0.000 claims description 3
• 208000002200 Respiratory Hypersensitivity Diseases 0.000 claims description 3
• 208000024799 Thyroid disease Diseases 0.000 claims description 3
• 208000030886 Traumatic Brain injury Diseases 0.000 claims description 3
• 201000006966 adult T-cell leukemia Diseases 0.000 claims description 3
• 230000010085 airway hyperresponsiveness Effects 0.000 claims description 3
• 235000009508 confectionery Nutrition 0.000 claims description 3
• 206010012818 diffuse large B-cell lymphoma Diseases 0.000 claims description 3
• 230000002757 inflammatory effect Effects 0.000 claims description 3
• 201000002528 pancreatic cancer Diseases 0.000 claims description 3
• 230000002685 pulmonary effect Effects 0.000 claims description 3
• 238000002054 transplantation Methods 0.000 claims description 3
• 230000009529 traumatic brain injury Effects 0.000 claims description 3
• 125000004206 2,2,2-trifluoroethyl group Chemical group [H]C([H])(*)C(F)(F)F 0.000 claims description 2
• 125000004200 2-methoxyethyl group Chemical group [H]C([H])([H])OC([H])([H])C([H])([H])* 0.000 claims description 2
• DSPTWRMHHAHXPT-GASCZTMLSA-N C(C)C(CS(=O)(=O)C[C@H]1C[C@H](C1)N(C=1C2=C(N=CN=1)NC=C2)C)CC Chemical compound C(C)C(CS(=O)(=O)C[C@H]1C[C@H](C1)N(C=1C2=C(N=CN=1)NC=C2)C)CC DSPTWRMHHAHXPT-GASCZTMLSA-N 0.000 claims description 2
• MXNJJUQPQYBAPN-YIONKMFJSA-N C(C)C1CN(CCO1)S(=O)(=O)C[C@H]1C[C@H](C1)N(C=1C2=C(N=CN=1)NC=C2)C Chemical compound C(C)C1CN(CCO1)S(=O)(=O)C[C@H]1C[C@H](C1)N(C=1C2=C(N=CN=1)NC=C2)C MXNJJUQPQYBAPN-YIONKMFJSA-N 0.000 claims description 2
• WPKFVOMIANZVBJ-GASCZTMLSA-N C(C)OC1=CC=C(C=C1)S(=O)(=O)C[C@H]1C[C@H](C1)N(C=1C2=C(N=CN=1)NC=C2)C Chemical compound C(C)OC1=CC=C(C=C1)S(=O)(=O)C[C@H]1C[C@H](C1)N(C=1C2=C(N=CN=1)NC=C2)C WPKFVOMIANZVBJ-GASCZTMLSA-N 0.000 claims description 2
• LUVSHWSDJWZREL-OKILXGFUSA-N C(C)OC1=CC=C(C=N1)S(=O)(=O)C[C@H]1C[C@H](C1)N(C=1C2=C(N=CN=1)NC=C2)C Chemical compound C(C)OC1=CC=C(C=N1)S(=O)(=O)C[C@H]1C[C@H](C1)N(C=1C2=C(N=CN=1)NC=C2)C LUVSHWSDJWZREL-OKILXGFUSA-N 0.000 claims description 2
• BNYRMKQMDQUUAU-OKILXGFUSA-N C(C)OC1=NC=CC(=C1)S(=O)(=O)C[C@H]1C[C@H](C1)N(C=1C2=C(N=CN=1)NC=C2)C Chemical compound C(C)OC1=NC=CC(=C1)S(=O)(=O)C[C@H]1C[C@H](C1)N(C=1C2=C(N=CN=1)NC=C2)C BNYRMKQMDQUUAU-OKILXGFUSA-N 0.000 claims description 2
• QWODIMBFQKNKDV-OKILXGFUSA-N C(C)OC1=NC=CC=C1S(=O)(=O)C[C@H]1C[C@H](C1)N(C=1C2=C(N=CN=1)NC=C2)C Chemical compound C(C)OC1=NC=CC=C1S(=O)(=O)C[C@H]1C[C@H](C1)N(C=1C2=C(N=CN=1)NC=C2)C QWODIMBFQKNKDV-OKILXGFUSA-N 0.000 claims description 2
• OULORHJOSYJPAD-GASCZTMLSA-N C(C)OC=1C=C(C=CC=1)S(=O)(=O)C[C@H]1C[C@H](C1)N(C=1C2=C(N=CN=1)NC=C2)C Chemical compound C(C)OC=1C=C(C=CC=1)S(=O)(=O)C[C@H]1C[C@H](C1)N(C=1C2=C(N=CN=1)NC=C2)C OULORHJOSYJPAD-GASCZTMLSA-N 0.000 claims description 2
• GRRCTTZJFTYZNU-IYBDPMFKSA-N C(C)OCC1(CCN(CC1)S(=O)(=O)C[C@H]1C[C@H](C1)N(C=1C2=C(N=CN=1)NC=C2)C)F Chemical class C(C)OCC1(CCN(CC1)S(=O)(=O)C[C@H]1C[C@H](C1)N(C=1C2=C(N=CN=1)NC=C2)C)F GRRCTTZJFTYZNU-IYBDPMFKSA-N 0.000 claims description 2
• YVABUYNWXZDUSI-CALCHBBNSA-N C(C)OCC1CCN(CC1)S(=O)(=O)C[C@H]1C[C@H](C1)N(C=1C2=C(N=CN=1)NC=C2)C Chemical compound C(C)OCC1CCN(CC1)S(=O)(=O)C[C@H]1C[C@H](C1)N(C=1C2=C(N=CN=1)NC=C2)C YVABUYNWXZDUSI-CALCHBBNSA-N 0.000 claims description 2
• CRRFNRQNSZLBHV-IYBDPMFKSA-N C(C1=CC=CC=C1)S(=O)(=O)C[C@H]1C[C@H](C1)N(C=1C2=C(N=CN=1)NC=C2)C Chemical compound C(C1=CC=CC=C1)S(=O)(=O)C[C@H]1C[C@H](C1)N(C=1C2=C(N=CN=1)NC=C2)C CRRFNRQNSZLBHV-IYBDPMFKSA-N 0.000 claims description 2
• HRRLZKHIEGDCQZ-APIJFGDWSA-N C([C@H]1C[C@H](C1)N(C)C=1C=2C=CNC=2N=CN=1)S(=O)(=O)[C@@H]1CC[C@@H](C#N)C1 Chemical compound C([C@H]1C[C@H](C1)N(C)C=1C=2C=CNC=2N=CN=1)S(=O)(=O)[C@@H]1CC[C@@H](C#N)C1 HRRLZKHIEGDCQZ-APIJFGDWSA-N 0.000 claims description 2
• NJZBXVUGZNBKSX-XBXGTLAGSA-N C1(CC1)C(=O)N1CC(C1)S(=O)(=O)C[C@@H]1C[C@@H](C1)N(C=1C2=C(N=CN=1)NC=C2)C Chemical compound C1(CC1)C(=O)N1CC(C1)S(=O)(=O)C[C@@H]1C[C@@H](C1)N(C=1C2=C(N=CN=1)NC=C2)C NJZBXVUGZNBKSX-XBXGTLAGSA-N 0.000 claims description 2
• NFIDOTBRPBKHQX-FZNQNYSPSA-N C1(CC1)C(=O)N1CCN(CC1)S(=O)(=O)C[C@@H]1C[C@@H](C1)N(C=1C2=C(N=CN=1)NC=C2)C Chemical compound C1(CC1)C(=O)N1CCN(CC1)S(=O)(=O)C[C@@H]1C[C@@H](C1)N(C=1C2=C(N=CN=1)NC=C2)C NFIDOTBRPBKHQX-FZNQNYSPSA-N 0.000 claims description 2
• LHWRCZJJTCQUOF-GASCZTMLSA-N C1(CC1)CN1CC(C1)S(=O)(=O)C[C@H]1C[C@H](C1)N(C=1C2=C(N=CN=1)NC=C2)C Chemical compound C1(CC1)CN1CC(C1)S(=O)(=O)C[C@H]1C[C@H](C1)N(C=1C2=C(N=CN=1)NC=C2)C LHWRCZJJTCQUOF-GASCZTMLSA-N 0.000 claims description 2
• NAGOVPAHANTRPK-XBXGTLAGSA-N C1(CC1)N1CC(C1)S(=O)(=O)C[C@H]1C[C@H](C1)N(C=1C2=C(N=CN=1)NC=C2)C Chemical compound C1(CC1)N1CC(C1)S(=O)(=O)C[C@H]1C[C@H](C1)N(C=1C2=C(N=CN=1)NC=C2)C NAGOVPAHANTRPK-XBXGTLAGSA-N 0.000 claims description 2
• YWCRTQZBTUCMTK-OTVXOJSOSA-N C1(CCC1)N1CC(C1)S(=O)(=O)C[C@H]1C[C@H](C1)N(C=1C2=C(N=CN=1)NC=C2)C Chemical compound C1(CCC1)N1CC(C1)S(=O)(=O)C[C@H]1C[C@H](C1)N(C=1C2=C(N=CN=1)NC=C2)C YWCRTQZBTUCMTK-OTVXOJSOSA-N 0.000 claims description 2
• QNEHTPKTYOFLPX-IYBDPMFKSA-N C1(CCCC1)CCS(=O)(=O)C[C@H]1C[C@H](C1)N(C=1C2=C(N=CN=1)NC=C2)C Chemical compound C1(CCCC1)CCS(=O)(=O)C[C@H]1C[C@H](C1)N(C=1C2=C(N=CN=1)NC=C2)C QNEHTPKTYOFLPX-IYBDPMFKSA-N 0.000 claims description 2
• VOZQQRCGIWGQEA-IYBDPMFKSA-N C1(CCCCC1)CS(=O)(=O)C[C@H]1C[C@H](C1)N(C=1C2=C(N=CN=1)NC=C2)C Chemical compound C1(CCCCC1)CS(=O)(=O)C[C@H]1C[C@H](C1)N(C=1C2=C(N=CN=1)NC=C2)C VOZQQRCGIWGQEA-IYBDPMFKSA-N 0.000 claims description 2
• VERTWIIVDDOBSG-FZNQNYSPSA-N C1=NC=CC2=C(C=CC=C12)S(=O)(=O)C[C@H]1C[C@H](C1)N(C=1C2=C(N=CN=1)NC=C2)C Chemical compound C1=NC=CC2=C(C=CC=C12)S(=O)(=O)C[C@H]1C[C@H](C1)N(C=1C2=C(N=CN=1)NC=C2)C VERTWIIVDDOBSG-FZNQNYSPSA-N 0.000 claims description 2
• KFPFHFNFCCTGOO-FZNQNYSPSA-N C1C=2N(CCN1S(=O)(=O)C[C@H]1C[C@H](C1)N(C=1C3=C(N=CN=1)NC=C3)C)C=CC=2 Chemical compound C1C=2N(CCN1S(=O)(=O)C[C@H]1C[C@H](C1)N(C=1C3=C(N=CN=1)NC=C3)C)C=CC=2 KFPFHFNFCCTGOO-FZNQNYSPSA-N 0.000 claims description 2
• SWXWAHZCVHZSAQ-GASCZTMLSA-N C1CC11CCN(CC1)S(=O)(=O)C[C@H]1C[C@H](C1)N(C=1C2=C(N=CN=1)NC=C2)C Chemical compound C1CC11CCN(CC1)S(=O)(=O)C[C@H]1C[C@H](C1)N(C=1C2=C(N=CN=1)NC=C2)C SWXWAHZCVHZSAQ-GASCZTMLSA-N 0.000 claims description 2
• QIUJVZGYISFYIX-RHNCMZPLSA-N C1N(CCC2=CC=CC=C12)S(=O)(=O)C[C@H]1C[C@H](C1)N(C=1C2=C(N=CN=1)NC=C2)C Chemical compound C1N(CCC2=CC=CC=C12)S(=O)(=O)C[C@H]1C[C@H](C1)N(C=1C2=C(N=CN=1)NC=C2)C QIUJVZGYISFYIX-RHNCMZPLSA-N 0.000 claims description 2
• RSDFFPQIXSYTDD-OKILXGFUSA-N C=1N=CN2C=1CN(CC2)S(=O)(=O)C[C@H]1C[C@H](C1)N(C=1C2=C(N=CN=1)NC=C2)C Chemical compound C=1N=CN2C=1CN(CC2)S(=O)(=O)C[C@H]1C[C@H](C1)N(C=1C2=C(N=CN=1)NC=C2)C RSDFFPQIXSYTDD-OKILXGFUSA-N 0.000 claims description 2
• BDMDTFXLXASXJR-OKILXGFUSA-N CC(C(=O)N1CC(C1)S(=O)(=O)C[C@@H]1C[C@@H](C1)N(C=1C2=C(N=CN=1)NC=C2)C)C Chemical compound CC(C(=O)N1CC(C1)S(=O)(=O)C[C@@H]1C[C@@H](C1)N(C=1C2=C(N=CN=1)NC=C2)C)C BDMDTFXLXASXJR-OKILXGFUSA-N 0.000 claims description 2
• VNBYHELLMWHTBX-MFJLWXAKSA-N CC1(CC(C1)CS(=O)(=O)C[C@@H]1C[C@@H](C1)N(C=1C2=C(N=CN=1)NC=C2)C)C#N Chemical compound CC1(CC(C1)CS(=O)(=O)C[C@@H]1C[C@@H](C1)N(C=1C2=C(N=CN=1)NC=C2)C)C#N VNBYHELLMWHTBX-MFJLWXAKSA-N 0.000 claims description 2
• MUZVDGVEXFQZIP-TXEJJXNPSA-N CC1(CN(C1)S(=O)(=O)C[C@@H]1C[C@@H](C1)N(C=1C2=C(N=CN=1)NC=C2)C)O Chemical compound CC1(CN(C1)S(=O)(=O)C[C@@H]1C[C@@H](C1)N(C=1C2=C(N=CN=1)NC=C2)C)O MUZVDGVEXFQZIP-TXEJJXNPSA-N 0.000 claims description 2
• HBOBPFABMCQOIY-IYBDPMFKSA-N CC1=C(C=C(C=C1)C)S(=O)(=O)C[C@H]1C[C@H](C1)N(C=1C2=C(N=CN=1)NC=C2)C Chemical compound CC1=C(C=C(C=C1)C)S(=O)(=O)C[C@H]1C[C@H](C1)N(C=1C2=C(N=CN=1)NC=C2)C HBOBPFABMCQOIY-IYBDPMFKSA-N 0.000 claims description 2
• IMJWRPPOQVYHRQ-GASCZTMLSA-N CC1=C(C=NC(=C1)C)S(=O)(=O)C[C@H]1C[C@H](C1)N(C=1C2=C(N=CN=1)NC=C2)C Chemical compound CC1=C(C=NC(=C1)C)S(=O)(=O)C[C@H]1C[C@H](C1)N(C=1C2=C(N=CN=1)NC=C2)C IMJWRPPOQVYHRQ-GASCZTMLSA-N 0.000 claims description 2
• PMCNHBRGNUQKHF-GASCZTMLSA-N CC1=NC=CC(=C1C)S(=O)(=O)C[C@H]1C[C@H](C1)N(C=1C2=C(N=CN=1)NC=C2)C Chemical compound CC1=NC=CC(=C1C)S(=O)(=O)C[C@H]1C[C@H](C1)N(C=1C2=C(N=CN=1)NC=C2)C PMCNHBRGNUQKHF-GASCZTMLSA-N 0.000 claims description 2
• VMLVHRAAZGJBIV-BETUJISGSA-N CC1=NOC(=C1S(=O)(=O)C[C@H]1C[C@H](C1)N(C=1C2=C(N=CN=1)NC=C2)C)C Chemical class CC1=NOC(=C1S(=O)(=O)C[C@H]1C[C@H](C1)N(C=1C2=C(N=CN=1)NC=C2)C)C VMLVHRAAZGJBIV-BETUJISGSA-N 0.000 claims description 2
• UJUKGVOCFHHOGU-BETUJISGSA-N CN(C=1C2=C(N=CN=1)NC=C2)[C@@H]1C[C@@H](C1)CS(=O)(=O)C(CC)CC Chemical compound CN(C=1C2=C(N=CN=1)NC=C2)[C@@H]1C[C@@H](C1)CS(=O)(=O)C(CC)CC UJUKGVOCFHHOGU-BETUJISGSA-N 0.000 claims description 2
• BPDXDZDEFQATRW-GASCZTMLSA-N CN(C=1C2=C(N=CN=1)NC=C2)[C@@H]1C[C@@H](C1)CS(=O)(=O)C1=C(C=CC=C1)C Chemical compound CN(C=1C2=C(N=CN=1)NC=C2)[C@@H]1C[C@@H](C1)CS(=O)(=O)C1=C(C=CC=C1)C BPDXDZDEFQATRW-GASCZTMLSA-N 0.000 claims description 2
• NTHZPSGORIKDQB-BETUJISGSA-N CN(C=1C2=C(N=CN=1)NC=C2)[C@@H]1C[C@@H](C1)CS(=O)(=O)C1=C(C=CC=C1)OC(F)(F)F Chemical compound CN(C=1C2=C(N=CN=1)NC=C2)[C@@H]1C[C@@H](C1)CS(=O)(=O)C1=C(C=CC=C1)OC(F)(F)F NTHZPSGORIKDQB-BETUJISGSA-N 0.000 claims description 2
• JIQQEQXPBPQIPX-GASCZTMLSA-N CN(C=1C2=C(N=CN=1)NC=C2)[C@@H]1C[C@@H](C1)CS(=O)(=O)C1=C2C=CC=NC2=CC=C1 Chemical compound CN(C=1C2=C(N=CN=1)NC=C2)[C@@H]1C[C@@H](C1)CS(=O)(=O)C1=C2C=CC=NC2=CC=C1 JIQQEQXPBPQIPX-GASCZTMLSA-N 0.000 claims description 2
• VLAHIKLMFQZDPR-XBXGTLAGSA-N CN(C=1C2=C(N=CN=1)NC=C2)[C@@H]1C[C@@H](C1)CS(=O)(=O)C1=CC(=CC=C1)C(F)(F)F Chemical compound CN(C=1C2=C(N=CN=1)NC=C2)[C@@H]1C[C@@H](C1)CS(=O)(=O)C1=CC(=CC=C1)C(F)(F)F VLAHIKLMFQZDPR-XBXGTLAGSA-N 0.000 claims description 2
• XQDJIZPXYHDJDG-IYBDPMFKSA-N CN(C=1C2=C(N=CN=1)NC=C2)[C@@H]1C[C@@H](C1)CS(=O)(=O)C1=CC(=CC=C1)OC(C)C Chemical compound CN(C=1C2=C(N=CN=1)NC=C2)[C@@H]1C[C@@H](C1)CS(=O)(=O)C1=CC(=CC=C1)OC(C)C XQDJIZPXYHDJDG-IYBDPMFKSA-N 0.000 claims description 2
• CCMBJIATBMXYFC-BETUJISGSA-N CN(C=1C2=C(N=CN=1)NC=C2)[C@@H]1C[C@@H](C1)CS(=O)(=O)C1=CC(=CC=C1)OC(F)(F)F Chemical compound CN(C=1C2=C(N=CN=1)NC=C2)[C@@H]1C[C@@H](C1)CS(=O)(=O)C1=CC(=CC=C1)OC(F)(F)F CCMBJIATBMXYFC-BETUJISGSA-N 0.000 claims description 2
• UXRAMPPWHJVSRI-OTVXOJSOSA-N CN(C=1C2=C(N=CN=1)NC=C2)[C@@H]1C[C@@H](C1)CS(=O)(=O)C1=CC2=CN(N=C2C=C1)C Chemical compound CN(C=1C2=C(N=CN=1)NC=C2)[C@@H]1C[C@@H](C1)CS(=O)(=O)C1=CC2=CN(N=C2C=C1)C UXRAMPPWHJVSRI-OTVXOJSOSA-N 0.000 claims description 2
• DUCVKLWZWGMVAG-XBXGTLAGSA-N CN(C=1C2=C(N=CN=1)NC=C2)[C@@H]1C[C@@H](C1)CS(=O)(=O)C1=CC=C(C=C1)C(F)(F)F Chemical compound CN(C=1C2=C(N=CN=1)NC=C2)[C@@H]1C[C@@H](C1)CS(=O)(=O)C1=CC=C(C=C1)C(F)(F)F DUCVKLWZWGMVAG-XBXGTLAGSA-N 0.000 claims description 2
• UWCJNDNJYBLIQE-OTVXOJSOSA-N CN(C=1C2=C(N=CN=1)NC=C2)[C@@H]1C[C@@H](C1)CS(=O)(=O)C1=CC=C2C=NN(C2=C1)C Chemical compound CN(C=1C2=C(N=CN=1)NC=C2)[C@@H]1C[C@@H](C1)CS(=O)(=O)C1=CC=C2C=NN(C2=C1)C UWCJNDNJYBLIQE-OTVXOJSOSA-N 0.000 claims description 2
• JNOPCQSOHNYICW-OKILXGFUSA-N CN(C=1C2=C(N=CN=1)NC=C2)[C@@H]1C[C@@H](C1)CS(=O)(=O)C1=CC=CC=C1 Chemical compound CN(C=1C2=C(N=CN=1)NC=C2)[C@@H]1C[C@@H](C1)CS(=O)(=O)C1=CC=CC=C1 JNOPCQSOHNYICW-OKILXGFUSA-N 0.000 claims description 2
• PMOCYAUOLYFXTN-TXEJJXNPSA-N CN(C=1C2=C(N=CN=1)NC=C2)[C@@H]1C[C@@H](C1)CS(=O)(=O)C1=CN=C(S1)C Chemical compound CN(C=1C2=C(N=CN=1)NC=C2)[C@@H]1C[C@@H](C1)CS(=O)(=O)C1=CN=C(S1)C PMOCYAUOLYFXTN-TXEJJXNPSA-N 0.000 claims description 2
• RZEWPQVGDJVACC-TXEJJXNPSA-N CN(C=1C2=C(N=CN=1)NC=C2)[C@@H]1C[C@@H](C1)CS(=O)(=O)C1CN(C1)CC(F)(F)F Chemical compound CN(C=1C2=C(N=CN=1)NC=C2)[C@@H]1C[C@@H](C1)CS(=O)(=O)C1CN(C1)CC(F)(F)F RZEWPQVGDJVACC-TXEJJXNPSA-N 0.000 claims description 2
• YUHDXRJXMIGSPV-PHIMTYICSA-N CN(C=1C2=C(N=CN=1)NC=C2)[C@@H]1C[C@@H](C1)CS(=O)(=O)C1COC1 Chemical compound CN(C=1C2=C(N=CN=1)NC=C2)[C@@H]1C[C@@H](C1)CS(=O)(=O)C1COC1 YUHDXRJXMIGSPV-PHIMTYICSA-N 0.000 claims description 2
• DIUNXEXOCMDGQL-OKILXGFUSA-N CN(C=1C2=C(N=CN=1)NC=C2)[C@@H]1C[C@@H](C1)CS(=O)(=O)C=1C(=NN(C=1C)C)C Chemical class CN(C=1C2=C(N=CN=1)NC=C2)[C@@H]1C[C@@H](C1)CS(=O)(=O)C=1C(=NN(C=1C)C)C DIUNXEXOCMDGQL-OKILXGFUSA-N 0.000 claims description 2
• IWYQGKABFOIXJU-OTVXOJSOSA-N CN(C=1C2=C(N=CN=1)NC=C2)[C@@H]1C[C@@H](C1)CS(=O)(=O)C=1C=C2C=NN(C2=CC=1)C Chemical compound CN(C=1C2=C(N=CN=1)NC=C2)[C@@H]1C[C@@H](C1)CS(=O)(=O)C=1C=C2C=NN(C2=CC=1)C IWYQGKABFOIXJU-OTVXOJSOSA-N 0.000 claims description 2
• VTXMTPPGODARDG-FZNQNYSPSA-N CN(C=1C2=C(N=CN=1)NC=C2)[C@@H]1C[C@@H](C1)CS(=O)(=O)C=1C=CC=C2C=CC=NC=12 Chemical compound CN(C=1C2=C(N=CN=1)NC=C2)[C@@H]1C[C@@H](C1)CS(=O)(=O)C=1C=CC=C2C=CC=NC=12 VTXMTPPGODARDG-FZNQNYSPSA-N 0.000 claims description 2
• ZNYVCNNRCFFDAF-OTVXOJSOSA-N CN(C=1C2=C(N=CN=1)NC=C2)[C@@H]1C[C@@H](C1)CS(=O)(=O)C=1C=CC=C2C=NN(C=12)C Chemical compound CN(C=1C2=C(N=CN=1)NC=C2)[C@@H]1C[C@@H](C1)CS(=O)(=O)C=1C=CC=C2C=NN(C=12)C ZNYVCNNRCFFDAF-OTVXOJSOSA-N 0.000 claims description 2
• SPBQBLPDYVFLQK-OKILXGFUSA-N CN(C=1C2=C(N=CN=1)NC=C2)[C@@H]1C[C@@H](C1)CS(=O)(=O)C=1C=NC(=CC=1)C Chemical compound CN(C=1C2=C(N=CN=1)NC=C2)[C@@H]1C[C@@H](C1)CS(=O)(=O)C=1C=NC(=CC=1)C SPBQBLPDYVFLQK-OKILXGFUSA-N 0.000 claims description 2
• PYTYUNMFVXMLHB-TXEJJXNPSA-N CN(C=1C2=C(N=CN=1)NC=C2)[C@@H]1C[C@@H](C1)CS(=O)(=O)C=1C=NC(=CC=1)C(F)(F)F Chemical compound CN(C=1C2=C(N=CN=1)NC=C2)[C@@H]1C[C@@H](C1)CS(=O)(=O)C=1C=NC(=CC=1)C(F)(F)F PYTYUNMFVXMLHB-TXEJJXNPSA-N 0.000 claims description 2
• VTHLBHXTIANZQX-GASCZTMLSA-N CN(C=1C2=C(N=CN=1)NC=C2)[C@@H]1C[C@@H](C1)CS(=O)(=O)C=1C=NC(=NC=1)N1CCCC1 Chemical class CN(C=1C2=C(N=CN=1)NC=C2)[C@@H]1C[C@@H](C1)CS(=O)(=O)C=1C=NC(=NC=1)N1CCCC1 VTHLBHXTIANZQX-GASCZTMLSA-N 0.000 claims description 2
• ULCSWHXDOWVFMK-FZNQNYSPSA-N CN(C=1C2=C(N=CN=1)NC=C2)[C@@H]1C[C@@H](C1)CS(=O)(=O)C=1C=NC2=CC=CC=C2C=1 Chemical compound CN(C=1C2=C(N=CN=1)NC=C2)[C@@H]1C[C@@H](C1)CS(=O)(=O)C=1C=NC2=CC=CC=C2C=1 ULCSWHXDOWVFMK-FZNQNYSPSA-N 0.000 claims description 2
• ASKVWNDKMHFVHL-BETUJISGSA-N CN(C=1C2=C(N=CN=1)NC=C2)[C@@H]1C[C@@H](C1)CS(=O)(=O)C=1C=NC=CC=1 Chemical compound CN(C=1C2=C(N=CN=1)NC=C2)[C@@H]1C[C@@H](C1)CS(=O)(=O)C=1C=NC=CC=1 ASKVWNDKMHFVHL-BETUJISGSA-N 0.000 claims description 2
• LWEXBVKOJGMKLH-OKILXGFUSA-N CN(C=1C2=C(N=CN=1)NC=C2)[C@@H]1C[C@@H](C1)CS(=O)(=O)C=1C=NC=CC=1C Chemical compound CN(C=1C2=C(N=CN=1)NC=C2)[C@@H]1C[C@@H](C1)CS(=O)(=O)C=1C=NC=CC=1C LWEXBVKOJGMKLH-OKILXGFUSA-N 0.000 claims description 2
• OXZQZNRYJXBLDP-TXEJJXNPSA-N CN(C=1C2=C(N=CN=1)NC=C2)[C@@H]1C[C@@H](C1)CS(=O)(=O)C=1C=NC=CC=1C(F)(F)F Chemical compound CN(C=1C2=C(N=CN=1)NC=C2)[C@@H]1C[C@@H](C1)CS(=O)(=O)C=1C=NC=CC=1C(F)(F)F OXZQZNRYJXBLDP-TXEJJXNPSA-N 0.000 claims description 2
• IRIDDEHSOPFQKO-AGUYFDCRSA-N CN(C=1C2=C(N=CN=1)NC=C2)[C@@H]1C[C@@H](C1)CS(=O)(=O)CC(CC)C Chemical compound CN(C=1C2=C(N=CN=1)NC=C2)[C@@H]1C[C@@H](C1)CS(=O)(=O)CC(CC)C IRIDDEHSOPFQKO-AGUYFDCRSA-N 0.000 claims description 2
• BCMIRTHEUWYNHX-OKILXGFUSA-N CN(C=1C2=C(N=CN=1)NC=C2)[C@@H]1C[C@@H](C1)CS(=O)(=O)CC1(CCC1)C Chemical compound CN(C=1C2=C(N=CN=1)NC=C2)[C@@H]1C[C@@H](C1)CS(=O)(=O)CC1(CCC1)C BCMIRTHEUWYNHX-OKILXGFUSA-N 0.000 claims description 2
• NFKVKFFNFPQLRB-BETUJISGSA-N CN(C=1C2=C(N=CN=1)NC=C2)[C@@H]1C[C@@H](C1)CS(=O)(=O)CC1(COC1)C Chemical compound CN(C=1C2=C(N=CN=1)NC=C2)[C@@H]1C[C@@H](C1)CS(=O)(=O)CC1(COC1)C NFKVKFFNFPQLRB-BETUJISGSA-N 0.000 claims description 2
• JPRXZDKBZSNUSK-AGUYFDCRSA-N CN(C=1C2=C(N=CN=1)NC=C2)[C@@H]1C[C@@H](C1)CS(=O)(=O)CC1COCC1 Chemical compound CN(C=1C2=C(N=CN=1)NC=C2)[C@@H]1C[C@@H](C1)CS(=O)(=O)CC1COCC1 JPRXZDKBZSNUSK-AGUYFDCRSA-N 0.000 claims description 2
• PHTIKENROONGDQ-OKILXGFUSA-N CN(C=1C2=C(N=CN=1)NC=C2)[C@@H]1C[C@@H](C1)CS(=O)(=O)CCC(C)C Chemical compound CN(C=1C2=C(N=CN=1)NC=C2)[C@@H]1C[C@@H](C1)CS(=O)(=O)CCC(C)C PHTIKENROONGDQ-OKILXGFUSA-N 0.000 claims description 2
• GQMRJSLZRWZIAR-PHIMTYICSA-N CN(C=1C2=C(N=CN=1)NC=C2)[C@@H]1C[C@@H](C1)CS(=O)(=O)CCC(F)(F)F Chemical compound CN(C=1C2=C(N=CN=1)NC=C2)[C@@H]1C[C@@H](C1)CS(=O)(=O)CCC(F)(F)F GQMRJSLZRWZIAR-PHIMTYICSA-N 0.000 claims description 2
• LMJUBINGYKVMOE-TXEJJXNPSA-N CN(C=1C2=C(N=CN=1)NC=C2)[C@@H]1C[C@@H](C1)CS(=O)(=O)CCCC(F)(F)F Chemical compound CN(C=1C2=C(N=CN=1)NC=C2)[C@@H]1C[C@@H](C1)CS(=O)(=O)CCCC(F)(F)F LMJUBINGYKVMOE-TXEJJXNPSA-N 0.000 claims description 2
• IRIDDEHSOPFQKO-MCIONIFRSA-N CN(C=1C2=C(N=CN=1)NC=C2)[C@@H]1C[C@@H](C1)CS(=O)(=O)C[C@@H](CC)C Chemical compound CN(C=1C2=C(N=CN=1)NC=C2)[C@@H]1C[C@@H](C1)CS(=O)(=O)C[C@@H](CC)C IRIDDEHSOPFQKO-MCIONIFRSA-N 0.000 claims description 2
• IEZCQRWUHVGNAJ-RUPPMWDTSA-N CN(C=1C2=C(N=CN=1)NC=C2)[C@@H]1C[C@@H](C1)CS(=O)(=O)C[C@@H]1CC[C@@H](CC1)C(F)(F)F Chemical compound CN(C=1C2=C(N=CN=1)NC=C2)[C@@H]1C[C@@H](C1)CS(=O)(=O)C[C@@H]1CC[C@@H](CC1)C(F)(F)F IEZCQRWUHVGNAJ-RUPPMWDTSA-N 0.000 claims description 2
• IEZCQRWUHVGNAJ-ZNNBLSDJSA-N CN(C=1C2=C(N=CN=1)NC=C2)[C@@H]1C[C@@H](C1)CS(=O)(=O)C[C@@H]1CC[C@H](CC1)C(F)(F)F Chemical compound CN(C=1C2=C(N=CN=1)NC=C2)[C@@H]1C[C@@H](C1)CS(=O)(=O)C[C@@H]1CC[C@H](CC1)C(F)(F)F IEZCQRWUHVGNAJ-ZNNBLSDJSA-N 0.000 claims description 2
• IRIDDEHSOPFQKO-MELADBBJSA-N CN(C=1C2=C(N=CN=1)NC=C2)[C@@H]1C[C@@H](C1)CS(=O)(=O)C[C@H](CC)C Chemical compound CN(C=1C2=C(N=CN=1)NC=C2)[C@@H]1C[C@@H](C1)CS(=O)(=O)C[C@H](CC)C IRIDDEHSOPFQKO-MELADBBJSA-N 0.000 claims description 2
• LVGRNBGLLJCFBV-GOOCMWNKSA-N CN(C=1C2=C(N=CN=1)NC=C2)[C@@H]1C[C@@H](C1)CS(=O)(=O)N1C(CCCC1)C Chemical compound CN(C=1C2=C(N=CN=1)NC=C2)[C@@H]1C[C@@H](C1)CS(=O)(=O)N1C(CCCC1)C LVGRNBGLLJCFBV-GOOCMWNKSA-N 0.000 claims description 2
• FLHGGCZDQCEGDN-BETUJISGSA-N CN(C=1C2=C(N=CN=1)NC=C2)[C@@H]1C[C@@H](C1)CS(=O)(=O)N1CC(C1)C Chemical compound CN(C=1C2=C(N=CN=1)NC=C2)[C@@H]1C[C@@H](C1)CS(=O)(=O)N1CC(C1)C FLHGGCZDQCEGDN-BETUJISGSA-N 0.000 claims description 2
• GUGGRZLRTQXLTE-KLPPZKSPSA-N CN(C=1C2=C(N=CN=1)NC=C2)[C@@H]1C[C@@H](C1)CS(=O)(=O)N1CC(C1)C(F)(F)F Chemical compound CN(C=1C2=C(N=CN=1)NC=C2)[C@@H]1C[C@@H](C1)CS(=O)(=O)N1CC(C1)C(F)(F)F GUGGRZLRTQXLTE-KLPPZKSPSA-N 0.000 claims description 2
• UITGKEXJZPRUML-ZIHWECLZSA-N CN(C=1C2=C(N=CN=1)NC=C2)[C@@H]1C[C@@H](C1)CS(=O)(=O)N1CC(CC1)C(F)(F)F Chemical compound CN(C=1C2=C(N=CN=1)NC=C2)[C@@H]1C[C@@H](C1)CS(=O)(=O)N1CC(CC1)C(F)(F)F UITGKEXJZPRUML-ZIHWECLZSA-N 0.000 claims description 2
• IORFVKINRAWDSR-GOOCMWNKSA-N CN(C=1C2=C(N=CN=1)NC=C2)[C@@H]1C[C@@H](C1)CS(=O)(=O)N1CC(CCC1)C Chemical compound CN(C=1C2=C(N=CN=1)NC=C2)[C@@H]1C[C@@H](C1)CS(=O)(=O)N1CC(CCC1)C IORFVKINRAWDSR-GOOCMWNKSA-N 0.000 claims description 2
• AJSTYWNQMVMSLL-XMGJGUJMSA-N CN(C=1C2=C(N=CN=1)NC=C2)[C@@H]1C[C@@H](C1)CS(=O)(=O)N1CC(CCC1)C(F)(F)F Chemical compound CN(C=1C2=C(N=CN=1)NC=C2)[C@@H]1C[C@@H](C1)CS(=O)(=O)N1CC(CCC1)C(F)(F)F AJSTYWNQMVMSLL-XMGJGUJMSA-N 0.000 claims description 2
• MTKVAQMOPQFSOM-IYBDPMFKSA-N CN(C=1C2=C(N=CN=1)NC=C2)[C@@H]1C[C@@H](C1)CS(=O)(=O)N1CC2(CC1)CCOCC2 Chemical class CN(C=1C2=C(N=CN=1)NC=C2)[C@@H]1C[C@@H](C1)CS(=O)(=O)N1CC2(CC1)CCOCC2 MTKVAQMOPQFSOM-IYBDPMFKSA-N 0.000 claims description 2
• XSUUNVIUYATSNU-BETUJISGSA-N CN(C=1C2=C(N=CN=1)NC=C2)[C@@H]1C[C@@H](C1)CS(=O)(=O)N1CC2(COC2)C1 Chemical class CN(C=1C2=C(N=CN=1)NC=C2)[C@@H]1C[C@@H](C1)CS(=O)(=O)N1CC2(COC2)C1 XSUUNVIUYATSNU-BETUJISGSA-N 0.000 claims description 2
• HLYZMNDVOAJVDF-GASCZTMLSA-N CN(C=1C2=C(N=CN=1)NC=C2)[C@@H]1C[C@@H](C1)CS(=O)(=O)N1CC2(COC2)CCC1 Chemical class CN(C=1C2=C(N=CN=1)NC=C2)[C@@H]1C[C@@H](C1)CS(=O)(=O)N1CC2(COC2)CCC1 HLYZMNDVOAJVDF-GASCZTMLSA-N 0.000 claims description 2
• LMJGEGVYXUTLBG-FZNQNYSPSA-N CN(C=1C2=C(N=CN=1)NC=C2)[C@@H]1C[C@@H](C1)CS(=O)(=O)N1CC=2C(C(C1)(C)C)=NN(C=2)C Chemical compound CN(C=1C2=C(N=CN=1)NC=C2)[C@@H]1C[C@@H](C1)CS(=O)(=O)N1CC=2C(C(C1)(C)C)=NN(C=2)C LMJGEGVYXUTLBG-FZNQNYSPSA-N 0.000 claims description 2
• VTOHXCTUKVQTFB-XBXGTLAGSA-N CN(C=1C2=C(N=CN=1)NC=C2)[C@@H]1C[C@@H](C1)CS(=O)(=O)N1CC=2N(N=CC=2C1)C Chemical compound CN(C=1C2=C(N=CN=1)NC=C2)[C@@H]1C[C@@H](C1)CS(=O)(=O)N1CC=2N(N=CC=2C1)C VTOHXCTUKVQTFB-XBXGTLAGSA-N 0.000 claims description 2
• UOSTUAUIXSQYPZ-XBXGTLAGSA-N CN(C=1C2=C(N=CN=1)NC=C2)[C@@H]1C[C@@H](C1)CS(=O)(=O)N1CCC(CC1)C(F)(F)F Chemical compound CN(C=1C2=C(N=CN=1)NC=C2)[C@@H]1C[C@@H](C1)CS(=O)(=O)N1CCC(CC1)C(F)(F)F UOSTUAUIXSQYPZ-XBXGTLAGSA-N 0.000 claims description 2
• HJPUXRUWOGLSHD-FZNQNYSPSA-N CN(C=1C2=C(N=CN=1)NC=C2)[C@@H]1C[C@@H](C1)CS(=O)(=O)N1CCC(CC1)C1=CN=CO1 Chemical compound CN(C=1C2=C(N=CN=1)NC=C2)[C@@H]1C[C@@H](C1)CS(=O)(=O)N1CCC(CC1)C1=CN=CO1 HJPUXRUWOGLSHD-FZNQNYSPSA-N 0.000 claims description 2
• LNTSTFPYHHHPLZ-WOVMCDHWSA-N CN(C=1C2=C(N=CN=1)NC=C2)[C@@H]1C[C@@H](C1)CS(=O)(=O)N1CCC(CC1)C1=NN(C=C1)C Chemical compound CN(C=1C2=C(N=CN=1)NC=C2)[C@@H]1C[C@@H](C1)CS(=O)(=O)N1CCC(CC1)C1=NN(C=C1)C LNTSTFPYHHHPLZ-WOVMCDHWSA-N 0.000 claims description 2
• JYSFPYSVGWPCBC-FZNQNYSPSA-N CN(C=1C2=C(N=CN=1)NC=C2)[C@@H]1C[C@@H](C1)CS(=O)(=O)N1CCC(CC1)C=1OC=CN=1 Chemical compound CN(C=1C2=C(N=CN=1)NC=C2)[C@@H]1C[C@@H](C1)CS(=O)(=O)N1CCC(CC1)C=1OC=CN=1 JYSFPYSVGWPCBC-FZNQNYSPSA-N 0.000 claims description 2
• YTLDKUMYEUXYGQ-OKILXGFUSA-N CN(C=1C2=C(N=CN=1)NC=C2)[C@@H]1C[C@@H](C1)CS(=O)(=O)N1CCCCC1 Chemical compound CN(C=1C2=C(N=CN=1)NC=C2)[C@@H]1C[C@@H](C1)CS(=O)(=O)N1CCCCC1 YTLDKUMYEUXYGQ-OKILXGFUSA-N 0.000 claims description 2
• YDEYSAIBCALEFF-OKILXGFUSA-N CN(C=1C2=C(N=CN=1)NC=C2)[C@@H]1C[C@@H](C1)CS(=O)(=O)N1CCN(CC1)C Chemical compound CN(C=1C2=C(N=CN=1)NC=C2)[C@@H]1C[C@@H](C1)CS(=O)(=O)N1CCN(CC1)C YDEYSAIBCALEFF-OKILXGFUSA-N 0.000 claims description 2
• YUBGZWZBKRPZHK-IYBDPMFKSA-N CN(C=1C2=C(N=CN=1)NC=C2)[C@@H]1C[C@@H](C1)CS(=O)(=O)N1CCOC2(CCCC2)C1 Chemical class CN(C=1C2=C(N=CN=1)NC=C2)[C@@H]1C[C@@H](C1)CS(=O)(=O)N1CCOC2(CCCC2)C1 YUBGZWZBKRPZHK-IYBDPMFKSA-N 0.000 claims description 2
• GODNEHJKBMGCML-BETUJISGSA-N CN(C=1C2=C(N=CN=1)NC=C2)[C@@H]1C[C@@H](C1)CS(=O)(=O)N1CCOCC1 Chemical compound CN(C=1C2=C(N=CN=1)NC=C2)[C@@H]1C[C@@H](C1)CS(=O)(=O)N1CCOCC1 GODNEHJKBMGCML-BETUJISGSA-N 0.000 claims description 2
• NAIBQEDQOYMTDY-MELADBBJSA-N CN(C=1C2=C(N=CN=1)NC=C2)[C@@H]1C[C@@H](C1)CS(=O)(=O)N1C[C@@H](OCC1)C Chemical compound CN(C=1C2=C(N=CN=1)NC=C2)[C@@H]1C[C@@H](C1)CS(=O)(=O)N1C[C@@H](OCC1)C NAIBQEDQOYMTDY-MELADBBJSA-N 0.000 claims description 2
• HQUBADRFDQYRJZ-MJBXVCDLSA-N CN(C=1C2=C(N=CN=1)NC=C2)[C@@H]1C[C@@H](C1)CS(=O)(=O)N1C[C@H](CC1)S(=O)(=O)C Chemical class CN(C=1C2=C(N=CN=1)NC=C2)[C@@H]1C[C@@H](C1)CS(=O)(=O)N1C[C@H](CC1)S(=O)(=O)C HQUBADRFDQYRJZ-MJBXVCDLSA-N 0.000 claims description 2
• NAIBQEDQOYMTDY-MCIONIFRSA-N CN(C=1C2=C(N=CN=1)NC=C2)[C@@H]1C[C@@H](C1)CS(=O)(=O)N1C[C@H](OCC1)C Chemical compound CN(C=1C2=C(N=CN=1)NC=C2)[C@@H]1C[C@@H](C1)CS(=O)(=O)N1C[C@H](OCC1)C NAIBQEDQOYMTDY-MCIONIFRSA-N 0.000 claims description 2
• LVUKVCNAPPALAV-MCIONIFRSA-N CN(C=1C2=C(N=CN=1)NC=C2)[C@@H]1C[C@@H](C1)CS(=O)(=O)N1[C@@H](CCC1)C Chemical compound CN(C=1C2=C(N=CN=1)NC=C2)[C@@H]1C[C@@H](C1)CS(=O)(=O)N1[C@@H](CCC1)C LVUKVCNAPPALAV-MCIONIFRSA-N 0.000 claims description 2
• DZUZISPQONXYKX-MCIONIFRSA-N CN(C=1C2=C(N=CN=1)NC=C2)[C@@H]1C[C@@H](C1)CS(=O)(=O)N1[C@@H](COCC1)C Chemical compound CN(C=1C2=C(N=CN=1)NC=C2)[C@@H]1C[C@@H](C1)CS(=O)(=O)N1[C@@H](COCC1)C DZUZISPQONXYKX-MCIONIFRSA-N 0.000 claims description 2
• HRRLZKHIEGDCQZ-HFDVOGEKSA-N CN([C@H]1C[C@H](C1)CS(=O)(=O)C1CC(CC1)C#N)C=1C2=C(N=CN=1)NC=C2 Chemical compound CN([C@H]1C[C@H](C1)CS(=O)(=O)C1CC(CC1)C#N)C=1C2=C(N=CN=1)NC=C2 HRRLZKHIEGDCQZ-HFDVOGEKSA-N 0.000 claims description 2
• YIXPBQPWTOUUID-BETUJISGSA-N CN([C@H]1C[C@H](C1)CS(=O)(=O)C1CN(C1)C(C)=O)C=1C2=C(N=CN=1)NC=C2 Chemical compound CN([C@H]1C[C@H](C1)CS(=O)(=O)C1CN(C1)C(C)=O)C=1C2=C(N=CN=1)NC=C2 YIXPBQPWTOUUID-BETUJISGSA-N 0.000 claims description 2
• LRJHFOMJPOSHDU-YHWZYXNKSA-N CN([C@H]1C[C@H](C1)CS(=O)(=O)CCC(C)O)C=1C2=C(N=CN=1)NC=C2 Chemical compound CN([C@H]1C[C@H](C1)CS(=O)(=O)CCC(C)O)C=1C2=C(N=CN=1)NC=C2 LRJHFOMJPOSHDU-YHWZYXNKSA-N 0.000 claims description 2
• GOVBNJVVLBICAP-BETUJISGSA-N CN([C@H]1C[C@H](C1)CS(=O)(=O)CCCCO)C=1C2=C(N=CN=1)NC=C2 Chemical compound CN([C@H]1C[C@H](C1)CS(=O)(=O)CCCCO)C=1C2=C(N=CN=1)NC=C2 GOVBNJVVLBICAP-BETUJISGSA-N 0.000 claims description 2
• IUKJDEJWJMTDOO-GASCZTMLSA-N CN([C@H]1C[C@H](C1)CS(=O)(=O)N1CCN(CC1)C(C)=O)C=1C2=C(N=CN=1)NC=C2 Chemical compound CN([C@H]1C[C@H](C1)CS(=O)(=O)N1CCN(CC1)C(C)=O)C=1C2=C(N=CN=1)NC=C2 IUKJDEJWJMTDOO-GASCZTMLSA-N 0.000 claims description 2
• HRRLZKHIEGDCQZ-KBXIAJHMSA-N CN([C@H]1C[C@H](C1)CS(=O)(=O)[C@@H]1C[C@@H](CC1)C#N)C=1C2=C(N=CN=1)NC=C2 Chemical compound CN([C@H]1C[C@H](C1)CS(=O)(=O)[C@@H]1C[C@@H](CC1)C#N)C=1C2=C(N=CN=1)NC=C2 HRRLZKHIEGDCQZ-KBXIAJHMSA-N 0.000 claims description 2
• XUBODOZNSMBJOD-OKILXGFUSA-N CN1C(C=C(C(=C1)S(=O)(=O)C[C@@H]1C[C@@H](C1)N(C=1C2=C(N=CN=1)NC=C2)C)C)=O Chemical compound CN1C(C=C(C(=C1)S(=O)(=O)C[C@@H]1C[C@@H](C1)N(C=1C2=C(N=CN=1)NC=C2)C)C)=O XUBODOZNSMBJOD-OKILXGFUSA-N 0.000 claims description 2
• NWGRIRNDHVPEDQ-BETUJISGSA-N CN1C(C=CC(=C1)S(=O)(=O)C[C@@H]1C[C@@H](C1)N(C=1C2=C(N=CN=1)NC=C2)C)=O Chemical compound CN1C(C=CC(=C1)S(=O)(=O)C[C@@H]1C[C@@H](C1)N(C=1C2=C(N=CN=1)NC=C2)C)=O NWGRIRNDHVPEDQ-BETUJISGSA-N 0.000 claims description 2
• DHWQGOLXINKFNQ-OKILXGFUSA-N CN1C(C=CC(=C1C)S(=O)(=O)C[C@@H]1C[C@@H](C1)N(C=1C2=C(N=CN=1)NC=C2)C)=O Chemical compound CN1C(C=CC(=C1C)S(=O)(=O)C[C@@H]1C[C@@H](C1)N(C=1C2=C(N=CN=1)NC=C2)C)=O DHWQGOLXINKFNQ-OKILXGFUSA-N 0.000 claims description 2
• SGCBQRMWMGNJGX-BETUJISGSA-N CN1C(CN(CC1)S(=O)(=O)C[C@@H]1C[C@@H](C1)N(C=1C2=C(N=CN=1)NC=C2)C)=O Chemical compound CN1C(CN(CC1)S(=O)(=O)C[C@@H]1C[C@@H](C1)N(C=1C2=C(N=CN=1)NC=C2)C)=O SGCBQRMWMGNJGX-BETUJISGSA-N 0.000 claims description 2
• KRLPVQAMTJYSFK-GASCZTMLSA-N CN1N=C(C=2CN(CCC=21)S(=O)(=O)C[C@H]1C[C@H](C1)N(C=1C2=C(N=CN=1)NC=C2)C)C Chemical compound CN1N=C(C=2CN(CCC=21)S(=O)(=O)C[C@H]1C[C@H](C1)N(C=1C2=C(N=CN=1)NC=C2)C)C KRLPVQAMTJYSFK-GASCZTMLSA-N 0.000 claims description 2
• YKQOWJNVADRIPJ-BJHJDKERSA-N CNC1=NC([C@H]2C[C@@H](CS(N(CC3)CCC3C(F)F)(=O)=O)C2)=NC2=C1C=CN2 Chemical compound CNC1=NC([C@H]2C[C@@H](CS(N(CC3)CCC3C(F)F)(=O)=O)C2)=NC2=C1C=CN2 YKQOWJNVADRIPJ-BJHJDKERSA-N 0.000 claims description 2
• SPWAURFUZZSOJK-YHKVIRHGSA-N COC(C)C1=CC=C(C=C1)S(=O)(=O)C[C@H]1C[C@H](C1)N(C=1C2=C(N=CN=1)NC=C2)C Chemical compound COC(C)C1=CC=C(C=C1)S(=O)(=O)C[C@H]1C[C@H](C1)N(C=1C2=C(N=CN=1)NC=C2)C SPWAURFUZZSOJK-YHKVIRHGSA-N 0.000 claims description 2
• OZDFKECLFIDGPK-YHKVIRHGSA-N COC(C)C1CCN(CC1)S(=O)(=O)C[C@H]1C[C@H](C1)N(C=1C2=C(N=CN=1)NC=C2)C Chemical compound COC(C)C1CCN(CC1)S(=O)(=O)C[C@H]1C[C@H](C1)N(C=1C2=C(N=CN=1)NC=C2)C OZDFKECLFIDGPK-YHKVIRHGSA-N 0.000 claims description 2
• FOKWJDXYIMECRZ-BETUJISGSA-N COC1(CN(C1)S(=O)(=O)C[C@H]1C[C@H](C1)N(C=1C2=C(N=CN=1)NC=C2)C)C Chemical compound COC1(CN(C1)S(=O)(=O)C[C@H]1C[C@H](C1)N(C=1C2=C(N=CN=1)NC=C2)C)C FOKWJDXYIMECRZ-BETUJISGSA-N 0.000 claims description 2
• MDTIFFXIWIDZBH-BETUJISGSA-N COC1=C(C=NC=C1)S(=O)(=O)C[C@H]1C[C@H](C1)N(C=1C2=C(N=CN=1)NC=C2)C Chemical compound COC1=C(C=NC=C1)S(=O)(=O)C[C@H]1C[C@H](C1)N(C=1C2=C(N=CN=1)NC=C2)C MDTIFFXIWIDZBH-BETUJISGSA-N 0.000 claims description 2
• FUEIJOICQSRCFR-OKILXGFUSA-N COC1=CC(=C(C=N1)S(=O)(=O)C[C@H]1C[C@H](C1)N(C=1C2=C(N=CN=1)NC=C2)C)C Chemical compound COC1=CC(=C(C=N1)S(=O)(=O)C[C@H]1C[C@H](C1)N(C=1C2=C(N=CN=1)NC=C2)C)C FUEIJOICQSRCFR-OKILXGFUSA-N 0.000 claims description 2
• BRIUDIRHWGESSC-TXEJJXNPSA-N COC1=CC(=C(C=N1)S(=O)(=O)C[C@H]1C[C@H](C1)N(C=1C2=C(N=CN=1)NC=C2)C)C(F)(F)F Chemical compound COC1=CC(=C(C=N1)S(=O)(=O)C[C@H]1C[C@H](C1)N(C=1C2=C(N=CN=1)NC=C2)C)C(F)(F)F BRIUDIRHWGESSC-TXEJJXNPSA-N 0.000 claims description 2
• VBIIHZOALUSRNV-TXEJJXNPSA-N COC1=CC=C(C(=N1)C(F)(F)F)S(=O)(=O)C[C@H]1C[C@H](C1)N(C=1C2=C(N=CN=1)NC=C2)C Chemical compound COC1=CC=C(C(=N1)C(F)(F)F)S(=O)(=O)C[C@H]1C[C@H](C1)N(C=1C2=C(N=CN=1)NC=C2)C VBIIHZOALUSRNV-TXEJJXNPSA-N 0.000 claims description 2
• GPVUZLBZXFYXOK-OKILXGFUSA-N COC1=CC=C(C(=N1)C)S(=O)(=O)C[C@H]1C[C@H](C1)N(C=1C2=C(N=CN=1)NC=C2)C Chemical compound COC1=CC=C(C(=N1)C)S(=O)(=O)C[C@H]1C[C@H](C1)N(C=1C2=C(N=CN=1)NC=C2)C GPVUZLBZXFYXOK-OKILXGFUSA-N 0.000 claims description 2
• SCWPVGKRRGXLMF-OKILXGFUSA-N COC1=CC=C(C=C1)S(=O)(=O)C[C@H]1C[C@H](C1)N(C=1C2=C(N=CN=1)NC=C2)C Chemical compound COC1=CC=C(C=C1)S(=O)(=O)C[C@H]1C[C@H](C1)N(C=1C2=C(N=CN=1)NC=C2)C SCWPVGKRRGXLMF-OKILXGFUSA-N 0.000 claims description 2
• WRFANJMETRKSFA-BETUJISGSA-N COC1=CC=C(C=N1)S(=O)(=O)C[C@H]1C[C@H](C1)N(C=1C2=C(N=CN=1)NC=C2)C Chemical compound COC1=CC=C(C=N1)S(=O)(=O)C[C@H]1C[C@H](C1)N(C=1C2=C(N=CN=1)NC=C2)C WRFANJMETRKSFA-BETUJISGSA-N 0.000 claims description 2
• FGMDTAYCXKEAOG-FZNQNYSPSA-N COC1=NC=2CCN(CC=2C=C1)S(=O)(=O)C[C@H]1C[C@H](C1)N(C=1C2=C(N=CN=1)NC=C2)C Chemical compound COC1=NC=2CCN(CC=2C=C1)S(=O)(=O)C[C@H]1C[C@H](C1)N(C=1C2=C(N=CN=1)NC=C2)C FGMDTAYCXKEAOG-FZNQNYSPSA-N 0.000 claims description 2
• RZVBCGFEXPDAAN-OKILXGFUSA-N COC1=NC=C(C(=C1)S(=O)(=O)C[C@H]1C[C@H](C1)N(C=1C2=C(N=CN=1)NC=C2)C)C Chemical compound COC1=NC=C(C(=C1)S(=O)(=O)C[C@H]1C[C@H](C1)N(C=1C2=C(N=CN=1)NC=C2)C)C RZVBCGFEXPDAAN-OKILXGFUSA-N 0.000 claims description 2
• YYUFVSMURUQLMO-BETUJISGSA-N COC1=NC=C(C(=N1)C)S(=O)(=O)C[C@H]1C[C@H](C1)N(C=1C2=C(N=CN=1)NC=C2)C Chemical compound COC1=NC=C(C(=N1)C)S(=O)(=O)C[C@H]1C[C@H](C1)N(C=1C2=C(N=CN=1)NC=C2)C YYUFVSMURUQLMO-BETUJISGSA-N 0.000 claims description 2
• VRYUZSRAENQEKH-TXEJJXNPSA-N COC1=NC=C(C=N1)S(=O)(=O)C[C@H]1C[C@H](C1)N(C=1C2=C(N=CN=1)NC=C2)C Chemical compound COC1=NC=C(C=N1)S(=O)(=O)C[C@H]1C[C@H](C1)N(C=1C2=C(N=CN=1)NC=C2)C VRYUZSRAENQEKH-TXEJJXNPSA-N 0.000 claims description 2
• UAYHCEIKWIDIQO-BETUJISGSA-N COC1=NC=CC(=C1)S(=O)(=O)C[C@H]1C[C@H](C1)N(C=1C2=C(N=CN=1)NC=C2)C Chemical compound COC1=NC=CC(=C1)S(=O)(=O)C[C@H]1C[C@H](C1)N(C=1C2=C(N=CN=1)NC=C2)C UAYHCEIKWIDIQO-BETUJISGSA-N 0.000 claims description 2
• HJVNBZSJPWXICA-FKEKPDDDSA-N COC1CC11CCN(CC1)S(=O)(=O)C[C@H]1C[C@H](C1)N(C=1C2=C(N=CN=1)NC=C2)C Chemical compound COC1CC11CCN(CC1)S(=O)(=O)C[C@H]1C[C@H](C1)N(C=1C2=C(N=CN=1)NC=C2)C HJVNBZSJPWXICA-FKEKPDDDSA-N 0.000 claims description 2
• TYYAPZRDCWZCMJ-OKILXGFUSA-N COC1CCN(CC1)S(=O)(=O)C[C@H]1C[C@H](C1)N(C=1C2=C(N=CN=1)NC=C2)C Chemical compound COC1CCN(CC1)S(=O)(=O)C[C@H]1C[C@H](C1)N(C=1C2=C(N=CN=1)NC=C2)C TYYAPZRDCWZCMJ-OKILXGFUSA-N 0.000 claims description 2
• NTXRILNNLCIRGS-TXEJJXNPSA-N COC1CN(C1)S(=O)(=O)C[C@H]1C[C@H](C1)N(C=1C2=C(N=CN=1)NC=C2)C Chemical compound COC1CN(C1)S(=O)(=O)C[C@H]1C[C@H](C1)N(C=1C2=C(N=CN=1)NC=C2)C NTXRILNNLCIRGS-TXEJJXNPSA-N 0.000 claims description 2
• IIIZBXHGWNJDDF-YIONKMFJSA-N COC1CN(CCC1)S(=O)(=O)C[C@H]1C[C@H](C1)N(C=1C2=C(N=CN=1)NC=C2)C Chemical compound COC1CN(CCC1)S(=O)(=O)C[C@H]1C[C@H](C1)N(C=1C2=C(N=CN=1)NC=C2)C IIIZBXHGWNJDDF-YIONKMFJSA-N 0.000 claims description 2
• ZSTUJCOZGCERSU-OKILXGFUSA-N COC=1C=C(C(=NC=1)C)S(=O)(=O)C[C@H]1C[C@H](C1)N(C=1C2=C(N=CN=1)NC=C2)C Chemical compound COC=1C=C(C(=NC=1)C)S(=O)(=O)C[C@H]1C[C@H](C1)N(C=1C2=C(N=CN=1)NC=C2)C ZSTUJCOZGCERSU-OKILXGFUSA-N 0.000 claims description 2
• NRYOXXMMQVNECT-BETUJISGSA-N COC=1C=C(C=NC=1)S(=O)(=O)C[C@H]1C[C@H](C1)N(C=1C2=C(N=CN=1)NC=C2)C Chemical compound COC=1C=C(C=NC=1)S(=O)(=O)C[C@H]1C[C@H](C1)N(C=1C2=C(N=CN=1)NC=C2)C NRYOXXMMQVNECT-BETUJISGSA-N 0.000 claims description 2
• FNVZUMZCEAGHIK-OKILXGFUSA-N COC=1C=C(C=NC=1C)S(=O)(=O)C[C@H]1C[C@H](C1)N(C=1C2=C(N=CN=1)NC=C2)C Chemical compound COC=1C=C(C=NC=1C)S(=O)(=O)C[C@H]1C[C@H](C1)N(C=1C2=C(N=CN=1)NC=C2)C FNVZUMZCEAGHIK-OKILXGFUSA-N 0.000 claims description 2
• QAHCNFSHWLDZBS-BETUJISGSA-N COC=1C=C(C=NC=1OC)S(=O)(=O)C[C@H]1C[C@H](C1)N(C=1C2=C(N=CN=1)NC=C2)C Chemical compound COC=1C=C(C=NC=1OC)S(=O)(=O)C[C@H]1C[C@H](C1)N(C=1C2=C(N=CN=1)NC=C2)C QAHCNFSHWLDZBS-BETUJISGSA-N 0.000 claims description 2
• SCFXRVXGXNBVDI-KDYLLFBJSA-N COC=1C=C2CN(CC2=CC=1)S(=O)(=O)C[C@H]1C[C@H](C1)N(C=1C2=C(N=CN=1)NC=C2)C Chemical compound COC=1C=C2CN(CC2=CC=1)S(=O)(=O)C[C@H]1C[C@H](C1)N(C=1C2=C(N=CN=1)NC=C2)C SCFXRVXGXNBVDI-KDYLLFBJSA-N 0.000 claims description 2
• SJNBIIAJDAEGMT-IYBDPMFKSA-N COCC1CCN(CC1)S(=O)(=O)C[C@H]1C[C@H](C1)N(C=1C2=C(N=CN=1)NC=C2)C Chemical compound COCC1CCN(CC1)S(=O)(=O)C[C@H]1C[C@H](C1)N(C=1C2=C(N=CN=1)NC=C2)C SJNBIIAJDAEGMT-IYBDPMFKSA-N 0.000 claims description 2
• DQXVDJJGGAPUCQ-GOOCMWNKSA-N COCC1CN(CC1)S(=O)(=O)C[C@H]1C[C@H](C1)N(C=1C2=C(N=CN=1)NC=C2)C Chemical compound COCC1CN(CC1)S(=O)(=O)C[C@H]1C[C@H](C1)N(C=1C2=C(N=CN=1)NC=C2)C DQXVDJJGGAPUCQ-GOOCMWNKSA-N 0.000 claims description 2
• RJWXGUFPSYQCCR-MQVJKMGUSA-N COCC1CN(CCC1)S(=O)(=O)C[C@H]1C[C@H](C1)N(C=1C2=C(N=CN=1)NC=C2)C Chemical compound COCC1CN(CCC1)S(=O)(=O)C[C@H]1C[C@H](C1)N(C=1C2=C(N=CN=1)NC=C2)C RJWXGUFPSYQCCR-MQVJKMGUSA-N 0.000 claims description 2
• PGEQUQNGHNPYLE-YIONKMFJSA-N COCC1CN(CCO1)S(=O)(=O)C[C@H]1C[C@H](C1)N(C=1C2=C(N=CN=1)NC=C2)C Chemical compound COCC1CN(CCO1)S(=O)(=O)C[C@H]1C[C@H](C1)N(C=1C2=C(N=CN=1)NC=C2)C PGEQUQNGHNPYLE-YIONKMFJSA-N 0.000 claims description 2
• KFFMTKTXYCWBCR-IYBDPMFKSA-N COCC=1C=C(C=CC=1)S(=O)(=O)C[C@H]1C[C@H](C1)N(C=1C2=C(N=CN=1)NC=C2)C Chemical compound COCC=1C=C(C=CC=1)S(=O)(=O)C[C@H]1C[C@H](C1)N(C=1C2=C(N=CN=1)NC=C2)C KFFMTKTXYCWBCR-IYBDPMFKSA-N 0.000 claims description 2
• UONVIEOKLWGTRA-BETUJISGSA-N COCCCS(=O)(=O)C[C@H]1C[C@H](C1)N(C=1C2=C(N=CN=1)NC=C2)C Chemical compound COCCCS(=O)(=O)C[C@H]1C[C@H](C1)N(C=1C2=C(N=CN=1)NC=C2)C UONVIEOKLWGTRA-BETUJISGSA-N 0.000 claims description 2
• QKMKXINTXJLTEU-IYBDPMFKSA-N COCCOC1CCN(CC1)S(=O)(=O)C[C@H]1C[C@H](C1)N(C=1C2=C(N=CN=1)NC=C2)C Chemical compound COCCOC1CCN(CC1)S(=O)(=O)C[C@H]1C[C@H](C1)N(C=1C2=C(N=CN=1)NC=C2)C QKMKXINTXJLTEU-IYBDPMFKSA-N 0.000 claims description 2
• MXRGRNIICPTRCZ-LNTUMIRASA-N COC[C@@H]1CC[C@H](CC1)S(=O)(=O)C[C@H]1C[C@H](C1)N(C=1C2=C(N=CN=1)NC=C2)C Chemical compound COC[C@@H]1CC[C@H](CC1)S(=O)(=O)C[C@H]1C[C@H](C1)N(C=1C2=C(N=CN=1)NC=C2)C MXRGRNIICPTRCZ-LNTUMIRASA-N 0.000 claims description 2
• OZDFKECLFIDGPK-YQQAZPJKSA-N CO[C@@H](C)C1CCN(CC1)S(=O)(=O)C[C@H]1C[C@H](C1)N(C=1C2=C(N=CN=1)NC=C2)C Chemical compound CO[C@@H](C)C1CCN(CC1)S(=O)(=O)C[C@H]1C[C@H](C1)N(C=1C2=C(N=CN=1)NC=C2)C OZDFKECLFIDGPK-YQQAZPJKSA-N 0.000 claims description 2
• IQTIWHPPLGNVLI-LDKKBFSKSA-N CO[C@@H]1C[C@H](C1)N1CC(C1)S(=O)(=O)C[C@H]1C[C@H](C1)N(C=1C2=C(N=CN=1)NC=C2)C Chemical compound CO[C@@H]1C[C@H](C1)N1CC(C1)S(=O)(=O)C[C@H]1C[C@H](C1)N(C=1C2=C(N=CN=1)NC=C2)C IQTIWHPPLGNVLI-LDKKBFSKSA-N 0.000 claims description 2
• OZDFKECLFIDGPK-INMHGKMJSA-N CO[C@H](C)C1CCN(CC1)S(=O)(=O)C[C@H]1C[C@H](C1)N(C=1C2=C(N=CN=1)NC=C2)C Chemical compound CO[C@H](C)C1CCN(CC1)S(=O)(=O)C[C@H]1C[C@H](C1)N(C=1C2=C(N=CN=1)NC=C2)C OZDFKECLFIDGPK-INMHGKMJSA-N 0.000 claims description 2
• HIDFAYIDEQWSLS-HZSPNIEDSA-N CO[C@H]1CN(CC1)S(=O)(=O)C[C@H]1C[C@H](C1)N(C=1C2=C(N=CN=1)NC=C2)C Chemical compound CO[C@H]1CN(CC1)S(=O)(=O)C[C@H]1C[C@H](C1)N(C=1C2=C(N=CN=1)NC=C2)C HIDFAYIDEQWSLS-HZSPNIEDSA-N 0.000 claims description 2
• IIIZBXHGWNJDDF-QLFBSQMISA-N CO[C@H]1CN(CCC1)S(=O)(=O)C[C@H]1C[C@H](C1)N(C=1C2=C(N=CN=1)NC=C2)C Chemical compound CO[C@H]1CN(CCC1)S(=O)(=O)C[C@H]1C[C@H](C1)N(C=1C2=C(N=CN=1)NC=C2)C IIIZBXHGWNJDDF-QLFBSQMISA-N 0.000 claims description 2
• IQTIWHPPLGNVLI-GEEKYZPCSA-N CO[C@H]1C[C@H](C1)N1CC(C1)S(=O)(=O)C[C@H]1C[C@H](C1)N(C=1C2=C(N=CN=1)NC=C2)C Chemical compound CO[C@H]1C[C@H](C1)N1CC(C1)S(=O)(=O)C[C@H]1C[C@H](C1)N(C=1C2=C(N=CN=1)NC=C2)C IQTIWHPPLGNVLI-GEEKYZPCSA-N 0.000 claims description 2
• FSRICXSBCNMWMF-NMWPEEMBSA-N C[C@@H]1CN(C[C@@H](O1)C)S(=O)(=O)C[C@H]1C[C@H](C1)N(C=1C2=C(N=CN=1)NC=C2)C Chemical compound C[C@@H]1CN(C[C@@H](O1)C)S(=O)(=O)C[C@H]1C[C@H](C1)N(C=1C2=C(N=CN=1)NC=C2)C FSRICXSBCNMWMF-NMWPEEMBSA-N 0.000 claims description 2
• HKZZSJLXRUHYMQ-TUVASFSCSA-N C[C@@H]1CN([C@@H](CO1)C)S(=O)(=O)C[C@H]1C[C@H](C1)N(C=1C2=C(N=CN=1)NC=C2)C Chemical compound C[C@@H]1CN([C@@H](CO1)C)S(=O)(=O)C[C@H]1C[C@H](C1)N(C=1C2=C(N=CN=1)NC=C2)C HKZZSJLXRUHYMQ-TUVASFSCSA-N 0.000 claims description 2
• XOBYWVCCKFXUKO-BJHJDKERSA-N ClC1=C(C=C(C=C1)C(F)(F)F)S(=O)(=O)C[C@H]1C[C@H](C1)N(C=1C2=C(N=CN=1)NC=C2)C Chemical compound ClC1=C(C=C(C=C1)C(F)(F)F)S(=O)(=O)C[C@H]1C[C@H](C1)N(C=1C2=C(N=CN=1)NC=C2)C XOBYWVCCKFXUKO-BJHJDKERSA-N 0.000 claims description 2
• RLMMSHIOBVKROE-BETUJISGSA-N ClC1=C(C=C(C=C1)OC)S(=O)(=O)C[C@H]1C[C@H](C1)N(C=1C2=C(N=CN=1)NC=C2)C Chemical compound ClC1=C(C=C(C=C1)OC)S(=O)(=O)C[C@H]1C[C@H](C1)N(C=1C2=C(N=CN=1)NC=C2)C RLMMSHIOBVKROE-BETUJISGSA-N 0.000 claims description 2
• SJAPARWBVYBGJO-BETUJISGSA-N ClC1=C(C=CC=C1)S(=O)(=O)C[C@H]1C[C@H](C1)N(C=1C2=C(N=CN=1)NC=C2)C Chemical compound ClC1=C(C=CC=C1)S(=O)(=O)C[C@H]1C[C@H](C1)N(C=1C2=C(N=CN=1)NC=C2)C SJAPARWBVYBGJO-BETUJISGSA-N 0.000 claims description 2
• NDKIFWJDZDKTCC-BJHJDKERSA-N ClC1=CC(=C(C=C1)S(=O)(=O)C[C@H]1C[C@H](C1)N(C=1C2=C(N=CN=1)NC=C2)C)F Chemical compound ClC1=CC(=C(C=C1)S(=O)(=O)C[C@H]1C[C@H](C1)N(C=1C2=C(N=CN=1)NC=C2)C)F NDKIFWJDZDKTCC-BJHJDKERSA-N 0.000 claims description 2
• MNJZYSVSFNQWBL-XBXGTLAGSA-N ClC1=CC(=C(C=C1)S(=O)(=O)C[C@H]1C[C@H](C1)N(C=1C2=C(N=CN=1)NC=C2)C)OC Chemical compound ClC1=CC(=C(C=C1)S(=O)(=O)C[C@H]1C[C@H](C1)N(C=1C2=C(N=CN=1)NC=C2)C)OC MNJZYSVSFNQWBL-XBXGTLAGSA-N 0.000 claims description 2
• BVPZJEVFOUJWDN-KLPPZKSPSA-N ClC1CN(C1)S(=O)(=O)C[C@H]1C[C@H](C1)N(C=1C2=C(N=CN=1)NC=C2)C Chemical compound ClC1CN(C1)S(=O)(=O)C[C@H]1C[C@H](C1)N(C=1C2=C(N=CN=1)NC=C2)C BVPZJEVFOUJWDN-KLPPZKSPSA-N 0.000 claims description 2
• LTGGHOLQJAWCLY-OKILXGFUSA-N ClC=1C=C(C=CC=1OCC)S(=O)(=O)C[C@H]1C[C@H](C1)N(C=1C2=C(N=CN=1)NC=C2)C Chemical compound ClC=1C=C(C=CC=1OCC)S(=O)(=O)C[C@H]1C[C@H](C1)N(C=1C2=C(N=CN=1)NC=C2)C LTGGHOLQJAWCLY-OKILXGFUSA-N 0.000 claims description 2
• CPQRGOCKOZRFQE-BJHJDKERSA-N ClC=1C=CC(=NC=1)S(=O)(=O)C[C@H]1C[C@H](C1)N(C=1C2=C(N=CN=1)NC=C2)C Chemical compound ClC=1C=CC(=NC=1)S(=O)(=O)C[C@H]1C[C@H](C1)N(C=1C2=C(N=CN=1)NC=C2)C CPQRGOCKOZRFQE-BJHJDKERSA-N 0.000 claims description 2
• ZVAWPZNMAUAGOW-UODQLWRSSA-N FC(C1CC(C1)S(=O)(=O)C[C@H]1C[C@H](C1)N(C=1C2=C(N=CN=1)NC=C2)C)F Chemical compound FC(C1CC(C1)S(=O)(=O)C[C@H]1C[C@H](C1)N(C=1C2=C(N=CN=1)NC=C2)C)F ZVAWPZNMAUAGOW-UODQLWRSSA-N 0.000 claims description 2
• YAFUYUFFOGTZGH-KLPPZKSPSA-N FC(C1CN(C1)S(=O)(=O)C[C@H]1C[C@H](C1)N(C=1C2=C(N=CN=1)NC=C2)C)F Chemical compound FC(C1CN(C1)S(=O)(=O)C[C@H]1C[C@H](C1)N(C=1C2=C(N=CN=1)NC=C2)C)F YAFUYUFFOGTZGH-KLPPZKSPSA-N 0.000 claims description 2
• LZYADDZYJYUBGG-ZIHWECLZSA-N FC(C1CN(CC1)S(=O)(=O)C[C@H]1C[C@H](C1)N(C=1C2=C(N=CN=1)NC=C2)C)F Chemical compound FC(C1CN(CC1)S(=O)(=O)C[C@H]1C[C@H](C1)N(C=1C2=C(N=CN=1)NC=C2)C)F LZYADDZYJYUBGG-ZIHWECLZSA-N 0.000 claims description 2
• VZMBJDMHDUJNSV-TXEJJXNPSA-N FC(CCCS(=O)(=O)C[C@H]1C[C@H](C1)N(C=1C2=C(N=CN=1)NC=C2)C)F Chemical compound FC(CCCS(=O)(=O)C[C@H]1C[C@H](C1)N(C=1C2=C(N=CN=1)NC=C2)C)F VZMBJDMHDUJNSV-TXEJJXNPSA-N 0.000 claims description 2
• FPLDLCFSEQHYEF-PHIMTYICSA-N FC(CCS(=O)(=O)C[C@H]1C[C@H](C1)N(C=1C2=C(N=CN=1)NC=C2)C)F Chemical compound FC(CCS(=O)(=O)C[C@H]1C[C@H](C1)N(C=1C2=C(N=CN=1)NC=C2)C)F FPLDLCFSEQHYEF-PHIMTYICSA-N 0.000 claims description 2
• APFRBCIXTUCAMJ-TXEJJXNPSA-N FC(CN1CC(C1)S(=O)(=O)C[C@H]1C[C@H](C1)N(C=1C2=C(N=CN=1)NC=C2)C)F Chemical class FC(CN1CC(C1)S(=O)(=O)C[C@H]1C[C@H](C1)N(C=1C2=C(N=CN=1)NC=C2)C)F APFRBCIXTUCAMJ-TXEJJXNPSA-N 0.000 claims description 2
• NCDAOBBXOKEHFH-PHIMTYICSA-N FC(OC1CN(C1)S(=O)(=O)C[C@H]1C[C@H](C1)N(C=1C2=C(N=CN=1)NC=C2)C)F Chemical compound FC(OC1CN(C1)S(=O)(=O)C[C@H]1C[C@H](C1)N(C=1C2=C(N=CN=1)NC=C2)C)F NCDAOBBXOKEHFH-PHIMTYICSA-N 0.000 claims description 2
• WZHKRYGGBXNTMW-GASCZTMLSA-N FC(OCC1CCN(CC1)S(=O)(=O)C[C@H]1C[C@H](C1)N(C=1C2=C(N=CN=1)NC=C2)C)F Chemical class FC(OCC1CCN(CC1)S(=O)(=O)C[C@H]1C[C@H](C1)N(C=1C2=C(N=CN=1)NC=C2)C)F WZHKRYGGBXNTMW-GASCZTMLSA-N 0.000 claims description 2
• DTHKKIMDOOBIOP-BJHJDKERSA-N FC(OCC1CN(C1)S(=O)(=O)C[C@H]1C[C@H](C1)N(C=1C2=C(N=CN=1)NC=C2)C)F Chemical class FC(OCC1CN(C1)S(=O)(=O)C[C@H]1C[C@H](C1)N(C=1C2=C(N=CN=1)NC=C2)C)F DTHKKIMDOOBIOP-BJHJDKERSA-N 0.000 claims description 2
• AVRFACACEWCPRC-FRRDWIJNSA-N FC(O[C@H]1CN(CC1)S(=O)(=O)C[C@H]1C[C@H](C1)N(C=1C2=C(N=CN=1)NC=C2)C)F Chemical class FC(O[C@H]1CN(CC1)S(=O)(=O)C[C@H]1C[C@H](C1)N(C=1C2=C(N=CN=1)NC=C2)C)F AVRFACACEWCPRC-FRRDWIJNSA-N 0.000 claims description 2
• TUEQXSLLTMWDFV-BETUJISGSA-N FC1(CC(C1)(C)CS(=O)(=O)C[C@H]1C[C@H](C1)N(C=1C2=C(N=CN=1)NC=C2)C)F Chemical class FC1(CC(C1)(C)CS(=O)(=O)C[C@H]1C[C@H](C1)N(C=1C2=C(N=CN=1)NC=C2)C)F TUEQXSLLTMWDFV-BETUJISGSA-N 0.000 claims description 2
• BNOPEBHGDTWAQX-PHIMTYICSA-N FC1(CC(C1)S(=O)(=O)C[C@H]1C[C@H](C1)N(C=1C2=C(N=CN=1)NC=C2)C)F Chemical compound FC1(CC(C1)S(=O)(=O)C[C@H]1C[C@H](C1)N(C=1C2=C(N=CN=1)NC=C2)C)F BNOPEBHGDTWAQX-PHIMTYICSA-N 0.000 claims description 2
• ZAKXPDYMSATSNV-OKILXGFUSA-N FC1(CC11CCN(CC1)S(=O)(=O)C[C@H]1C[C@H](C1)N(C=1C2=C(N=CN=1)NC=C2)C)F Chemical compound FC1(CC11CCN(CC1)S(=O)(=O)C[C@H]1C[C@H](C1)N(C=1C2=C(N=CN=1)NC=C2)C)F ZAKXPDYMSATSNV-OKILXGFUSA-N 0.000 claims description 2
• QATVMVPAHQPMOK-GASCZTMLSA-N FC1(CCC(CC1)CS(=O)(=O)C[C@H]1C[C@H](C1)N(C=1C2=C(N=CN=1)NC=C2)C)F Chemical compound FC1(CCC(CC1)CS(=O)(=O)C[C@H]1C[C@H](C1)N(C=1C2=C(N=CN=1)NC=C2)C)F QATVMVPAHQPMOK-GASCZTMLSA-N 0.000 claims description 2
• GDRNCIWFAFKWDQ-TXEJJXNPSA-N FC1(CN(CC1)S(=O)(=O)C[C@H]1C[C@H](C1)N(C=1C2=C(N=CN=1)NC=C2)C)F Chemical compound FC1(CN(CC1)S(=O)(=O)C[C@H]1C[C@H](C1)N(C=1C2=C(N=CN=1)NC=C2)C)F GDRNCIWFAFKWDQ-TXEJJXNPSA-N 0.000 claims description 2
• RKDYFKWEFAJOHF-FZNQNYSPSA-N FC1(CN(CC2=CC=CC=C12)S(=O)(=O)C[C@H]1C[C@H](C1)N(C=1C2=C(N=CN=1)NC=C2)C)F Chemical compound FC1(CN(CC2=CC=CC=C12)S(=O)(=O)C[C@H]1C[C@H](C1)N(C=1C2=C(N=CN=1)NC=C2)C)F RKDYFKWEFAJOHF-FZNQNYSPSA-N 0.000 claims description 2
• WCQVVINBTJFFGB-BETUJISGSA-N FC1=C(C=CC(=C1)OC)S(=O)(=O)C[C@H]1C[C@H](C1)N(C=1C2=C(N=CN=1)NC=C2)C Chemical compound FC1=C(C=CC(=C1)OC)S(=O)(=O)C[C@H]1C[C@H](C1)N(C=1C2=C(N=CN=1)NC=C2)C WCQVVINBTJFFGB-BETUJISGSA-N 0.000 claims description 2
• LSQWGVOEBUCSKN-BETUJISGSA-N FC1=C(C=CC=C1)S(=O)(=O)C[C@H]1C[C@H](C1)N(C=1C2=C(N=CN=1)NC=C2)C Chemical compound FC1=C(C=CC=C1)S(=O)(=O)C[C@H]1C[C@H](C1)N(C=1C2=C(N=CN=1)NC=C2)C LSQWGVOEBUCSKN-BETUJISGSA-N 0.000 claims description 2
• LJGKJOABCDCQLE-XBXGTLAGSA-N FC1=CC=C(C=C1)S(=O)(=O)C[C@H]1C[C@H](C1)N(C=1C2=C(N=CN=1)NC=C2)C Chemical compound FC1=CC=C(C=C1)S(=O)(=O)C[C@H]1C[C@H](C1)N(C=1C2=C(N=CN=1)NC=C2)C LJGKJOABCDCQLE-XBXGTLAGSA-N 0.000 claims description 2
• UFCACMYEIHPYDQ-XBXGTLAGSA-N FC1CCN(CC1)S(=O)(=O)C[C@H]1C[C@H](C1)N(C=1C2=C(N=CN=1)NC=C2)C Chemical compound FC1CCN(CC1)S(=O)(=O)C[C@H]1C[C@H](C1)N(C=1C2=C(N=CN=1)NC=C2)C UFCACMYEIHPYDQ-XBXGTLAGSA-N 0.000 claims description 2
• QCWNMRWFKYCESL-KLPPZKSPSA-N FC1CN(C1)S(=O)(=O)C[C@H]1C[C@H](C1)N(C=1C2=C(N=CN=1)NC=C2)C Chemical compound FC1CN(C1)S(=O)(=O)C[C@H]1C[C@H](C1)N(C=1C2=C(N=CN=1)NC=C2)C QCWNMRWFKYCESL-KLPPZKSPSA-N 0.000 claims description 2
• ACXRPKBVTFNUBE-XBXGTLAGSA-N FC=1C=C(C=CC=1)S(=O)(=O)C[C@H]1C[C@H](C1)N(C=1C2=C(N=CN=1)NC=C2)C Chemical compound FC=1C=C(C=CC=1)S(=O)(=O)C[C@H]1C[C@H](C1)N(C=1C2=C(N=CN=1)NC=C2)C ACXRPKBVTFNUBE-XBXGTLAGSA-N 0.000 claims description 2
• OEMOIOUFFOLZQP-TXEJJXNPSA-N FC=1C=C(C=CC=1C(F)(F)F)S(=O)(=O)C[C@H]1C[C@H](C1)N(C=1C2=C(N=CN=1)NC=C2)C Chemical compound FC=1C=C(C=CC=1C(F)(F)F)S(=O)(=O)C[C@H]1C[C@H](C1)N(C=1C2=C(N=CN=1)NC=C2)C OEMOIOUFFOLZQP-TXEJJXNPSA-N 0.000 claims description 2
• XQZMCWSNDJGPHN-BJHJDKERSA-N FC=1C=C(C=NC=1)S(=O)(=O)C[C@H]1C[C@H](C1)N(C=1C2=C(N=CN=1)NC=C2)C Chemical compound FC=1C=C(C=NC=1)S(=O)(=O)C[C@H]1C[C@H](C1)N(C=1C2=C(N=CN=1)NC=C2)C XQZMCWSNDJGPHN-BJHJDKERSA-N 0.000 claims description 2
• ZCIBTYIZEOBKOI-XBXGTLAGSA-N FC=1C=CC(=C(C=1)S(=O)(=O)C[C@H]1C[C@H](C1)N(C=1C2=C(N=CN=1)NC=C2)C)OC Chemical compound FC=1C=CC(=C(C=1)S(=O)(=O)C[C@H]1C[C@H](C1)N(C=1C2=C(N=CN=1)NC=C2)C)OC ZCIBTYIZEOBKOI-XBXGTLAGSA-N 0.000 claims description 2
• GJVBDBDAEXZQHK-GASCZTMLSA-N FCC1CCN(CC1)S(=O)(=O)C[C@H]1C[C@H](C1)N(C=1C2=C(N=CN=1)NC=C2)C Chemical compound FCC1CCN(CC1)S(=O)(=O)C[C@H]1C[C@H](C1)N(C=1C2=C(N=CN=1)NC=C2)C GJVBDBDAEXZQHK-GASCZTMLSA-N 0.000 claims description 2
• FLPGRFLJPKNKQT-BETUJISGSA-N FCCCCS(=O)(=O)C[C@H]1C[C@H](C1)N(C=1C2=C(N=CN=1)NC=C2)C Chemical compound FCCCCS(=O)(=O)C[C@H]1C[C@H](C1)N(C=1C2=C(N=CN=1)NC=C2)C FLPGRFLJPKNKQT-BETUJISGSA-N 0.000 claims description 2
• KTJBMQTUEPLIPQ-TXEJJXNPSA-N FCCCS(=O)(=O)C[C@H]1C[C@H](C1)N(C=1C2=C(N=CN=1)NC=C2)C Chemical compound FCCCS(=O)(=O)C[C@H]1C[C@H](C1)N(C=1C2=C(N=CN=1)NC=C2)C KTJBMQTUEPLIPQ-TXEJJXNPSA-N 0.000 claims description 2
• CMNOJKQJWWLNPL-UPJWGTAASA-N F[C@H]1CN(CC1)S(=O)(=O)C[C@H]1C[C@H](C1)N(C=1C2=C(N=CN=1)NC=C2)C Chemical compound F[C@H]1CN(CC1)S(=O)(=O)C[C@H]1C[C@H](C1)N(C=1C2=C(N=CN=1)NC=C2)C CMNOJKQJWWLNPL-UPJWGTAASA-N 0.000 claims description 2
• 208000032612 Glial tumor Diseases 0.000 claims description 2
• PPUCWLVSPNIYBQ-BETUJISGSA-N O1C=CC2=NC=C(C=C21)S(=O)(=O)C[C@H]1C[C@H](C1)N(C=1C2=C(N=CN=1)NC=C2)C Chemical compound O1C=CC2=NC=C(C=C21)S(=O)(=O)C[C@H]1C[C@H](C1)N(C=1C2=C(N=CN=1)NC=C2)C PPUCWLVSPNIYBQ-BETUJISGSA-N 0.000 claims description 2
• 230000006720 chronic neuroinflammation Effects 0.000 claims description 2
• SDAXRHHPNYTELL-UHFFFAOYSA-N heptanenitrile Chemical compound CCCCCCC#N SDAXRHHPNYTELL-UHFFFAOYSA-N 0.000 claims description 2
• 208000024714 major depressive disease Diseases 0.000 claims description 2
• DQFBSLMKJXSWMF-XYWGHXNESA-N CN(C=1C2=C(N=CN=1)NC=C2)[C@@H]1C[C@@H](C1)CS(=O)(=O)N1CC2C(C2C1)C(F)(F)F Chemical compound CN(C=1C2=C(N=CN=1)NC=C2)[C@@H]1C[C@@H](C1)CS(=O)(=O)N1CC2C(C2C1)C(F)(F)F DQFBSLMKJXSWMF-XYWGHXNESA-N 0.000 claims 1
• DAZIGESCRQMWOU-BJHJDKERSA-N FC(CC1CN(C1)S(=O)(=O)C[C@H]1C[C@H](C1)N(C=1C2=C(N=CN=1)NC=C2)C)F Chemical compound FC(CC1CN(C1)S(=O)(=O)C[C@H]1C[C@H](C1)N(C=1C2=C(N=CN=1)NC=C2)C)F DAZIGESCRQMWOU-BJHJDKERSA-N 0.000 claims 1
• CMNOJKQJWWLNPL-RWMBFGLXSA-N F[C@@H]1CN(CC1)S(=O)(=O)C[C@H]1C[C@H](C1)N(C=1C2=C(N=CN=1)NC=C2)C Chemical compound F[C@@H]1CN(CC1)S(=O)(=O)C[C@H]1C[C@H](C1)N(C=1C2=C(N=CN=1)NC=C2)C CMNOJKQJWWLNPL-RWMBFGLXSA-N 0.000 claims 1
• PBIUUJCEMUAWJJ-UHFFFAOYSA-N azetidine-3-carbonitrile Chemical compound N#CC1CNC1 PBIUUJCEMUAWJJ-UHFFFAOYSA-N 0.000 claims 1
• 208000029028 brain injury Diseases 0.000 claims 1
• 230000000472 traumatic effect Effects 0.000 claims 1
• 125000000217 alkyl group Chemical group 0.000 description 429
• YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 276
• XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 156
• 125000003118 aryl group Chemical group 0.000 description 153
• OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 141
• 125000001072 heteroaryl group Chemical group 0.000 description 124
• 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 description 117
• 125000005843 halogen group Chemical group 0.000 description 109
• LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 90
• 125000000753 cycloalkyl group Chemical group 0.000 description 90
• 238000000034 method Methods 0.000 description 87
• 239000000243 solution Substances 0.000 description 82
• 238000005481 NMR spectroscopy Methods 0.000 description 80
• WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 77
• 238000006243 chemical reaction Methods 0.000 description 77
• 239000007787 solid Substances 0.000 description 74
• 125000003545 alkoxy group Chemical group 0.000 description 73
• ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 72
• 125000002887 hydroxy group Chemical group [H]O* 0.000 description 71
• 229910052739 hydrogen Inorganic materials 0.000 description 65
• 239000001257 hydrogen Substances 0.000 description 65
• 125000006297 carbonyl amino group Chemical group [H]N([*:2])C([*:1])=O 0.000 description 64
• RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 63
• XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 63
• YZCKVEUIGOORGS-OUBTZVSYSA-N Deuterium Chemical group [2H] YZCKVEUIGOORGS-OUBTZVSYSA-N 0.000 description 60
• 229910052805 deuterium Inorganic materials 0.000 description 60
• 150000002431 hydrogen Chemical group 0.000 description 57
• 125000001424 substituent group Chemical group 0.000 description 54
• 235000019439 ethyl acetate Nutrition 0.000 description 52
• IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 45
• 239000002904 solvent Substances 0.000 description 45
• ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 44
• 125000000623 heterocyclic group Chemical group 0.000 description 41
• 229910052757 nitrogen Inorganic materials 0.000 description 41
• 125000004429 atom Chemical group 0.000 description 40
• 239000002585 base Substances 0.000 description 40
• PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 38
• 239000012044 organic layer Substances 0.000 description 38
• 229910052938 sodium sulfate Inorganic materials 0.000 description 37
• 235000011152 sodium sulphate Nutrition 0.000 description 37
• YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 37
• WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 33
• VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 32
• 239000011541 reaction mixture Substances 0.000 description 32
• 229920006395 saturated elastomer Polymers 0.000 description 32
• 125000002950 monocyclic group Chemical group 0.000 description 29
• 239000000741 silica gel Substances 0.000 description 29
• 229910002027 silica gel Inorganic materials 0.000 description 29
• OKKJLVBELUTLKV-MZCSYVLQSA-N Deuterated methanol Chemical compound [2H]OC([2H])([2H])[2H] OKKJLVBELUTLKV-MZCSYVLQSA-N 0.000 description 28
• 125000002619 bicyclic group Chemical group 0.000 description 28
• HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 27
• 125000004453 alkoxycarbonyl group Chemical group 0.000 description 26
• QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 24
• JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 24
• 238000010511 deprotection reaction Methods 0.000 description 24
• BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 24
• 229940086542 triethylamine Drugs 0.000 description 24
• 125000005842 heteroatom Chemical group 0.000 description 23
• 239000003112 inhibitor Substances 0.000 description 23
• 229910052760 oxygen Inorganic materials 0.000 description 23
• 239000003208 petroleum Substances 0.000 description 23
• QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 description 22
• VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 21
• QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 21
• 239000001301 oxygen Substances 0.000 description 21
• 229910052717 sulfur Inorganic materials 0.000 description 21
• 101000997835 Homo sapiens Tyrosine-protein kinase JAK1 Proteins 0.000 description 20
• NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 20
• 102100033438 Tyrosine-protein kinase JAK1 Human genes 0.000 description 20
• 239000012267 brine Substances 0.000 description 20
• HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 20
• 241001465754 Metazoa Species 0.000 description 19
• UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 19
• 229910052799 carbon Inorganic materials 0.000 description 19
• 230000002829 reductive effect Effects 0.000 description 19
• 239000011593 sulfur Substances 0.000 description 19
• CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 18
• 201000010099 disease Diseases 0.000 description 18
• 239000003921 oil Substances 0.000 description 17
• 125000006239 protecting group Chemical group 0.000 description 17
• 239000012043 crude product Substances 0.000 description 16
• 239000002253 acid Substances 0.000 description 15
• 125000000524 functional group Chemical group 0.000 description 15
• 239000010410 layer Substances 0.000 description 15
• 238000010898 silica gel chromatography Methods 0.000 description 15
• 238000004808 supercritical fluid chromatography Methods 0.000 description 15
• 150000001721 carbon Chemical group 0.000 description 14
• 125000004433 nitrogen atom Chemical group N* 0.000 description 13
• YBBRCQOCSYXUOC-UHFFFAOYSA-N sulfuryl dichloride Chemical class ClS(Cl)(=O)=O YBBRCQOCSYXUOC-UHFFFAOYSA-N 0.000 description 13
• HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 12
• BZLVMXJERCGZMT-UHFFFAOYSA-N Methyl tert-butyl ether Chemical compound COC(C)(C)C BZLVMXJERCGZMT-UHFFFAOYSA-N 0.000 description 12
• 238000004587 chromatography analysis Methods 0.000 description 12
• 239000012230 colorless oil Substances 0.000 description 12
• 229910000027 potassium carbonate Inorganic materials 0.000 description 12
• 125000004432 carbon atom Chemical group C* 0.000 description 11
• 230000000694 effects Effects 0.000 description 11
• 125000001028 difluoromethyl group Chemical group [H]C(F)(F)* 0.000 description 10
• 125000001188 haloalkyl group Chemical group 0.000 description 10
• 239000008194 pharmaceutical composition Substances 0.000 description 10
• KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical group CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 9
• 241000124008 Mammalia Species 0.000 description 9
• 239000000706 filtrate Substances 0.000 description 9
• 235000017557 sodium bicarbonate Nutrition 0.000 description 9
• 229910000030 sodium bicarbonate Inorganic materials 0.000 description 9
• NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical compound [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 8
• 101000997832 Homo sapiens Tyrosine-protein kinase JAK2 Proteins 0.000 description 8
• 206010061218 Inflammation Diseases 0.000 description 8
• IMNFDUFMRHMDMM-UHFFFAOYSA-N N-Heptane Chemical compound CCCCCCC IMNFDUFMRHMDMM-UHFFFAOYSA-N 0.000 description 8
• 102100033444 Tyrosine-protein kinase JAK2 Human genes 0.000 description 8
• 125000004391 aryl sulfonyl group Chemical group 0.000 description 8
• 150000001602 bicycloalkyls Chemical group 0.000 description 8
• HGCIXCUEYOPUTN-UHFFFAOYSA-N cyclohexene Chemical compound C1CCC=CC1 HGCIXCUEYOPUTN-UHFFFAOYSA-N 0.000 description 8
• 230000004054 inflammatory process Effects 0.000 description 8
• 230000014759 maintenance of location Effects 0.000 description 8
• QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 8
• 238000002953 preparative HPLC Methods 0.000 description 8
• 229940044551 receptor antagonist Drugs 0.000 description 8
• 239000002464 receptor antagonist Substances 0.000 description 8
• 238000010992 reflux Methods 0.000 description 8
• 239000011734 sodium Substances 0.000 description 8
• 125000002088 tosyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1C([H])([H])[H])S(*)(=O)=O 0.000 description 8
• HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 7
• 208000023275 Autoimmune disease Diseases 0.000 description 7
• UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 7
• MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 7
• CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 7
• 239000012425 OXONE® Substances 0.000 description 7
• 239000005557 antagonist Substances 0.000 description 7
• 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 7
• 125000001584 benzyloxycarbonyl group Chemical group C(=O)(OCC1=CC=CC=C1)* 0.000 description 7
• 230000015572 biosynthetic process Effects 0.000 description 7
• 239000003795 chemical substances by application Substances 0.000 description 7
• 238000001914 filtration Methods 0.000 description 7
• 229910052736 halogen Inorganic materials 0.000 description 7
• 150000002367 halogens Chemical class 0.000 description 7
• OKBMCNHOEMXPTM-UHFFFAOYSA-M potassium peroxymonosulfate Chemical compound [K+].OOS([O-])(=O)=O OKBMCNHOEMXPTM-UHFFFAOYSA-M 0.000 description 7
• BNRNXUUZRGQAQC-UHFFFAOYSA-N sildenafil Chemical compound CCCC1=NN(C)C(C(N2)=O)=C1N=C2C(C(=CC=1)OCC)=CC=1S(=O)(=O)N1CCN(C)CC1 BNRNXUUZRGQAQC-UHFFFAOYSA-N 0.000 description 7
• DYLIWHYUXAJDOJ-OWOJBTEDSA-N (e)-4-(6-aminopurin-9-yl)but-2-en-1-ol Chemical compound NC1=NC=NC2=C1N=CN2C\C=C\CO DYLIWHYUXAJDOJ-OWOJBTEDSA-N 0.000 description 6
• VHYFNPMBLIVWCW-UHFFFAOYSA-N 4-Dimethylaminopyridine Chemical compound CN(C)C1=CC=NC=C1 VHYFNPMBLIVWCW-UHFFFAOYSA-N 0.000 description 6
• YYROPELSRYBVMQ-UHFFFAOYSA-N 4-toluenesulfonyl chloride Chemical compound CC1=CC=C(S(Cl)(=O)=O)C=C1 YYROPELSRYBVMQ-UHFFFAOYSA-N 0.000 description 6
• PMATZTZNYRCHOR-CGLBZJNRSA-N Cyclosporin A Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 description 6
• IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 6
• NTYJJOPFIAHURM-UHFFFAOYSA-N Histamine Chemical compound NCCC1=CN=CN1 NTYJJOPFIAHURM-UHFFFAOYSA-N 0.000 description 6
• WMFOQBRAJBCJND-UHFFFAOYSA-M Lithium hydroxide Chemical compound [Li+].[OH-] WMFOQBRAJBCJND-UHFFFAOYSA-M 0.000 description 6
• UCKMPCXJQFINFW-UHFFFAOYSA-N Sulphide Chemical compound [S-2] UCKMPCXJQFINFW-UHFFFAOYSA-N 0.000 description 6
• 210000004027 cell Anatomy 0.000 description 6
• 239000003153 chemical reaction reagent Substances 0.000 description 6
• 239000000460 chlorine Substances 0.000 description 6
• 229940079593 drug Drugs 0.000 description 6
• 239000003814 drug Substances 0.000 description 6
• 239000003937 drug carrier Substances 0.000 description 6
• 238000004128 high performance liquid chromatography Methods 0.000 description 6
• UYWQUFXKFGHYNT-UHFFFAOYSA-N phenylmethyl ester of formic acid Natural products O=COCC1=CC=CC=C1 UYWQUFXKFGHYNT-UHFFFAOYSA-N 0.000 description 6
• NLKNQRATVPKPDG-UHFFFAOYSA-M potassium iodide Chemical compound [K+].[I-] NLKNQRATVPKPDG-UHFFFAOYSA-M 0.000 description 6
• 238000003786 synthesis reaction Methods 0.000 description 6
• FYSNRJHAOHDILO-UHFFFAOYSA-N thionyl chloride Chemical compound ClS(Cl)=O FYSNRJHAOHDILO-UHFFFAOYSA-N 0.000 description 6
• YIVCUHSQLMHGAY-UHFFFAOYSA-N 1-pyrimidin-4-ylcyclobutane-1,3-diamine hydrochloride Chemical compound Cl.N1=CN=C(C=C1)C1(CC(C1)N)N YIVCUHSQLMHGAY-UHFFFAOYSA-N 0.000 description 5
• NHQDETIJWKXCTC-UHFFFAOYSA-N 3-chloroperbenzoic acid Chemical compound OOC(=O)C1=CC=CC(Cl)=C1 NHQDETIJWKXCTC-UHFFFAOYSA-N 0.000 description 5
• 102000004127 Cytokines Human genes 0.000 description 5
• 108090000695 Cytokines Proteins 0.000 description 5
• 229940122245 Janus kinase inhibitor Drugs 0.000 description 5
• 239000008346 aqueous phase Substances 0.000 description 5
• 239000013058 crude material Substances 0.000 description 5
• 125000004186 cyclopropylmethyl group Chemical group [H]C([H])(*)C1([H])C([H])([H])C1([H])[H] 0.000 description 5
• 244000144972 livestock Species 0.000 description 5
• 208000015122 neurodegenerative disease Diseases 0.000 description 5
• 238000012746 preparative thin layer chromatography Methods 0.000 description 5
• 125000004527 pyrimidin-4-yl group Chemical group N1=CN=C(C=C1)* 0.000 description 5
• 102000005962 receptors Human genes 0.000 description 5
• 108020003175 receptors Proteins 0.000 description 5
• 239000002002 slurry Substances 0.000 description 5
• 239000000126 substance Substances 0.000 description 5
• NVBFHJWHLNUMCV-UHFFFAOYSA-N sulfamide Chemical class NS(N)(=O)=O NVBFHJWHLNUMCV-UHFFFAOYSA-N 0.000 description 5
• 230000001225 therapeutic effect Effects 0.000 description 5
• JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 5
• 230000009466 transformation Effects 0.000 description 5
• 125000004454 (C1-C6) alkoxycarbonyl group Chemical group 0.000 description 4
• 241000282472 Canis lupus familiaris Species 0.000 description 4
• 108010036949 Cyclosporine Proteins 0.000 description 4
• 108090001050 Phosphoric Diester Hydrolases Proteins 0.000 description 4
• 102000004861 Phosphoric Diester Hydrolases Human genes 0.000 description 4
• DWAQJAXMDSEUJJ-UHFFFAOYSA-M Sodium bisulfite Chemical compound [Na+].OS([O-])=O DWAQJAXMDSEUJJ-UHFFFAOYSA-M 0.000 description 4
• DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 4
• 239000004480 active ingredient Substances 0.000 description 4
• 235000019270 ammonium chloride Nutrition 0.000 description 4
• 239000000010 aprotic solvent Substances 0.000 description 4
• 230000008499 blood brain barrier function Effects 0.000 description 4
• 210000001218 blood-brain barrier Anatomy 0.000 description 4
• 230000037396 body weight Effects 0.000 description 4
• 238000004296 chiral HPLC Methods 0.000 description 4
• IJOOHPMOJXWVHK-UHFFFAOYSA-N chlorotrimethylsilane Chemical compound C[Si](C)(C)Cl IJOOHPMOJXWVHK-UHFFFAOYSA-N 0.000 description 4
• 239000012065 filter cake Substances 0.000 description 4
• 238000010438 heat treatment Methods 0.000 description 4
• 239000000543 intermediate Substances 0.000 description 4
• NUJOXMJBOLGQSY-UHFFFAOYSA-N manganese dioxide Chemical compound O=[Mn]=O NUJOXMJBOLGQSY-UHFFFAOYSA-N 0.000 description 4
• LDDHMLJTFXJGPI-UHFFFAOYSA-N memantine hydrochloride Chemical compound Cl.C1C(C2)CC3(C)CC1(C)CC2(N)C3 LDDHMLJTFXJGPI-UHFFFAOYSA-N 0.000 description 4
• BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 4
• 125000005010 perfluoroalkyl group Chemical group 0.000 description 4
• 239000000546 pharmaceutical excipient Substances 0.000 description 4
• 238000002360 preparation method Methods 0.000 description 4
• 229940044601 receptor agonist Drugs 0.000 description 4
• 239000000018 receptor agonist Substances 0.000 description 4
• 125000006413 ring segment Chemical group 0.000 description 4
• 229940076279 serotonin Drugs 0.000 description 4
• 230000011664 signaling Effects 0.000 description 4
• 235000010267 sodium hydrogen sulphite Nutrition 0.000 description 4
• 239000012453 solvate Substances 0.000 description 4
• 150000003458 sulfonic acid derivatives Chemical class 0.000 description 4
• 238000005694 sulfonylation reaction Methods 0.000 description 4
• 239000000725 suspension Substances 0.000 description 4
• 230000009885 systemic effect Effects 0.000 description 4
• KSDQPTTTZMJYGQ-OLZOCXBDSA-N (1r,3s)-3-n-benzyl-1-n-methylcyclopentane-1,3-diamine Chemical compound C1[C@H](NC)CC[C@@H]1NCC1=CC=CC=C1 KSDQPTTTZMJYGQ-OLZOCXBDSA-N 0.000 description 3
• RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 3
• AVFZOVWCLRSYKC-UHFFFAOYSA-N 1-methylpyrrolidine Chemical compound CN1CCCC1 AVFZOVWCLRSYKC-UHFFFAOYSA-N 0.000 description 3
• HFFXLYHRNRKAPM-UHFFFAOYSA-N 2,4,5-trichloro-n-(5-methyl-1,2-oxazol-3-yl)benzenesulfonamide Chemical compound O1C(C)=CC(NS(=O)(=O)C=2C(=CC(Cl)=C(Cl)C=2)Cl)=N1 HFFXLYHRNRKAPM-UHFFFAOYSA-N 0.000 description 3
• ZMMHJHWUKIEUJA-UHFFFAOYSA-N 3-azabicyclo[3.1.0]hexane-1-carbonitrile Chemical compound C1NCC2(C#N)C1C2 ZMMHJHWUKIEUJA-UHFFFAOYSA-N 0.000 description 3
• QCQCHGYLTSGIGX-GHXANHINSA-N 4-[[(3ar,5ar,5br,7ar,9s,11ar,11br,13as)-5a,5b,8,8,11a-pentamethyl-3a-[(5-methylpyridine-3-carbonyl)amino]-2-oxo-1-propan-2-yl-4,5,6,7,7a,9,10,11,11b,12,13,13a-dodecahydro-3h-cyclopenta[a]chrysen-9-yl]oxy]-2,2-dimethyl-4-oxobutanoic acid Chemical compound N([C@@]12CC[C@@]3(C)[C@]4(C)CC[C@H]5C(C)(C)[C@@H](OC(=O)CC(C)(C)C(O)=O)CC[C@]5(C)[C@H]4CC[C@@H]3C1=C(C(C2)=O)C(C)C)C(=O)C1=CN=CC(C)=C1 QCQCHGYLTSGIGX-GHXANHINSA-N 0.000 description 3
• KPYSYYIEGFHWSV-UHFFFAOYSA-N Baclofen Chemical compound OC(=O)CC(CN)C1=CC=C(Cl)C=C1 KPYSYYIEGFHWSV-UHFFFAOYSA-N 0.000 description 3
• UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 3
• RQYJLWOKIRQLAA-BJHJDKERSA-N C([C@H]1C[C@H](C1)N(C)C=1C=2C=CNC=2N=CN=1)S(=O)(=O)CC1CC(F)(F)C1 Chemical compound C([C@H]1C[C@H](C1)N(C)C=1C=2C=CNC=2N=CN=1)S(=O)(=O)CC1CC(F)(F)C1 RQYJLWOKIRQLAA-BJHJDKERSA-N 0.000 description 3
• AYQMQHMCFYCBTJ-OKILXGFUSA-N C([C@H]1C[C@H](C1)N(C)C=1C=2C=CNC=2N=CN=1)S(=O)(=O)CCC1CC1 Chemical compound C([C@H]1C[C@H](C1)N(C)C=1C=2C=CNC=2N=CN=1)S(=O)(=O)CCC1CC1 AYQMQHMCFYCBTJ-OKILXGFUSA-N 0.000 description 3
• KZSUFPIJESVIGH-BETUJISGSA-N C([C@H]1C[C@H](C1)N(C)C=1C=2C=CNC=2N=CN=1)S(=O)(=O)N1CCC(F)(F)CC1 Chemical compound C([C@H]1C[C@H](C1)N(C)C=1C=2C=CNC=2N=CN=1)S(=O)(=O)N1CCC(F)(F)CC1 KZSUFPIJESVIGH-BETUJISGSA-N 0.000 description 3
• 241000282693 Cercopithecidae Species 0.000 description 3
• VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 3
• RGHNJXZEOKUKBD-SQOUGZDYSA-M D-gluconate Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O RGHNJXZEOKUKBD-SQOUGZDYSA-M 0.000 description 3
• QMMFVYPAHWMCMS-UHFFFAOYSA-N Dimethyl sulfide Chemical compound CSC QMMFVYPAHWMCMS-UHFFFAOYSA-N 0.000 description 3
• 102000004190 Enzymes Human genes 0.000 description 3
• 108090000790 Enzymes Proteins 0.000 description 3
• 102000003951 Erythropoietin Human genes 0.000 description 3
• 108090000394 Erythropoietin Proteins 0.000 description 3
• 101000844245 Homo sapiens Non-receptor tyrosine-protein kinase TYK2 Proteins 0.000 description 3
• 101000934996 Homo sapiens Tyrosine-protein kinase JAK3 Proteins 0.000 description 3
• CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical class Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 3
• DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 3
• 108010005716 Interferon beta-1a Proteins 0.000 description 3
• 108010005714 Interferon beta-1b Proteins 0.000 description 3
• FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 3
• UEQUQVLFIPOEMF-UHFFFAOYSA-N Mianserin Chemical compound C1C2=CC=CC=C2N2CCN(C)CC2C2=CC=CC=C21 UEQUQVLFIPOEMF-UHFFFAOYSA-N 0.000 description 3
• IUEWXNHSKRWHDY-UHFFFAOYSA-N N-[3-[methyl(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino]cyclobutyl]propane-1-sulfonamide Chemical compound C1C(NS(=O)(=O)CCC)CC1N(C)C1=NC=NC2=C1C=CN2 IUEWXNHSKRWHDY-UHFFFAOYSA-N 0.000 description 3
• AHVYPIQETPWLSZ-UHFFFAOYSA-N N-methyl-pyrrolidine Natural products CN1CC=CC1 AHVYPIQETPWLSZ-UHFFFAOYSA-N 0.000 description 3
• FAIIFDPAEUKBEP-UHFFFAOYSA-N Nilvadipine Chemical compound COC(=O)C1=C(C#N)NC(C)=C(C(=O)OC(C)C)C1C1=CC=CC([N+]([O-])=O)=C1 FAIIFDPAEUKBEP-UHFFFAOYSA-N 0.000 description 3
• 102100032028 Non-receptor tyrosine-protein kinase TYK2 Human genes 0.000 description 3
• 241000283973 Oryctolagus cuniculus Species 0.000 description 3
• 102000001253 Protein Kinase Human genes 0.000 description 3
• RWRDLPDLKQPQOW-UHFFFAOYSA-N Pyrrolidine Chemical compound C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 description 3
• KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 3
• 102100025387 Tyrosine-protein kinase JAK3 Human genes 0.000 description 3
• 206010046851 Uveitis Diseases 0.000 description 3
• 239000000556 agonist Substances 0.000 description 3
• 125000002877 alkyl aryl group Chemical group 0.000 description 3
• 150000001350 alkyl halides Chemical class 0.000 description 3
• KRMDCWKBEZIMAB-UHFFFAOYSA-N amitriptyline Chemical compound C1CC2=CC=CC=C2C(=CCCN(C)C)C2=CC=CC=C21 KRMDCWKBEZIMAB-UHFFFAOYSA-N 0.000 description 3
• WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 3
• DRROTPCCFFMHNX-UHFFFAOYSA-N benzyl n-[3-(methylamino)cyclobutyl]carbamate Chemical compound C1C(NC)CC1NC(=O)OCC1=CC=CC=C1 DRROTPCCFFMHNX-UHFFFAOYSA-N 0.000 description 3
• XXRMYXBSBOVVBH-UHFFFAOYSA-N bethanechol chloride Chemical compound [Cl-].C[N+](C)(C)CC(C)OC(N)=O XXRMYXBSBOVVBH-UHFFFAOYSA-N 0.000 description 3
• WQAQPCDUOCURKW-UHFFFAOYSA-N butanethiol Chemical compound CCCCS WQAQPCDUOCURKW-UHFFFAOYSA-N 0.000 description 3
• FJDQFPXHSGXQBY-UHFFFAOYSA-L caesium carbonate Chemical compound [Cs+].[Cs+].[O-]C([O-])=O FJDQFPXHSGXQBY-UHFFFAOYSA-L 0.000 description 3
• 229910000024 caesium carbonate Inorganic materials 0.000 description 3
• 239000003054 catalyst Substances 0.000 description 3
• 125000001309 chloro group Chemical group Cl* 0.000 description 3
• KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
• 125000004122 cyclic group Chemical group 0.000 description 3
• SVPZJHKVRMRREG-UHFFFAOYSA-N cyclopentanecarbonitrile Chemical compound N#CC1CCCC1 SVPZJHKVRMRREG-UHFFFAOYSA-N 0.000 description 3
• IGSKHXTUVXSOMB-UHFFFAOYSA-N cyclopropylmethanamine Chemical compound NCC1CC1 IGSKHXTUVXSOMB-UHFFFAOYSA-N 0.000 description 3
• XJPMSKSCGIBWPC-UHFFFAOYSA-N cyclopropylmethanesulfonyl chloride Chemical compound ClS(=O)(=O)CC1CC1 XJPMSKSCGIBWPC-UHFFFAOYSA-N 0.000 description 3
• 108010057085 cytokine receptors Proteins 0.000 description 3
• 102000003675 cytokine receptors Human genes 0.000 description 3
• UAOMVDZJSHZZME-UHFFFAOYSA-N diisopropylamine Chemical compound CC(C)NC(C)C UAOMVDZJSHZZME-UHFFFAOYSA-N 0.000 description 3
• XWAIAVWHZJNZQQ-UHFFFAOYSA-N donepezil hydrochloride Chemical compound [H+].[Cl-].O=C1C=2C=C(OC)C(OC)=CC=2CC1CC(CC1)CCN1CC1=CC=CC=C1 XWAIAVWHZJNZQQ-UHFFFAOYSA-N 0.000 description 3
• VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 description 3
• 239000002552 dosage form Substances 0.000 description 3
• 230000008482 dysregulation Effects 0.000 description 3
• 201000002491 encephalomyelitis Diseases 0.000 description 3
• 229940088598 enzyme Drugs 0.000 description 3
• 229940105423 erythropoietin Drugs 0.000 description 3
• PQVSTLUFSYVLTO-UHFFFAOYSA-N ethyl n-ethoxycarbonylcarbamate Chemical compound CCOC(=O)NC(=O)OCC PQVSTLUFSYVLTO-UHFFFAOYSA-N 0.000 description 3
• 238000001704 evaporation Methods 0.000 description 3
• 230000008020 evaporation Effects 0.000 description 3
• 239000000284 extract Substances 0.000 description 3
• 238000005755 formation reaction Methods 0.000 description 3
• 238000009472 formulation Methods 0.000 description 3
• BTCSSZJGUNDROE-UHFFFAOYSA-N gamma-aminobutyric acid Chemical compound NCCCC(O)=O BTCSSZJGUNDROE-UHFFFAOYSA-N 0.000 description 3
• 229940050410 gluconate Drugs 0.000 description 3
• 150000004820 halides Chemical class 0.000 description 3
• 229960001340 histamine Drugs 0.000 description 3
• 150000002430 hydrocarbons Chemical group 0.000 description 3
• 125000004435 hydrogen atom Chemical group [H]* 0.000 description 3
• XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 3
• DOUHZFSGSXMPIE-UHFFFAOYSA-N hydroxidooxidosulfur(.) Chemical compound [O]SO DOUHZFSGSXMPIE-UHFFFAOYSA-N 0.000 description 3
• 206010023332 keratitis Diseases 0.000 description 3
• 229940040692 lithium hydroxide monohydrate Drugs 0.000 description 3
• GLXDVVHUTZTUQK-UHFFFAOYSA-M lithium hydroxide monohydrate Substances [Li+].O.[OH-] GLXDVVHUTZTUQK-UHFFFAOYSA-M 0.000 description 3
• 229910052943 magnesium sulfate Inorganic materials 0.000 description 3
• 235000019341 magnesium sulphate Nutrition 0.000 description 3
• 239000000463 material Substances 0.000 description 3
• VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 3
• 150000002825 nitriles Chemical class 0.000 description 3
• 239000007800 oxidant agent Substances 0.000 description 3
• NXJCBFBQEVOTOW-UHFFFAOYSA-L palladium(2+);dihydroxide Chemical compound O[Pd]O NXJCBFBQEVOTOW-UHFFFAOYSA-L 0.000 description 3
• 230000037361 pathway Effects 0.000 description 3
• OSHXXOCGXCIKKN-UHFFFAOYSA-N phenylmethoxycarbamic acid Chemical class OC(=O)NOCC1=CC=CC=C1 OSHXXOCGXCIKKN-UHFFFAOYSA-N 0.000 description 3
• 239000002798 polar solvent Substances 0.000 description 3
• OXCMYAYHXIHQOA-UHFFFAOYSA-N potassium;[2-butyl-5-chloro-3-[[4-[2-(1,2,4-triaza-3-azanidacyclopenta-1,4-dien-5-yl)phenyl]phenyl]methyl]imidazol-4-yl]methanol Chemical compound [K+].CCCCC1=NC(Cl)=C(CO)N1CC1=CC=C(C=2C(=CC=CC=2)C2=N[N-]N=N2)C=C1 OXCMYAYHXIHQOA-UHFFFAOYSA-N 0.000 description 3
• XOFYZVNMUHMLCC-ZPOLXVRWSA-N prednisone Chemical compound O=C1C=C[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 XOFYZVNMUHMLCC-ZPOLXVRWSA-N 0.000 description 3
• 230000008569 process Effects 0.000 description 3
• 239000000047 product Substances 0.000 description 3
• KPBSJEBFALFJTO-UHFFFAOYSA-N propane-1-sulfonyl chloride Chemical compound CCCS(Cl)(=O)=O KPBSJEBFALFJTO-UHFFFAOYSA-N 0.000 description 3
• 108060006633 protein kinase Proteins 0.000 description 3
• 108090000623 proteins and genes Proteins 0.000 description 3
• 238000004007 reversed phase HPLC Methods 0.000 description 3
• UPZKWBRGTGMPPT-UHFFFAOYSA-N s-[3-(cyanomethyl)-3-methylcyclobutyl] ethanethioate Chemical compound CC(=O)SC1CC(C)(CC#N)C1 UPZKWBRGTGMPPT-UHFFFAOYSA-N 0.000 description 3
• 238000000926 separation method Methods 0.000 description 3
• 229910052708 sodium Inorganic materials 0.000 description 3
• 239000012312 sodium hydride Substances 0.000 description 3
• 229910000104 sodium hydride Inorganic materials 0.000 description 3
• 239000011877 solvent mixture Substances 0.000 description 3
• QAHVHSLSRLSVGS-UHFFFAOYSA-N sulfamoyl chloride Chemical group NS(Cl)(=O)=O QAHVHSLSRLSVGS-UHFFFAOYSA-N 0.000 description 3
• 150000003457 sulfones Chemical class 0.000 description 3
• 230000006103 sulfonylation Effects 0.000 description 3
• 208000024891 symptom Diseases 0.000 description 3
• 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 3
• 238000002560 therapeutic procedure Methods 0.000 description 3
• 150000007970 thio esters Chemical class 0.000 description 3
• 238000012546 transfer Methods 0.000 description 3
• SFLSHLFXELFNJZ-QMMMGPOBSA-N (-)-norepinephrine Chemical compound NC[C@H](O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-QMMMGPOBSA-N 0.000 description 2
• VHWVXFKITKKZGZ-UHFFFAOYSA-N (1-methyl-3-methylidenecyclobutyl)methanol Chemical compound OCC1(C)CC(=C)C1 VHWVXFKITKKZGZ-UHFFFAOYSA-N 0.000 description 2
• UUMFLEUTZDVHNQ-UHFFFAOYSA-N (3,3-difluorocyclobutyl)methanesulfonyl chloride Chemical compound FC1(F)CC(CS(Cl)(=O)=O)C1 UUMFLEUTZDVHNQ-UHFFFAOYSA-N 0.000 description 2
• BCKQZBURCGQHFI-UHFFFAOYSA-N (3,3-difluorocyclobutyl)methyl 4-methylbenzenesulfonate Chemical compound C1=CC(C)=CC=C1S(=O)(=O)OCC1CC(F)(F)C1 BCKQZBURCGQHFI-UHFFFAOYSA-N 0.000 description 2
• MKJIEFSOBYUXJB-HOCLYGCPSA-N (3S,11bS)-9,10-dimethoxy-3-isobutyl-1,3,4,6,7,11b-hexahydro-2H-pyrido[2,1-a]isoquinolin-2-one Chemical compound C1CN2C[C@H](CC(C)C)C(=O)C[C@H]2C2=C1C=C(OC)C(OC)=C2 MKJIEFSOBYUXJB-HOCLYGCPSA-N 0.000 description 2
• VSTXCZGEEVFJES-UHFFFAOYSA-N 1-cycloundecyl-1,5-diazacycloundec-5-ene Chemical compound C1CCCCCC(CCCC1)N1CCCCCC=NCCC1 VSTXCZGEEVFJES-UHFFFAOYSA-N 0.000 description 2
• CXCHEKCRJQRVNG-UHFFFAOYSA-N 2,2,2-trifluoroethanesulfonyl chloride Chemical compound FC(F)(F)CS(Cl)(=O)=O CXCHEKCRJQRVNG-UHFFFAOYSA-N 0.000 description 2
• GHXBPCSSQOKKGB-UHFFFAOYSA-N 2,4-dichloro-7h-pyrrolo[2,3-d]pyrimidine Chemical compound ClC1=NC(Cl)=C2C=CNC2=N1 GHXBPCSSQOKKGB-UHFFFAOYSA-N 0.000 description 2
• JYWKEVKEKOTYEX-UHFFFAOYSA-N 2,6-dibromo-4-chloroiminocyclohexa-2,5-dien-1-one Chemical compound ClN=C1C=C(Br)C(=O)C(Br)=C1 JYWKEVKEKOTYEX-UHFFFAOYSA-N 0.000 description 2
• DEAYGFQVUHWMCP-UHFFFAOYSA-N 2-(3-hydroxycyclobutyl)acetonitrile Chemical compound OC1CC(CC#N)C1 DEAYGFQVUHWMCP-UHFFFAOYSA-N 0.000 description 2
• IZXIZTKNFFYFOF-UHFFFAOYSA-N 2-Oxazolidone Chemical class O=C1NCCO1 IZXIZTKNFFYFOF-UHFFFAOYSA-N 0.000 description 2
• LDLCZOVUSADOIV-UHFFFAOYSA-N 2-bromoethanol Chemical compound OCCBr LDLCZOVUSADOIV-UHFFFAOYSA-N 0.000 description 2
• 125000001731 2-cyanoethyl group Chemical group [H]C([H])(*)C([H])([H])C#N 0.000 description 2
• IOSAAWHGJUZBOG-UHFFFAOYSA-N 3-(6-amino-9h-purin-9-yl)nonan-2-ol Chemical compound N1=CN=C2N(C(C(C)O)CCCCCC)C=NC2=C1N IOSAAWHGJUZBOG-UHFFFAOYSA-N 0.000 description 2
• FFAAXAGACNIQJH-UHFFFAOYSA-N 3-cyanopyrrolidine-1-sulfonyl chloride Chemical compound ClS(=O)(=O)N1CCC(C#N)C1 FFAAXAGACNIQJH-UHFFFAOYSA-N 0.000 description 2
• OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 2
• RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 description 2
• 102000013455 Amyloid beta-Peptides Human genes 0.000 description 2
• 108010090849 Amyloid beta-Peptides Proteins 0.000 description 2
• 102000001381 Arachidonate 5-Lipoxygenase Human genes 0.000 description 2
• 108010093579 Arachidonate 5-lipoxygenase Proteins 0.000 description 2
• BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 2
• 241000271566 Aves Species 0.000 description 2
• 241000283690 Bos taurus Species 0.000 description 2
• 102000004219 Brain-derived neurotrophic factor Human genes 0.000 description 2
• 108090000715 Brain-derived neurotrophic factor Proteins 0.000 description 2
• CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 description 2
• CRHXEKUJKIWFQM-NWDGAFQWSA-N C(N)(O[C@H]1C[C@H](CC1)NCC1=CC=CC=C1)=O Chemical compound C(N)(O[C@H]1C[C@H](CC1)NCC1=CC=CC=C1)=O CRHXEKUJKIWFQM-NWDGAFQWSA-N 0.000 description 2
• WSXWVQVIBYGVLW-BGYRXZFFSA-N C([C@H]1C[C@H](C1)N(C)C=1C=2C=CN(C=2N=CN=1)S(=O)(=O)C=1C=CC(C)=CC=1)S(=O)(=O)CCC1CC1 Chemical compound C([C@H]1C[C@H](C1)N(C)C=1C=2C=CN(C=2N=CN=1)S(=O)(=O)C=1C=CC(C)=CC=1)S(=O)(=O)CCC1CC1 WSXWVQVIBYGVLW-BGYRXZFFSA-N 0.000 description 2
• OTYJYNWMTCGGCJ-BGYRXZFFSA-N C([C@H]1C[C@H](C1)N(C)C=1C=2C=CN(C=2N=CN=1)S(=O)(=O)C=1C=CC(C)=CC=1)SCCC1CC1 Chemical compound C([C@H]1C[C@H](C1)N(C)C=1C=2C=CN(C=2N=CN=1)S(=O)(=O)C=1C=CC(C)=CC=1)SCCC1CC1 OTYJYNWMTCGGCJ-BGYRXZFFSA-N 0.000 description 2
• AHTMSATVFMHGNS-BETUJISGSA-N C([C@H]1C[C@H](C1)N(C)C=1C=2C=CNC=2N=CN=1)S(=O)(=O)N1CCC(O)(C(F)(F)F)CC1 Chemical compound C([C@H]1C[C@H](C1)N(C)C=1C=2C=CNC=2N=CN=1)S(=O)(=O)N1CCC(O)(C(F)(F)F)CC1 AHTMSATVFMHGNS-BETUJISGSA-N 0.000 description 2
• WVPXLLNKSSQYKI-MELADBBJSA-N C([C@H]1C[C@H](C1)N(C)C=1C=2C=CNC=2N=CN=1)S(=O)(=O)N1CC[C@@H](C#N)C1 Chemical compound C([C@H]1C[C@H](C1)N(C)C=1C=2C=CNC=2N=CN=1)S(=O)(=O)N1CC[C@@H](C#N)C1 WVPXLLNKSSQYKI-MELADBBJSA-N 0.000 description 2
• WVPXLLNKSSQYKI-MCIONIFRSA-N C([C@H]1C[C@H](C1)N(C)C=1C=2C=CNC=2N=CN=1)S(=O)(=O)N1CC[C@H](C#N)C1 Chemical compound C([C@H]1C[C@H](C1)N(C)C=1C=2C=CNC=2N=CN=1)S(=O)(=O)N1CC[C@H](C#N)C1 WVPXLLNKSSQYKI-MCIONIFRSA-N 0.000 description 2
• ABNHVRDQFQPUGK-BJHJDKERSA-N C([C@H]1C[C@H](C1)N(C)C=1C=2C=CNC=2N=CN=1)SCC1CC(F)(F)C1 Chemical compound C([C@H]1C[C@H](C1)N(C)C=1C=2C=CNC=2N=CN=1)SCC1CC(F)(F)C1 ABNHVRDQFQPUGK-BJHJDKERSA-N 0.000 description 2
• PMBVJRGBYOKWGM-XYPWUTKMSA-N C1N(C(C)C)CCC1S(=O)(=O)C[C@@H]1C[C@H](N(C)C=2C=3C=CNC=3N=CN=2)C1 Chemical class C1N(C(C)C)CCC1S(=O)(=O)C[C@@H]1C[C@H](N(C)C=2C=3C=CNC=3N=CN=2)C1 PMBVJRGBYOKWGM-XYPWUTKMSA-N 0.000 description 2
• JXXOAWDMPAWACX-HAQNSBGRSA-N C1[C@@H](CS(=O)(=O)CCC)C[C@@H]1N(C)C1=NC=NC2=C1C=CN2 Chemical compound C1[C@@H](CS(=O)(=O)CCC)C[C@@H]1N(C)C1=NC=NC2=C1C=CN2 JXXOAWDMPAWACX-HAQNSBGRSA-N 0.000 description 2
• MWMGOQSAHFDXOV-BETUJISGSA-N C1[C@@H](CS(=O)(=O)CCCC)C[C@H]1N(C)C1=NC=NC2=C1C=CN2 Chemical compound C1[C@@H](CS(=O)(=O)CCCC)C[C@H]1N(C)C1=NC=NC2=C1C=CN2 MWMGOQSAHFDXOV-BETUJISGSA-N 0.000 description 2
• KDQWCMXENDRNQA-CALCHBBNSA-N CN([C@@H]1C[C@H](CSC(C)=O)C1)c1ncnc2n(ccc12)S(=O)(=O)c1ccc(C)cc1 Chemical compound CN([C@@H]1C[C@H](CSC(C)=O)C1)c1ncnc2n(ccc12)S(=O)(=O)c1ccc(C)cc1 KDQWCMXENDRNQA-CALCHBBNSA-N 0.000 description 2
• SEGOMLOBKLSFQA-LPOKXYRGSA-N CN([C@H]1C[C@H](C1)NS(=O)(=O)N1CC2CC(O2)C1)C(C=1C=C2)=NC=NC=1N2S(=O)(=O)C1=CC=C(C)C=C1 Chemical compound CN([C@H]1C[C@H](C1)NS(=O)(=O)N1CC2CC(O2)C1)C(C=1C=C2)=NC=NC=1N2S(=O)(=O)C1=CC=C(C)C=C1 SEGOMLOBKLSFQA-LPOKXYRGSA-N 0.000 description 2
• KITABLLENVFMQT-KOFHJDLBSA-N CN([C@H]1C[C@H](C1)NS(=O)(=O)N1C[C@@]2(C[C@@H]2C1)C#N)C1=NC=NC2=C1C=CN2 Chemical compound CN([C@H]1C[C@H](C1)NS(=O)(=O)N1C[C@@]2(C[C@@H]2C1)C#N)C1=NC=NC2=C1C=CN2 KITABLLENVFMQT-KOFHJDLBSA-N 0.000 description 2
• OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 2
• 102100028892 Cardiotrophin-1 Human genes 0.000 description 2
• 102100029391 Cardiotrophin-like cytokine factor 1 Human genes 0.000 description 2
• 101710107109 Cardiotrophin-like cytokine factor 1 Proteins 0.000 description 2
• 208000024172 Cardiovascular disease Diseases 0.000 description 2
• 102000006378 Catechol O-methyltransferase Human genes 0.000 description 2
• 108020002739 Catechol O-methyltransferase Proteins 0.000 description 2
• 241000700198 Cavia Species 0.000 description 2
• KZBUYRJDOAKODT-UHFFFAOYSA-N Chlorine Chemical compound ClCl KZBUYRJDOAKODT-UHFFFAOYSA-N 0.000 description 2
• 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 description 2
• ROWGHYMBNGHROG-IZLXSQMJSA-N ClS(=O)(=O)[C@H]1C[C@H](CC#N)C1 Chemical compound ClS(=O)(=O)[C@H]1C[C@H](CC#N)C1 ROWGHYMBNGHROG-IZLXSQMJSA-N 0.000 description 2
• GJSURZIOUXUGAL-UHFFFAOYSA-N Clonidine Chemical compound ClC1=CC=CC(Cl)=C1NC1=NCCN1 GJSURZIOUXUGAL-UHFFFAOYSA-N 0.000 description 2
• 206010010904 Convulsion Diseases 0.000 description 2
• XTHFKEDIFFGKHM-UHFFFAOYSA-N Dimethoxyethane Chemical compound COCCOC XTHFKEDIFFGKHM-UHFFFAOYSA-N 0.000 description 2
• 102000003837 Epithelial Sodium Channels Human genes 0.000 description 2
• 108090000140 Epithelial Sodium Channels Proteins 0.000 description 2
• 241000283086 Equidae Species 0.000 description 2
• 241000282326 Felis catus Species 0.000 description 2
• 108090000379 Fibroblast growth factor 2 Proteins 0.000 description 2
• 241000699694 Gerbillinae Species 0.000 description 2
• 208000007465 Giant cell arteritis Diseases 0.000 description 2
• 108010072051 Glatiramer Acetate Proteins 0.000 description 2
• 102000034615 Glial cell line-derived neurotrophic factor Human genes 0.000 description 2
• 108091010837 Glial cell line-derived neurotrophic factor Proteins 0.000 description 2
• DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
• 241000282412 Homo Species 0.000 description 2
• WTDHULULXKLSOZ-UHFFFAOYSA-N Hydroxylamine hydrochloride Chemical compound Cl.ON WTDHULULXKLSOZ-UHFFFAOYSA-N 0.000 description 2
• 206010021143 Hypoxia Diseases 0.000 description 2
• HEFNNWSXXWATRW-UHFFFAOYSA-N Ibuprofen Chemical compound CC(C)CC1=CC=C(C(C)C(O)=O)C=C1 HEFNNWSXXWATRW-UHFFFAOYSA-N 0.000 description 2
• 108090000467 Interferon-beta Proteins 0.000 description 2
• 102000003814 Interleukin-10 Human genes 0.000 description 2
• 108090000174 Interleukin-10 Proteins 0.000 description 2
• 102100030703 Interleukin-22 Human genes 0.000 description 2
• 102000042838 JAK family Human genes 0.000 description 2
• 108091082332 JAK family Proteins 0.000 description 2
• 208000003456 Juvenile Arthritis Diseases 0.000 description 2
• 239000012359 Methanesulfonyl chloride Substances 0.000 description 2
• BAVYZALUXZFZLV-UHFFFAOYSA-N Methylamine Chemical compound NC BAVYZALUXZFZLV-UHFFFAOYSA-N 0.000 description 2
• 102000010909 Monoamine Oxidase Human genes 0.000 description 2
• 108010062431 Monoamine oxidase Proteins 0.000 description 2
• 229940122694 Muscarinic M3 receptor antagonist Drugs 0.000 description 2
• YGPVQOGJEBLMHD-IYBDPMFKSA-N N([C@H]1C[C@H](C1)N(C)C=1C=2C=CN(C=2N=CN=1)S(=O)(=O)C=1C=CC(C)=CC=1)S(=O)(=O)N1CCOC1=O Chemical compound N([C@H]1C[C@H](C1)N(C)C=1C=2C=CN(C=2N=CN=1)S(=O)(=O)C=1C=CC(C)=CC=1)S(=O)(=O)N1CCOC1=O YGPVQOGJEBLMHD-IYBDPMFKSA-N 0.000 description 2
• XHRZECXFXFEXHN-PHIMTYICSA-N N([C@H]1C[C@H](C1)N(C)C=1C=2C=CNC=2N=CN=1)S(=O)(=O)C1=CN=C(C)S1 Chemical compound N([C@H]1C[C@H](C1)N(C)C=1C=2C=CNC=2N=CN=1)S(=O)(=O)C1=CN=C(C)S1 XHRZECXFXFEXHN-PHIMTYICSA-N 0.000 description 2
• DSNWWEIXZLXIAO-TXEJJXNPSA-N N([C@H]1C[C@H](C1)N(C)C=1C=2C=CNC=2N=CN=1)S(=O)(=O)CC1COC1 Chemical compound N([C@H]1C[C@H](C1)N(C)C=1C=2C=CNC=2N=CN=1)S(=O)(=O)CC1COC1 DSNWWEIXZLXIAO-TXEJJXNPSA-N 0.000 description 2
• HOKKHZGPKSLGJE-GSVOUGTGSA-N N-Methyl-D-aspartic acid Chemical compound CN[C@@H](C(O)=O)CC(O)=O HOKKHZGPKSLGJE-GSVOUGTGSA-N 0.000 description 2
• SECXISVLQFMRJM-UHFFFAOYSA-N N-Methylpyrrolidone Chemical compound CN1CCCC1=O SECXISVLQFMRJM-UHFFFAOYSA-N 0.000 description 2
• JRNVZBWKYDBUCA-UHFFFAOYSA-N N-chlorosuccinimide Chemical compound ClN1C(=O)CCC1=O JRNVZBWKYDBUCA-UHFFFAOYSA-N 0.000 description 2
• 108010025020 Nerve Growth Factor Proteins 0.000 description 2
• 102000015336 Nerve Growth Factor Human genes 0.000 description 2
• 208000025966 Neurological disease Diseases 0.000 description 2
• 102000004230 Neurotrophin 3 Human genes 0.000 description 2
• 108090000742 Neurotrophin 3 Proteins 0.000 description 2
• PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 2
• 108091007960 PI3Ks Proteins 0.000 description 2
• 102000003993 Phosphatidylinositol 3-kinases Human genes 0.000 description 2
• 108090000430 Phosphatidylinositol 3-kinases Proteins 0.000 description 2
• 229940123932 Phosphodiesterase 4 inhibitor Drugs 0.000 description 2
• 229940123333 Phosphodiesterase 5 inhibitor Drugs 0.000 description 2
• 108091000080 Phosphotransferase Proteins 0.000 description 2
• ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 2
• 102000004022 Protein-Tyrosine Kinases Human genes 0.000 description 2
• 108090000412 Protein-Tyrosine Kinases Proteins 0.000 description 2
• LOUPRKONTZGTKE-WZBLMQSHSA-N Quinine Chemical compound C([C@H]([C@H](C1)C=C)C2)C[N@@]1[C@@H]2[C@H](O)C1=CC=NC2=CC=C(OC)C=C21 LOUPRKONTZGTKE-WZBLMQSHSA-N 0.000 description 2
• SMWDFEZZVXVKRB-UHFFFAOYSA-N Quinoline Chemical compound N1=CC=CC2=CC=CC=C21 SMWDFEZZVXVKRB-UHFFFAOYSA-N 0.000 description 2
• 241000283984 Rodentia Species 0.000 description 2
• WQDUMFSSJAZKTM-UHFFFAOYSA-N Sodium methoxide Chemical compound [Na+].[O-]C WQDUMFSSJAZKTM-UHFFFAOYSA-N 0.000 description 2
• 241000282887 Suidae Species 0.000 description 2
• QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 2
• 206010042742 Sympathetic ophthalmia Diseases 0.000 description 2
• 102100034195 Thrombopoietin Human genes 0.000 description 2
• HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 2
• DIZHTQAXUYZPBW-UHFFFAOYSA-N [3-(cyanomethyl)oxetan-3-yl]methanesulfonyl chloride Chemical compound ClS(=O)(=O)CC1(CC#N)COC1 DIZHTQAXUYZPBW-UHFFFAOYSA-N 0.000 description 2
• LXXIHOWGNXTMOG-UHFFFAOYSA-N [3-(methylamino)cyclobutyl]methanol Chemical compound CNC1CC(CO)C1 LXXIHOWGNXTMOG-UHFFFAOYSA-N 0.000 description 2
• 229960001138 acetylsalicylic acid Drugs 0.000 description 2
• NDAUXUAQIAJITI-UHFFFAOYSA-N albuterol Chemical compound CC(C)(C)NCC(O)C1=CC=C(O)C(CO)=C1 NDAUXUAQIAJITI-UHFFFAOYSA-N 0.000 description 2
• 239000002168 alkylating agent Substances 0.000 description 2
• 229940100198 alkylating agent Drugs 0.000 description 2
• 150000001414 amino alcohols Chemical class 0.000 description 2
• 230000003110 anti-inflammatory effect Effects 0.000 description 2
• VMWNQDUVQKEIOC-CYBMUJFWSA-N apomorphine Chemical compound C([C@H]1N(C)CC2)C3=CC=C(O)C(O)=C3C3=C1C2=CC=C3 VMWNQDUVQKEIOC-CYBMUJFWSA-N 0.000 description 2
• 239000007864 aqueous solution Substances 0.000 description 2
• 206010003246 arthritis Diseases 0.000 description 2
• VHGCDTVCOLNTBX-QGZVFWFLSA-N atomoxetine Chemical compound O([C@H](CCNC)C=1C=CC=CC=1)C1=CC=CC=C1C VHGCDTVCOLNTBX-QGZVFWFLSA-N 0.000 description 2
• 229940072885 atopica Drugs 0.000 description 2
• LMEKQMALGUDUQG-UHFFFAOYSA-N azathioprine Chemical compound CN1C=NC([N+]([O-])=O)=C1SC1=NC=NC2=C1NC=N2 LMEKQMALGUDUQG-UHFFFAOYSA-N 0.000 description 2
• HUMNYLRZRPPJDN-UHFFFAOYSA-N benzaldehyde Chemical compound O=CC1=CC=CC=C1 HUMNYLRZRPPJDN-UHFFFAOYSA-N 0.000 description 2
• ZMHVOVQAUQAVMY-NWDGAFQWSA-N benzyl n-[(1r,3s)-3-aminocyclopentyl]carbamate Chemical compound C1[C@@H](N)CC[C@H]1NC(=O)OCC1=CC=CC=C1 ZMHVOVQAUQAVMY-NWDGAFQWSA-N 0.000 description 2
• 210000001185 bone marrow Anatomy 0.000 description 2
• 125000001246 bromo group Chemical group Br* 0.000 description 2
• QJIXIPKLVVDFDO-UHFFFAOYSA-N bromo(iodo)methanesulfonic acid Chemical compound OS(=O)(=O)C(Br)I QJIXIPKLVVDFDO-UHFFFAOYSA-N 0.000 description 2
• 230000005587 bubbling Effects 0.000 description 2
• YSHOWEKUVWPFNR-UHFFFAOYSA-N burgess reagent Chemical compound CC[N+](CC)(CC)S(=O)(=O)N=C([O-])OC YSHOWEKUVWPFNR-UHFFFAOYSA-N 0.000 description 2
• RYYVLZVUVIJVGH-UHFFFAOYSA-N caffeine Chemical compound CN1C(=O)N(C)C(=O)C2=C1N=CN2C RYYVLZVUVIJVGH-UHFFFAOYSA-N 0.000 description 2
• 238000004364 calculation method Methods 0.000 description 2
• FFGPTBGBLSHEPO-UHFFFAOYSA-N carbamazepine Chemical compound C1=CC2=CC=CC=C2N(C(=O)N)C2=CC=CC=C21 FFGPTBGBLSHEPO-UHFFFAOYSA-N 0.000 description 2
• 125000005518 carboxamido group Chemical group 0.000 description 2
• 108010041776 cardiotrophin 1 Proteins 0.000 description 2
• 230000003197 catalytic effect Effects 0.000 description 2
• 239000012320 chlorinating reagent Substances 0.000 description 2
• WRJWRGBVPUUDLA-UHFFFAOYSA-N chlorosulfonyl isocyanate Chemical compound ClS(=O)(=O)N=C=O WRJWRGBVPUUDLA-UHFFFAOYSA-N 0.000 description 2
• 229960001265 ciclosporin Drugs 0.000 description 2
• 238000002648 combination therapy Methods 0.000 description 2
• OPQARKPSCNTWTJ-UHFFFAOYSA-L copper(ii) acetate Chemical compound [Cu+2].CC([O-])=O.CC([O-])=O OPQARKPSCNTWTJ-UHFFFAOYSA-L 0.000 description 2
• 239000003246 corticosteroid Substances 0.000 description 2
• 229960001334 corticosteroids Drugs 0.000 description 2
• 229930182912 cyclosporin Natural products 0.000 description 2
• 230000001419 dependent effect Effects 0.000 description 2
• 229960003957 dexamethasone Drugs 0.000 description 2
• UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 description 2
• 206010012601 diabetes mellitus Diseases 0.000 description 2
• 150000004985 diamines Chemical class 0.000 description 2
• 239000003136 dopamine receptor stimulating agent Substances 0.000 description 2
• 238000001035 drying Methods 0.000 description 2
• 238000005538 encapsulation Methods 0.000 description 2
• DUYAAUVXQSMXQP-UHFFFAOYSA-N ethanethioic S-acid Chemical class CC(S)=O DUYAAUVXQSMXQP-UHFFFAOYSA-N 0.000 description 2
• JEJWYGQWKNHONY-UHFFFAOYSA-N ethyl 3-aminocyclobutane-1-carboxylate;hydrochloride Chemical compound Cl.CCOC(=O)C1CC(N)C1 JEJWYGQWKNHONY-UHFFFAOYSA-N 0.000 description 2
• 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 2
• 208000030533 eye disease Diseases 0.000 description 2
• 235000019253 formic acid Nutrition 0.000 description 2
• 239000012634 fragment Substances 0.000 description 2
• 229960003692 gamma aminobutyric acid Drugs 0.000 description 2
• 125000004438 haloalkoxy group Chemical group 0.000 description 2
• NCTRLWWHIUUNBE-UHFFFAOYSA-N hexane-3-sulfonamide Chemical compound CCCC(CC)S(N)(=O)=O NCTRLWWHIUUNBE-UHFFFAOYSA-N 0.000 description 2
• 238000005984 hydrogenation reaction Methods 0.000 description 2
• 238000007327 hydrogenolysis reaction Methods 0.000 description 2
• QAOWNCQODCNURD-UHFFFAOYSA-M hydrogensulfate Chemical compound OS([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-M 0.000 description 2
• 125000004029 hydroxymethyl group Chemical group [H]OC([H])([H])* 0.000 description 2
• 230000007954 hypoxia Effects 0.000 description 2
• 229960001680 ibuprofen Drugs 0.000 description 2
• 239000003018 immunosuppressive agent Substances 0.000 description 2
• 229940124589 immunosuppressive drug Drugs 0.000 description 2
• 238000000338 in vitro Methods 0.000 description 2
• 238000001727 in vivo Methods 0.000 description 2
• 208000015181 infectious disease Diseases 0.000 description 2
• 230000002458 infectious effect Effects 0.000 description 2
• 230000002401 inhibitory effect Effects 0.000 description 2
• 238000002347 injection Methods 0.000 description 2
• 239000007924 injection Substances 0.000 description 2
• 230000000968 intestinal effect Effects 0.000 description 2
• 125000002346 iodo group Chemical group I* 0.000 description 2
• 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 2
• 201000010666 keratoconjunctivitis Diseases 0.000 description 2
• 239000003199 leukotriene receptor blocking agent Substances 0.000 description 2
• 239000007788 liquid Substances 0.000 description 2
• 239000012280 lithium aluminium hydride Substances 0.000 description 2
• YNESATAKKCNGOF-UHFFFAOYSA-N lithium bis(trimethylsilyl)amide Chemical compound [Li+].C[Si](C)(C)[N-][Si](C)(C)C YNESATAKKCNGOF-UHFFFAOYSA-N 0.000 description 2
• NXPHGHWWQRMDIA-UHFFFAOYSA-M magnesium;carbanide;bromide Chemical compound [CH3-].[Mg+2].[Br-] NXPHGHWWQRMDIA-UHFFFAOYSA-M 0.000 description 2
• 238000004519 manufacturing process Methods 0.000 description 2
• 229960004640 memantine Drugs 0.000 description 2
• QARBMVPHQWIHKH-UHFFFAOYSA-N methanesulfonyl chloride Chemical compound CS(Cl)(=O)=O QARBMVPHQWIHKH-UHFFFAOYSA-N 0.000 description 2
• VUQUOGPMUUJORT-UHFFFAOYSA-N methyl 4-methylbenzenesulfonate Chemical compound COS(=O)(=O)C1=CC=C(C)C=C1 VUQUOGPMUUJORT-UHFFFAOYSA-N 0.000 description 2
• CZXGXYBOQYQXQD-UHFFFAOYSA-N methyl benzenesulfonate Chemical compound COS(=O)(=O)C1=CC=CC=C1 CZXGXYBOQYQXQD-UHFFFAOYSA-N 0.000 description 2
• HPNSFSBZBAHARI-UHFFFAOYSA-N micophenolic acid Natural products OC1=C(CC=C(C)CCC(O)=O)C(OC)=C(C)C2=C1C(=O)OC2 HPNSFSBZBAHARI-UHFFFAOYSA-N 0.000 description 2
• 239000002808 molecular sieve Substances 0.000 description 2
• 229940066491 mucolytics Drugs 0.000 description 2
• 239000003681 muscarinic M3 receptor antagonist Substances 0.000 description 2
• APLGHEBYNMYFAZ-NWDGAFQWSA-N n-[(1s,3r)-3-[methyl(7h-pyrrolo[2,3-d]pyrimidin-4-yl)amino]cyclopentyl]propane-1-sulfonamide Chemical compound C1[C@@H](NS(=O)(=O)CCC)CC[C@H]1N(C)C1=NC=NC2=C1C=CN2 APLGHEBYNMYFAZ-NWDGAFQWSA-N 0.000 description 2
• 210000005036 nerve Anatomy 0.000 description 2
• 229940053128 nerve growth factor Drugs 0.000 description 2
• 229940032018 neurotrophin 3 Drugs 0.000 description 2
• 235000001968 nicotinic acid Nutrition 0.000 description 2
• 239000011664 nicotinic acid Substances 0.000 description 2
• 229960005366 nilvadipine Drugs 0.000 description 2
• 231100000252 nontoxic Toxicity 0.000 description 2
• 230000003000 nontoxic effect Effects 0.000 description 2
• 229960002748 norepinephrine Drugs 0.000 description 2
• SFLSHLFXELFNJZ-UHFFFAOYSA-N norepinephrine Natural products NCC(O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-UHFFFAOYSA-N 0.000 description 2
• 125000002734 organomagnesium group Chemical group 0.000 description 2
• YKOWCKUSQRRSSZ-UHFFFAOYSA-N oxetan-3-ylmethanesulfonyl chloride Chemical compound ClS(=O)(=O)CC1COC1 YKOWCKUSQRRSSZ-UHFFFAOYSA-N 0.000 description 2
• XNRDAEVPJXGQEO-UHFFFAOYSA-N oxetan-3-ylmethyl thiocyanate Chemical compound N#CSCC1COC1 XNRDAEVPJXGQEO-UHFFFAOYSA-N 0.000 description 2
• 230000003647 oxidation Effects 0.000 description 2
• 238000007254 oxidation reaction Methods 0.000 description 2
• WYWIFABBXFUGLM-UHFFFAOYSA-N oxymetazoline Chemical compound CC1=CC(C(C)(C)C)=C(O)C(C)=C1CC1=NCCN1 WYWIFABBXFUGLM-UHFFFAOYSA-N 0.000 description 2
• KDLHZDBZIXYQEI-UHFFFAOYSA-N palladium Substances [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 2
• XQYZDYMELSJDRZ-UHFFFAOYSA-N papaverine Chemical compound C1=C(OC)C(OC)=CC=C1CC1=NC=CC2=CC(OC)=C(OC)C=C12 XQYZDYMELSJDRZ-UHFFFAOYSA-N 0.000 description 2
• 230000036961 partial effect Effects 0.000 description 2
• 239000012071 phase Substances 0.000 description 2
• 125000003170 phenylsulfonyl group Chemical group C1(=CC=CC=C1)S(=O)(=O)* 0.000 description 2
• 239000002587 phosphodiesterase IV inhibitor Substances 0.000 description 2
• 239000002590 phosphodiesterase V inhibitor Substances 0.000 description 2
• 102000020233 phosphotransferase Human genes 0.000 description 2
• 239000011591 potassium Substances 0.000 description 2
• 229910052700 potassium Inorganic materials 0.000 description 2
• SCVFZCLFOSHCOH-UHFFFAOYSA-M potassium acetate Chemical compound [K+].CC([O-])=O SCVFZCLFOSHCOH-UHFFFAOYSA-M 0.000 description 2
• 239000002244 precipitate Substances 0.000 description 2
• 239000002243 precursor Substances 0.000 description 2
• 229960005205 prednisolone Drugs 0.000 description 2
• OIGNJSKKLXVSLS-VWUMJDOOSA-N prednisolone Chemical compound O=C1C=C[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 OIGNJSKKLXVSLS-VWUMJDOOSA-N 0.000 description 2
• 150000003141 primary amines Chemical class 0.000 description 2
• SUVIGLJNEAMWEG-UHFFFAOYSA-N propane-1-thiol Chemical compound CCCS SUVIGLJNEAMWEG-UHFFFAOYSA-N 0.000 description 2
• NYCVCXMSZNOGDH-UHFFFAOYSA-N pyrrolidine-1-carboxylic acid Chemical compound OC(=O)N1CCCC1 NYCVCXMSZNOGDH-UHFFFAOYSA-N 0.000 description 2
• 238000010791 quenching Methods 0.000 description 2
• 238000010405 reoxidation reaction Methods 0.000 description 2
• 238000012552 review Methods 0.000 description 2
• ZKFAOIPWHUQJJH-UHFFFAOYSA-N s-[3-(cyanomethyl)cyclobutyl] ethanethioate Chemical compound CC(=O)SC1CC(CC#N)C1 ZKFAOIPWHUQJJH-UHFFFAOYSA-N 0.000 description 2
• 229960002052 salbutamol Drugs 0.000 description 2
• 229930195734 saturated hydrocarbon Natural products 0.000 description 2
• MEZLKOACVSPNER-GFCCVEGCSA-N selegiline Chemical compound C#CCN(C)[C@H](C)CC1=CC=CC=C1 MEZLKOACVSPNER-GFCCVEGCSA-N 0.000 description 2
• 229960003310 sildenafil Drugs 0.000 description 2
• 210000003491 skin Anatomy 0.000 description 2
• URGAHOPLAPQHLN-UHFFFAOYSA-N sodium aluminosilicate Chemical compound [Na+].[Al+3].[O-][Si]([O-])=O.[O-][Si]([O-])=O URGAHOPLAPQHLN-UHFFFAOYSA-N 0.000 description 2
• 239000012279 sodium borohydride Substances 0.000 description 2
• 229910000033 sodium borohydride Inorganic materials 0.000 description 2
• GEHJYWRUCIMESM-UHFFFAOYSA-L sodium sulfite Chemical compound [Na+].[Na+].[O-]S([O-])=O GEHJYWRUCIMESM-UHFFFAOYSA-L 0.000 description 2
• 150000003431 steroids Chemical class 0.000 description 2
• 238000003756 stirring Methods 0.000 description 2
• 229940124530 sulfonamide Drugs 0.000 description 2
• 150000003456 sulfonamides Chemical class 0.000 description 2
• 150000003462 sulfoxides Chemical class 0.000 description 2
• 230000001629 suppression Effects 0.000 description 2
• 230000004083 survival effect Effects 0.000 description 2
• 208000011580 syndromic disease Diseases 0.000 description 2
• LMBFAGIMSUYTBN-MPZNNTNKSA-N teixobactin Chemical compound C([C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H](CCC(N)=O)C(=O)N[C@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H]1C(N[C@@H](C)C(=O)N[C@@H](C[C@@H]2NC(=N)NC2)C(=O)N[C@H](C(=O)O[C@H]1C)[C@@H](C)CC)=O)NC)C1=CC=CC=C1 LMBFAGIMSUYTBN-MPZNNTNKSA-N 0.000 description 2
• 206010043207 temporal arteritis Diseases 0.000 description 2
• DYHSDKLCOJIUFX-UHFFFAOYSA-N tert-butoxycarbonyl anhydride Chemical compound CC(C)(C)OC(=O)OC(=O)OC(C)(C)C DYHSDKLCOJIUFX-UHFFFAOYSA-N 0.000 description 2
• USPTWTHJMZOWBA-UHFFFAOYSA-N tert-butyl 1-cyano-3-azabicyclo[3.1.0]hexane-3-carboxylate Chemical compound C1N(C(=O)OC(C)(C)C)CC2CC21C#N USPTWTHJMZOWBA-UHFFFAOYSA-N 0.000 description 2
• PUTOENHGHDTSSY-UHFFFAOYSA-N tert-butyl 1-formyl-3-azabicyclo[3.1.0]hexane-3-carboxylate Chemical compound C1N(C(=O)OC(C)(C)C)CC2CC21C=O PUTOENHGHDTSSY-UHFFFAOYSA-N 0.000 description 2
• WNAHEVXTGAEKIY-ZDUSSCGKSA-N tert-butyl n-[(2r)-1-phenylbut-3-en-2-yl]carbamate Chemical compound CC(C)(C)OC(=O)N[C@@H](C=C)CC1=CC=CC=C1 WNAHEVXTGAEKIY-ZDUSSCGKSA-N 0.000 description 2
• FPGGTKZVZWFYPV-UHFFFAOYSA-M tetrabutylammonium fluoride Chemical compound [F-].CCCC[N+](CCCC)(CCCC)CCCC FPGGTKZVZWFYPV-UHFFFAOYSA-M 0.000 description 2
• ZFXYFBGIUFBOJW-UHFFFAOYSA-N theophylline Chemical compound O=C1N(C)C(=O)N(C)C2=C1NC=N2 ZFXYFBGIUFBOJW-UHFFFAOYSA-N 0.000 description 2
• 238000004809 thin layer chromatography Methods 0.000 description 2
• 150000003568 thioethers Chemical class 0.000 description 2
• 150000003573 thiols Chemical class 0.000 description 2
• 210000001519 tissue Anatomy 0.000 description 2
• MIQPIUSUKVNLNT-UHFFFAOYSA-N tolcapone Chemical compound C1=CC(C)=CC=C1C(=O)C1=CC(O)=C(O)C([N+]([O-])=O)=C1 MIQPIUSUKVNLNT-UHFFFAOYSA-N 0.000 description 2
• 238000011200 topical administration Methods 0.000 description 2
• VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
• 238000000844 transformation Methods 0.000 description 2
• CSRZQMIRAZTJOY-UHFFFAOYSA-N trimethylsilyl iodide Chemical compound C[Si](C)(C)I CSRZQMIRAZTJOY-UHFFFAOYSA-N 0.000 description 2
• RIOQSEWOXXDEQQ-UHFFFAOYSA-N triphenylphosphine Chemical compound C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 RIOQSEWOXXDEQQ-UHFFFAOYSA-N 0.000 description 2
• 230000001228 trophic effect Effects 0.000 description 2
• 229960005486 vaccine Drugs 0.000 description 2
• 238000010626 work up procedure Methods 0.000 description 2
• 239000011701 zinc Substances 0.000 description 2
• OGNSCSPNOLGXSM-UHFFFAOYSA-N (+/-)-DABA Natural products NCCC(N)C(O)=O OGNSCSPNOLGXSM-UHFFFAOYSA-N 0.000 description 1
• BZMMRNKDONDVIB-UHFFFAOYSA-N (1-ethoxycyclopropyl)oxy-trimethylsilane Chemical compound CCOC1(O[Si](C)(C)C)CC1 BZMMRNKDONDVIB-UHFFFAOYSA-N 0.000 description 1
• XLBRKHYEERTGRA-UHFFFAOYSA-N (3-cyanocyclopentyl) 4-methylbenzenesulfonate Chemical compound C1=CC(C)=CC=C1S(=O)(=O)OC1CC(C#N)CC1 XLBRKHYEERTGRA-UHFFFAOYSA-N 0.000 description 1
• DATJETPTDKFEEF-YFKPBYRVSA-N (3r)-pyrrolidine-3-carbonitrile Chemical compound N#C[C@@H]1CCNC1 DATJETPTDKFEEF-YFKPBYRVSA-N 0.000 description 1
• DATJETPTDKFEEF-RXMQYKEDSA-N (3s)-pyrrolidine-3-carbonitrile Chemical class N#C[C@H]1CCNC1 DATJETPTDKFEEF-RXMQYKEDSA-N 0.000 description 1
• 125000004191 (C1-C6) alkoxy group Chemical group 0.000 description 1
• 125000004169 (C1-C6) alkyl group Chemical group 0.000 description 1
• WSEQXVZVJXJVFP-HXUWFJFHSA-N (R)-citalopram Chemical compound C1([C@@]2(C3=CC=C(C=C3CO2)C#N)CCCN(C)C)=CC=C(F)C=C1 WSEQXVZVJXJVFP-HXUWFJFHSA-N 0.000 description 1
• HQKDFKRGDIWHLX-CLFYSBASSA-N (z)-2-acetylsulfanylethoxyimino-(dimethylamino)-oxidoazanium Chemical compound CN(C)[N+](\[O-])=N\OCCSC(C)=O HQKDFKRGDIWHLX-CLFYSBASSA-N 0.000 description 1
• GEOCVSMCLVIOEV-BTJKTKAUSA-N (z)-but-2-enedioic acid;2-methyl-4-phenyl-3,4-dihydro-1h-isoquinolin-8-amine Chemical compound OC(=O)\C=C/C(O)=O.C12=CC=CC(N)=C2CN(C)CC1C1=CC=CC=C1 GEOCVSMCLVIOEV-BTJKTKAUSA-N 0.000 description 1
• BEQLOSVHRBTANS-UHFFFAOYSA-N 1,1,1,2,2,3,3,4,4,5,5,6,6-tridecafluoro-8-iodododecane Chemical compound CCCCC(I)CC(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)F BEQLOSVHRBTANS-UHFFFAOYSA-N 0.000 description 1
• WORJRXHJTUTINR-UHFFFAOYSA-N 1,4-dioxane;hydron;chloride Chemical compound Cl.C1COCCO1 WORJRXHJTUTINR-UHFFFAOYSA-N 0.000 description 1
• 125000005940 1,4-dioxanyl group Chemical group 0.000 description 1
• SGUVLZREKBPKCE-UHFFFAOYSA-N 1,5-diazabicyclo[4.3.0]-non-5-ene Chemical compound C1CCN=C2CCCN21 SGUVLZREKBPKCE-UHFFFAOYSA-N 0.000 description 1
• JPHHGFNKNXDZSD-BVDKZHGWSA-N 1-(2-chlorophenyl)-6-[(2s)-3,3,3-trifluoro-2-methylpropyl]-5,7a-dihydro-3ah-pyrazolo[3,4-d]pyrimidin-4-one Chemical compound O=C1NC(C[C@H](C)C(F)(F)F)=NC2C1C=NN2C1=CC=CC=C1Cl JPHHGFNKNXDZSD-BVDKZHGWSA-N 0.000 description 1
• WSEQXVZVJXJVFP-UHFFFAOYSA-N 1-[3-(dimethylamino)propyl]-1-(4-fluorophenyl)-1,3-dihydro-2-benzofuran-5-carbonitrile Chemical compound O1CC2=CC(C#N)=CC=C2C1(CCCN(C)C)C1=CC=C(F)C=C1 WSEQXVZVJXJVFP-UHFFFAOYSA-N 0.000 description 1
• WIHMBLDNRMIGDW-UHFFFAOYSA-N 1-[3-(dimethylamino)propyl]-1-(4-fluorophenyl)-3h-2-benzofuran-5-carbonitrile;hydron;bromide Chemical compound [Br-].O1CC2=CC(C#N)=CC=C2C1(CCC[NH+](C)C)C1=CC=C(F)C=C1 WIHMBLDNRMIGDW-UHFFFAOYSA-N 0.000 description 1
• 125000004066 1-hydroxyethyl group Chemical group [H]OC([H])([*])C([H])([H])[H] 0.000 description 1
• BWFQEOQVRYWZSG-UHFFFAOYSA-N 1-methyl-3-methylidenecyclobutane-1-carbonitrile Chemical compound N#CC1(C)CC(=C)C1 BWFQEOQVRYWZSG-UHFFFAOYSA-N 0.000 description 1
• IDHHSXMRNXRQSW-UHFFFAOYSA-N 1-methyl-3-methylidenecyclobutane-1-carboxylic acid Chemical compound OC(=O)C1(C)CC(=C)C1 IDHHSXMRNXRQSW-UHFFFAOYSA-N 0.000 description 1
• PDNHLCRMUIGNBV-UHFFFAOYSA-N 1-pyridin-2-ylethanamine Chemical compound CC(N)C1=CC=CC=N1 PDNHLCRMUIGNBV-UHFFFAOYSA-N 0.000 description 1
• YGTUPRIZNBMOFV-UHFFFAOYSA-N 2-(4-hydroxybenzoyl)benzoic acid Chemical compound OC(=O)C1=CC=CC=C1C(=O)C1=CC=C(O)C=C1 YGTUPRIZNBMOFV-UHFFFAOYSA-N 0.000 description 1
• MTKGPLGETVCLCF-UHFFFAOYSA-N 2-(methylamino)propanenitrile Chemical compound CNC(C)C#N MTKGPLGETVCLCF-UHFFFAOYSA-N 0.000 description 1
• ZKLPARSLTMPFCP-OAQYLSRUSA-N 2-[2-[4-[(R)-(4-chlorophenyl)-phenylmethyl]-1-piperazinyl]ethoxy]acetic acid Chemical compound C1CN(CCOCC(=O)O)CCN1[C@@H](C=1C=CC(Cl)=CC=1)C1=CC=CC=C1 ZKLPARSLTMPFCP-OAQYLSRUSA-N 0.000 description 1
• FQVIUCMKUIUWKC-UHFFFAOYSA-N 2-[3-(hydroxymethyl)oxetan-3-yl]acetonitrile Chemical compound N#CCC1(CO)COC1 FQVIUCMKUIUWKC-UHFFFAOYSA-N 0.000 description 1
• CSEJMYVAIPCCMY-UHFFFAOYSA-N 2-benzylsulfanylpyridine-4-carbonitrile Chemical compound N#CC1=CC=NC(SCC=2C=CC=CC=2)=C1 CSEJMYVAIPCCMY-UHFFFAOYSA-N 0.000 description 1
• QRXBTPFMCTXCRD-UHFFFAOYSA-N 2-chloropyridine-4-carbonitrile Chemical compound ClC1=CC(C#N)=CC=N1 QRXBTPFMCTXCRD-UHFFFAOYSA-N 0.000 description 1
• JVOCWIRGDNWGKH-UHFFFAOYSA-N 2-cyclopropylethyl 4-methylbenzenesulfonate Chemical compound C1=CC(C)=CC=C1S(=O)(=O)OCCC1CC1 JVOCWIRGDNWGKH-UHFFFAOYSA-N 0.000 description 1
• KWMBADTWRIGGGG-UHFFFAOYSA-N 2-diethoxyphosphorylacetonitrile Chemical compound CCOP(=O)(CC#N)OCC KWMBADTWRIGGGG-UHFFFAOYSA-N 0.000 description 1
• ONCWUIBQLZGBFF-UHFFFAOYSA-N 2-methyl-5,6-dihydro-4h-pyrrolo[3,4-c]pyrazole;hydrochloride Chemical compound Cl.C1NCC2=NN(C)C=C21 ONCWUIBQLZGBFF-UHFFFAOYSA-N 0.000 description 1
• JKWBMAJJDVYJNL-UHFFFAOYSA-N 2-oxo-1,3-oxazolidine-3-sulfonamide Chemical compound NS(=O)(=O)N1CCOC1=O JKWBMAJJDVYJNL-UHFFFAOYSA-N 0.000 description 1
• QXYNIWCYMQIZBV-UHFFFAOYSA-N 3,3-difluorocyclobutane-1-sulfonyl chloride Chemical compound FC1(F)CC(S(Cl)(=O)=O)C1 QXYNIWCYMQIZBV-UHFFFAOYSA-N 0.000 description 1
• JOGCIOBFISPMGA-UHFFFAOYSA-N 3-(cyanomethyl)-3-methylcyclobutane-1-sulfonyl chloride Chemical compound N#CCC1(C)CC(S(Cl)(=O)=O)C1 JOGCIOBFISPMGA-UHFFFAOYSA-N 0.000 description 1
• CBYFMEDJHNTXQX-UHFFFAOYSA-N 3-hydroxycyclopentane-1-carbonitrile Chemical compound OC1CCC(C#N)C1 CBYFMEDJHNTXQX-UHFFFAOYSA-N 0.000 description 1
• ZRWMAMOBIQQJSA-UHFFFAOYSA-N 3-methylidenecyclobutane-1-carbonitrile Chemical compound C=C1CC(C#N)C1 ZRWMAMOBIQQJSA-UHFFFAOYSA-N 0.000 description 1
• GPPSQLLIFNWNSB-UHFFFAOYSA-N 3-phenylmethoxycyclobutan-1-one Chemical compound C1C(=O)CC1OCC1=CC=CC=C1 GPPSQLLIFNWNSB-UHFFFAOYSA-N 0.000 description 1
• MJOUJKDTBGXKIU-UHFFFAOYSA-N 4,4-difluoropiperidine Chemical compound FC1(F)CCNCC1 MJOUJKDTBGXKIU-UHFFFAOYSA-N 0.000 description 1
• FCKYIGWJVZIPLK-UHFFFAOYSA-N 4-(1h-pyrazol-5-yl)piperidine Chemical compound C1CNCCC1C1=CC=NN1 FCKYIGWJVZIPLK-UHFFFAOYSA-N 0.000 description 1
• AXPLSJSIKGZOMF-UHFFFAOYSA-N 4-(trifluoromethyl)piperidin-4-ol Chemical compound FC(F)(F)C1(O)CCNCC1 AXPLSJSIKGZOMF-UHFFFAOYSA-N 0.000 description 1
• LKDMKWNDBAVNQZ-UHFFFAOYSA-N 4-[[1-[[1-[2-[[1-(4-nitroanilino)-1-oxo-3-phenylpropan-2-yl]carbamoyl]pyrrolidin-1-yl]-1-oxopropan-2-yl]amino]-1-oxopropan-2-yl]amino]-4-oxobutanoic acid Chemical compound OC(=O)CCC(=O)NC(C)C(=O)NC(C)C(=O)N1CCCC1C(=O)NC(C(=O)NC=1C=CC(=CC=1)[N+]([O-])=O)CC1=CC=CC=C1 LKDMKWNDBAVNQZ-UHFFFAOYSA-N 0.000 description 1
• BTOJSYRZQZOMOK-UHFFFAOYSA-N 4-chloro-7-(4-methylphenyl)sulfonylpyrrolo[2,3-d]pyrimidine Chemical compound C1=CC(C)=CC=C1S(=O)(=O)N1C2=NC=NC(Cl)=C2C=C1 BTOJSYRZQZOMOK-UHFFFAOYSA-N 0.000 description 1
• BPTCCCTWWAUJRK-UHFFFAOYSA-N 4-chloro-7h-pyrrolo[2,3-d]pyrimidine Chemical compound ClC1=NC=NC2=C1C=CN2 BPTCCCTWWAUJRK-UHFFFAOYSA-N 0.000 description 1
• SUJGVVCZKQCEOP-UHFFFAOYSA-N 4-cyanopyridine-2-sulfonyl chloride Chemical compound ClS(=O)(=O)C1=CC(C#N)=CC=N1 SUJGVVCZKQCEOP-UHFFFAOYSA-N 0.000 description 1
• 102000004023 5-Lipoxygenase-Activating Proteins Human genes 0.000 description 1
• 108090000411 5-Lipoxygenase-Activating Proteins Proteins 0.000 description 1
• LSLYOANBFKQKPT-DIFFPNOSSA-N 5-[(1r)-1-hydroxy-2-[[(2r)-1-(4-hydroxyphenyl)propan-2-yl]amino]ethyl]benzene-1,3-diol Chemical compound C([C@@H](C)NC[C@H](O)C=1C=C(O)C=C(O)C=1)C1=CC=C(O)C=C1 LSLYOANBFKQKPT-DIFFPNOSSA-N 0.000 description 1
• ODHCTXKNWHHXJC-VKHMYHEASA-N 5-oxo-L-proline Chemical compound OC(=O)[C@@H]1CCC(=O)N1 ODHCTXKNWHHXJC-VKHMYHEASA-N 0.000 description 1
• JJTNLWSCFYERCK-UHFFFAOYSA-N 7h-pyrrolo[2,3-d]pyrimidine Chemical group N1=CN=C2NC=CC2=C1 JJTNLWSCFYERCK-UHFFFAOYSA-N 0.000 description 1
• MKJIEFSOBYUXJB-UHFFFAOYSA-N 9,10-dimethoxy-3-isobutyl-1,3,4,6,7,11b-hexahydro-2H-pyrido[2,1-a]isoquinolin-2-one Chemical compound C1CN2CC(CC(C)C)C(=O)CC2C2=C1C=C(OC)C(OC)=C2 MKJIEFSOBYUXJB-UHFFFAOYSA-N 0.000 description 1
• 229930008281 A03AD01 - Papaverine Natural products 0.000 description 1
• 208000030507 AIDS Diseases 0.000 description 1
• 206010065040 AIDS dementia complex Diseases 0.000 description 1
• QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
• 201000004384 Alopecia Diseases 0.000 description 1
• 206010002556 Ankylosing Spondylitis Diseases 0.000 description 1
• 241000272517 Anseriformes Species 0.000 description 1
• 239000004475 Arginine Substances 0.000 description 1
• 102100026376 Artemin Human genes 0.000 description 1
• 206010003210 Arteriosclerosis Diseases 0.000 description 1
• 201000001320 Atherosclerosis Diseases 0.000 description 1
• 206010003645 Atopy Diseases 0.000 description 1
• 208000004300 Atrophic Gastritis Diseases 0.000 description 1
• 206010050245 Autoimmune thrombocytopenia Diseases 0.000 description 1
• 208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 description 1
• 208000023328 Basedow disease Diseases 0.000 description 1
• 208000009137 Behcet syndrome Diseases 0.000 description 1
• BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical compound OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 description 1
• 208000008439 Biliary Liver Cirrhosis Diseases 0.000 description 1
• 208000033222 Biliary cirrhosis primary Diseases 0.000 description 1
• 206010005003 Bladder cancer Diseases 0.000 description 1
• 206010005949 Bone cancer Diseases 0.000 description 1
• 208000020084 Bone disease Diseases 0.000 description 1
• 206010048396 Bone marrow transplant rejection Diseases 0.000 description 1
• 208000018084 Bone neoplasm Diseases 0.000 description 1
• BTBUEUYNUDRHOZ-UHFFFAOYSA-N Borate Chemical compound [O-]B([O-])[O-] BTBUEUYNUDRHOZ-UHFFFAOYSA-N 0.000 description 1
• 208000004020 Brain Abscess Diseases 0.000 description 1
• 201000006474 Brain Ischemia Diseases 0.000 description 1
• 206010006187 Breast cancer Diseases 0.000 description 1
• 208000026310 Breast neoplasm Diseases 0.000 description 1
• VOVIALXJUBGFJZ-KWVAZRHASA-N Budesonide Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@@H]2[C@@H]1[C@@H]1C[C@H]3OC(CCC)O[C@@]3(C(=O)CO)[C@@]1(C)C[C@@H]2O VOVIALXJUBGFJZ-KWVAZRHASA-N 0.000 description 1
• GZCZOUIXXNIHRA-UHFFFAOYSA-N C(#N)CC1(COC1)CSC#N.C(#N)CC1(COC1)CS(=O)(=O)Cl Chemical compound C(#N)CC1(COC1)CSC#N.C(#N)CC1(COC1)CS(=O)(=O)Cl GZCZOUIXXNIHRA-UHFFFAOYSA-N 0.000 description 1
• RHAZTZQFUMTZFE-UHFFFAOYSA-N C(C1=CC=CC=C1)OC1CC(C1)=CC#N.C(C1=CC=CC=C1)OC1CC(C1)CC#N Chemical compound C(C1=CC=CC=C1)OC1CC(C1)=CC#N.C(C1=CC=CC=C1)OC1CC(C1)CC#N RHAZTZQFUMTZFE-UHFFFAOYSA-N 0.000 description 1
• RDZZVVMAENBKFR-UHFFFAOYSA-N C(C1=CC=CC=C1)OC1CC(C1)CC#N.OC1CC(C1)CC#N Chemical compound C(C1=CC=CC=C1)OC1CC(C1)CC#N.OC1CC(C1)CC#N RDZZVVMAENBKFR-UHFFFAOYSA-N 0.000 description 1
• SWNMOOHEWXRHNI-UHFFFAOYSA-N C(C1=CC=CC=C1)SC=1C=C(C#N)C=CN1.C(#N)C1=CC(=NC=C1)S(=O)(=O)Cl Chemical compound C(C1=CC=CC=C1)SC=1C=C(C#N)C=CN1.C(#N)C1=CC(=NC=C1)S(=O)(=O)Cl SWNMOOHEWXRHNI-UHFFFAOYSA-N 0.000 description 1
• LSCNUDTZWBXXTQ-MQYCCELVSA-N C(CCC)SC[C@H]1C[C@H](C1)N(C=1C2=C(N=CN1)NC=C2)C.C(CCC)S(=O)(=O)C[C@H]2C[C@H](C2)N(C=2C1=C(N=CN2)NC=C1)C Chemical compound C(CCC)SC[C@H]1C[C@H](C1)N(C=1C2=C(N=CN1)NC=C2)C.C(CCC)S(=O)(=O)C[C@H]2C[C@H](C2)N(C=2C1=C(N=CN2)NC=C1)C LSCNUDTZWBXXTQ-MQYCCELVSA-N 0.000 description 1
• MFBDOMMLGZECKJ-URHBZAFASA-N C(N)(O[C@@H]1C[C@H](C1)NC)=O Chemical compound C(N)(O[C@@H]1C[C@H](C1)NC)=O MFBDOMMLGZECKJ-URHBZAFASA-N 0.000 description 1
• VFXLCPGNCQSXKE-KDURUIRLSA-N C([C@H]1C[C@H](C1)N(C)C=1C=2C=CN(C=2N=CN=1)S(=O)(=O)C=1C=CC(C)=CC=1)S(=O)(=O)N1CCC(F)(F)CC1 Chemical compound C([C@H]1C[C@H](C1)N(C)C=1C=2C=CN(C=2N=CN=1)S(=O)(=O)C=1C=CC(C)=CC=1)S(=O)(=O)N1CCC(F)(F)CC1 VFXLCPGNCQSXKE-KDURUIRLSA-N 0.000 description 1
• DUQRSTOWZHMSQI-DFNIBXOVSA-N C([C@H]1C[C@H](C1)N(C)C=1C=2C=CN(C=2N=CN=1)S(=O)(=O)C=1C=CC(C)=CC=1)SC1CCNC1 Chemical compound C([C@H]1C[C@H](C1)N(C)C=1C=2C=CN(C=2N=CN=1)S(=O)(=O)C=1C=CC(C)=CC=1)SC1CCNC1 DUQRSTOWZHMSQI-DFNIBXOVSA-N 0.000 description 1
• ISQGUVXYSCPBBI-OKILXGFUSA-N C([C@H]1C[C@H](C1)N(C)C=1C=2C=CNC=2N=CN=1)S(=O)(=O)C1=CC(C#N)=CC=N1 Chemical compound C([C@H]1C[C@H](C1)N(C)C=1C=2C=CNC=2N=CN=1)S(=O)(=O)C1=CC(C#N)=CC=N1 ISQGUVXYSCPBBI-OKILXGFUSA-N 0.000 description 1
• UDIPEBURYXADGV-TXEJJXNPSA-N C([C@H]1C[C@H](C1)N(C)C=1C=2C=CNC=2N=CN=1)S(=O)(=O)C1=CC=C(F)C(Cl)=C1 Chemical compound C([C@H]1C[C@H](C1)N(C)C=1C=2C=CNC=2N=CN=1)S(=O)(=O)C1=CC=C(F)C(Cl)=C1 UDIPEBURYXADGV-TXEJJXNPSA-N 0.000 description 1
• ORZMYXXUWUMELW-CBQGHPETSA-N C1N(C(C)C)CCC1SC[C@@H]1C[C@H](N(C)C=2C=3C=CN(C=3N=CN=2)S(=O)(=O)C=2C=CC(C)=CC=2)C1 Chemical compound C1N(C(C)C)CCC1SC[C@@H]1C[C@H](N(C)C=2C=3C=CN(C=3N=CN=2)S(=O)(=O)C=2C=CC(C)=CC=2)C1 ORZMYXXUWUMELW-CBQGHPETSA-N 0.000 description 1
• WUHMMERCBUBWHW-BETUJISGSA-N C1[C@@H](CSCCCC)C[C@H]1N(C)C1=NC=NC2=C1C=CN2 Chemical compound C1[C@@H](CSCCCC)C[C@H]1N(C)C1=NC=NC2=C1C=CN2 WUHMMERCBUBWHW-BETUJISGSA-N 0.000 description 1
• KNODANGCQRDZQB-UHFFFAOYSA-N CC1(CC(C1)=C)C#N.CC1(CC(C1)=C)C(=O)O Chemical compound CC1(CC(C1)=C)C#N.CC1(CC(C1)=C)C(=O)O KNODANGCQRDZQB-UHFFFAOYSA-N 0.000 description 1
• XHKABLYXLHZKBA-UHFFFAOYSA-N CC1(CC(C1)=C)C(=O)OCC.CC1(CC(C1)=C)CO Chemical compound CC1(CC(C1)=C)C(=O)OCC.CC1(CC(C1)=C)CO XHKABLYXLHZKBA-UHFFFAOYSA-N 0.000 description 1
• QHKUUCJKPCETRH-UHFFFAOYSA-N CC1(CC(C1)=C)CC#N.CC1(CC(C1)=O)CC#N Chemical compound CC1(CC(C1)=C)CC#N.CC1(CC(C1)=O)CC#N QHKUUCJKPCETRH-UHFFFAOYSA-N 0.000 description 1
• CCZNTRGBSMGANC-UHFFFAOYSA-N CC1(CC(C1)=O)CC#N.OC1CC(C1)(C)CC#N Chemical compound CC1(CC(C1)=O)CC#N.OC1CC(C1)(C)CC#N CCZNTRGBSMGANC-UHFFFAOYSA-N 0.000 description 1
• AKEUQPIANKYLQS-TXEJJXNPSA-N CC1(COC1)CS(=O)(=O)N[C@@H]1C[C@@H](C1)N(C=1C2=C(N=CN=1)NC=C2)C Chemical compound CC1(COC1)CS(=O)(=O)N[C@@H]1C[C@@H](C1)N(C=1C2=C(N=CN=1)NC=C2)C AKEUQPIANKYLQS-TXEJJXNPSA-N 0.000 description 1
• BSCHRFWJRJNXCK-UHFFFAOYSA-N CC1=CC=C(C=C1)S(=O)(=O)Cl.CC1=CC=C(C=C1)S(=O)(=O)OC1CC(CC1)C#N Chemical compound CC1=CC=C(C=C1)S(=O)(=O)Cl.CC1=CC=C(C=C1)S(=O)(=O)OC1CC(CC1)C#N BSCHRFWJRJNXCK-UHFFFAOYSA-N 0.000 description 1
• CHUJALYWQZENTG-BETUJISGSA-N CN(C=1C2=C(N=CN=1)NC=C2)[C@@H]1C[C@@H](C1)CS(=O)(=O)C1=CC=NC=C1 Chemical compound CN(C=1C2=C(N=CN=1)NC=C2)[C@@H]1C[C@@H](C1)CS(=O)(=O)C1=CC=NC=C1 CHUJALYWQZENTG-BETUJISGSA-N 0.000 description 1
• XICPAJWGOJHZEN-PHIMTYICSA-N CN([C@H]1C[C@H](C1)NS(=O)(=O)C1=CC=CC2=NON=C21)C=1C2=C(N=CN=1)NC=C2 Chemical compound CN([C@H]1C[C@H](C1)NS(=O)(=O)C1=CC=CC2=NON=C21)C=1C2=C(N=CN=1)NC=C2 XICPAJWGOJHZEN-PHIMTYICSA-N 0.000 description 1
• GGQSYXVCIYAHBR-MPEURRAXSA-N CN([C@H]1C[C@H](C1)NS(=O)(=O)N1CC2CC(O2)C1)C1=NC=NC2=C1C=CN2 Chemical compound CN([C@H]1C[C@H](C1)NS(=O)(=O)N1CC2CC(O2)C1)C1=NC=NC2=C1C=CN2 GGQSYXVCIYAHBR-MPEURRAXSA-N 0.000 description 1
• KITABLLENVFMQT-JRATXPSKSA-N CN([C@H]1C[C@H](C1)NS(=O)(=O)N1C[C@]2(C[C@H]2C1)C#N)C1=NC=NC2=C1C=CN2 Chemical compound CN([C@H]1C[C@H](C1)NS(=O)(=O)N1C[C@]2(C[C@H]2C1)C#N)C1=NC=NC2=C1C=CN2 KITABLLENVFMQT-JRATXPSKSA-N 0.000 description 1
• DETZRJUSZLVKLN-SHTZXODSSA-N CN([C@H]1C[C@H](CO)C1)c1ncnc2n(ccc12)S(=O)(=O)c1ccc(C)cc1 Chemical compound CN([C@H]1C[C@H](CO)C1)c1ncnc2n(ccc12)S(=O)(=O)c1ccc(C)cc1 DETZRJUSZLVKLN-SHTZXODSSA-N 0.000 description 1
• YXWVTPJSRASYTN-TUAOUCFPSA-N CNC1=NC([C@H]2C[C@@H](CS(N(CC3)C[C@H]3F)(=O)=O)C2)=NC2=C1C=CN2 Chemical compound CNC1=NC([C@H]2C[C@@H](CS(N(CC3)C[C@H]3F)(=O)=O)C2)=NC2=C1C=CN2 YXWVTPJSRASYTN-TUAOUCFPSA-N 0.000 description 1
• OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
• 229940127291 Calcium channel antagonist Drugs 0.000 description 1
• 241000283707 Capra Species 0.000 description 1
• KXDHJXZQYSOELW-UHFFFAOYSA-M Carbamate Chemical compound NC([O-])=O KXDHJXZQYSOELW-UHFFFAOYSA-M 0.000 description 1
• 239000004215 Carbon black (E152) Substances 0.000 description 1
• BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 1
• 206010007572 Cardiac hypertrophy Diseases 0.000 description 1
• 208000006029 Cardiomegaly Diseases 0.000 description 1
• 102000004173 Cathepsin G Human genes 0.000 description 1
• 108090000617 Cathepsin G Proteins 0.000 description 1
• 206010008120 Cerebral ischaemia Diseases 0.000 description 1
• 206010063094 Cerebral malaria Diseases 0.000 description 1
• ZKLPARSLTMPFCP-UHFFFAOYSA-N Cetirizine Chemical compound C1CN(CCOCC(=O)O)CCN1C(C=1C=CC(Cl)=CC=1)C1=CC=CC=C1 ZKLPARSLTMPFCP-UHFFFAOYSA-N 0.000 description 1
• 108010012236 Chemokines Proteins 0.000 description 1
• 102000019034 Chemokines Human genes 0.000 description 1
• 208000030939 Chronic inflammatory demyelinating polyneuropathy Diseases 0.000 description 1
• 208000010833 Chronic myeloid leukaemia Diseases 0.000 description 1
• 102100024539 Chymase Human genes 0.000 description 1
• 108090000227 Chymases Proteins 0.000 description 1
• LUKZNWIVRBCLON-GXOBDPJESA-N Ciclesonide Chemical compound C1([C@H]2O[C@@]3([C@H](O2)C[C@@H]2[C@@]3(C[C@H](O)[C@@H]3[C@@]4(C)C=CC(=O)C=C4CC[C@H]32)C)C(=O)COC(=O)C(C)C)CCCCC1 LUKZNWIVRBCLON-GXOBDPJESA-N 0.000 description 1
• 108010005939 Ciliary Neurotrophic Factor Proteins 0.000 description 1
• 102100031614 Ciliary neurotrophic factor Human genes 0.000 description 1
• 235000001258 Cinchona calisaya Nutrition 0.000 description 1
• KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
• MHKJSOCUGZPRAA-KMMPGQJCSA-N Cl.N=1C=NC=2NC=CC=2C=1N(C)[C@H]1C[C@H](N)C1 Chemical compound Cl.N=1C=NC=2NC=CC=2C=1N(C)[C@H]1C[C@H](N)C1 MHKJSOCUGZPRAA-KMMPGQJCSA-N 0.000 description 1
• SNWPWSZTPBXKNA-UHFFFAOYSA-N ClN1C(CCC1=O)=O.C(#N)CC1CC(C1)S(=O)(=O)Cl Chemical compound ClN1C(CCC1=O)=O.C(#N)CC1CC(C1)S(=O)(=O)Cl SNWPWSZTPBXKNA-UHFFFAOYSA-N 0.000 description 1
• 208000015943 Coeliac disease Diseases 0.000 description 1
• 206010009944 Colon cancer Diseases 0.000 description 1
• 206010010744 Conjunctivitis allergic Diseases 0.000 description 1
• RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 1
• 206010011224 Cough Diseases 0.000 description 1
• 241000699800 Cricetinae Species 0.000 description 1
• 229930105110 Cyclosporin A Natural products 0.000 description 1
• AEMOLEFTQBMNLQ-AQKNRBDQSA-N D-glucopyranuronic acid Chemical compound OC1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O AEMOLEFTQBMNLQ-AQKNRBDQSA-N 0.000 description 1
• 229940081615 DOPA decarboxylase inhibitor Drugs 0.000 description 1
• 206010012289 Dementia Diseases 0.000 description 1
• 206010012689 Diabetic retinopathy Diseases 0.000 description 1
• 229940127333 Dopamine D2 Antagonists Drugs 0.000 description 1
• 102000004980 Dopamine D2 Receptors Human genes 0.000 description 1
• 108090001111 Dopamine D2 Receptors Proteins 0.000 description 1
• 229940121891 Dopamine receptor antagonist Drugs 0.000 description 1
• 206010060742 Endocrine ophthalmopathy Diseases 0.000 description 1
• NLPRAJRHRHZCQQ-UHFFFAOYSA-N Epibatidine Natural products C1=NC(Cl)=CC=C1C1C(N2)CCC2C1 NLPRAJRHRHZCQQ-UHFFFAOYSA-N 0.000 description 1
• 108010008165 Etanercept Proteins 0.000 description 1
• FACCDFPDYDGMAZ-TXEJJXNPSA-N FC(CC1CN(C1)S(=O)(=O)N[C@@H]1C[C@@H](C1)N(C=1C2=C(N=CN=1)NC=C2)C)F Chemical compound FC(CC1CN(C1)S(=O)(=O)N[C@@H]1C[C@@H](C1)N(C=1C2=C(N=CN=1)NC=C2)C)F FACCDFPDYDGMAZ-TXEJJXNPSA-N 0.000 description 1
• BTXWNXLPXWTCQZ-PHIMTYICSA-N FC1(CN(C1)S(=O)(=O)C[C@H]1C[C@H](C1)N(C=1C2=C(N=CN=1)NC=C2)C)F Chemical compound FC1(CN(C1)S(=O)(=O)C[C@H]1C[C@H](C1)N(C=1C2=C(N=CN=1)NC=C2)C)F BTXWNXLPXWTCQZ-PHIMTYICSA-N 0.000 description 1
• CMNOJKQJWWLNPL-ZIHWECLZSA-N FC1CN(CC1)S(=O)(=O)C[C@H]1C[C@H](C1)N(C=1C2=C(N=CN=1)NC=C2)C Chemical compound FC1CN(CC1)S(=O)(=O)C[C@H]1C[C@H](C1)N(C=1C2=C(N=CN=1)NC=C2)C CMNOJKQJWWLNPL-ZIHWECLZSA-N 0.000 description 1
• SUZZRRNVJYFSQA-AYRXBEOTSA-N F[C@@H]1CN(C[C@H]1OC)S(=O)(=O)C[C@H]1C[C@H](C1)N(C=1C2=C(N=CN=1)NC=C2)C Chemical compound F[C@@H]1CN(C[C@H]1OC)S(=O)(=O)C[C@H]1C[C@H](C1)N(C=1C2=C(N=CN=1)NC=C2)C SUZZRRNVJYFSQA-AYRXBEOTSA-N 0.000 description 1
• 102000003974 Fibroblast growth factor 2 Human genes 0.000 description 1
• 102100024785 Fibroblast growth factor 2 Human genes 0.000 description 1
• 206010016654 Fibrosis Diseases 0.000 description 1
• KRHYYFGTRYWZRS-UHFFFAOYSA-M Fluoride anion Chemical compound [F-] KRHYYFGTRYWZRS-UHFFFAOYSA-M 0.000 description 1
• BDAGIHXWWSANSR-UHFFFAOYSA-M Formate Chemical compound [O-]C=O BDAGIHXWWSANSR-UHFFFAOYSA-M 0.000 description 1
• VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 1
• 102000003688 G-Protein-Coupled Receptors Human genes 0.000 description 1
• 108090000045 G-Protein-Coupled Receptors Proteins 0.000 description 1
• 230000005526 G1 to G0 transition Effects 0.000 description 1
• 241000287828 Gallus gallus Species 0.000 description 1
• 208000036495 Gastritis atrophic Diseases 0.000 description 1
• 206010017993 Gastrointestinal neoplasms Diseases 0.000 description 1
• 239000004471 Glycine Substances 0.000 description 1
• 208000024869 Goodpasture syndrome Diseases 0.000 description 1
• 208000009329 Graft vs Host Disease Diseases 0.000 description 1
• 108010017080 Granulocyte Colony-Stimulating Factor Proteins 0.000 description 1
• 102000004269 Granulocyte Colony-Stimulating Factor Human genes 0.000 description 1
• 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 description 1
• 102100039620 Granulocyte-macrophage colony-stimulating factor Human genes 0.000 description 1
• 206010072579 Granulomatosis with polyangiitis Diseases 0.000 description 1
• 208000015023 Graves' disease Diseases 0.000 description 1
• 208000035895 Guillain-Barré syndrome Diseases 0.000 description 1
• 102000006354 HLA-DR Antigens Human genes 0.000 description 1
• 108010058597 HLA-DR Antigens Proteins 0.000 description 1
• 208000001204 Hashimoto Disease Diseases 0.000 description 1
• 208000030836 Hashimoto thyroiditis Diseases 0.000 description 1
• 208000035186 Hemolytic Autoimmune Anemia Diseases 0.000 description 1
• 208000005100 Herpetic Keratitis Diseases 0.000 description 1
• 229940122236 Histamine receptor antagonist Drugs 0.000 description 1
• 101000785776 Homo sapiens Artemin Proteins 0.000 description 1
• 101000979342 Homo sapiens Nuclear factor NF-kappa-B p105 subunit Proteins 0.000 description 1
• 101001059454 Homo sapiens Serine/threonine-protein kinase MARK2 Proteins 0.000 description 1
• 101000845170 Homo sapiens Thymic stromal lymphopoietin Proteins 0.000 description 1
• 101000669447 Homo sapiens Toll-like receptor 4 Proteins 0.000 description 1
• 101000611183 Homo sapiens Tumor necrosis factor Proteins 0.000 description 1
• 101001072037 Homo sapiens cAMP and cAMP-inhibited cGMP 3',5'-cyclic phosphodiesterase 10A Proteins 0.000 description 1
• 241000714260 Human T-lymphotropic virus 1 Species 0.000 description 1
• 208000023105 Huntington disease Diseases 0.000 description 1
• 241000257303 Hymenoptera Species 0.000 description 1
• 239000003458 I kappa b kinase inhibitor Substances 0.000 description 1
• 102000039992 IL-3 family Human genes 0.000 description 1
• 108091069211 IL-3 family Proteins 0.000 description 1
• 229940127590 IRAK4 inhibitor Drugs 0.000 description 1
• ZJVFLBOZORBYFE-UHFFFAOYSA-N Ibudilast Chemical compound C1=CC=CC2=C(C(=O)C(C)C)C(C(C)C)=NN21 ZJVFLBOZORBYFE-UHFFFAOYSA-N 0.000 description 1
• 206010062016 Immunosuppression Diseases 0.000 description 1
• 108010008212 Integrin alpha4beta1 Proteins 0.000 description 1
• 102100026720 Interferon beta Human genes 0.000 description 1
• 102100037850 Interferon gamma Human genes 0.000 description 1
• 102000006992 Interferon-alpha Human genes 0.000 description 1
• 108010047761 Interferon-alpha Proteins 0.000 description 1
• 102000003996 Interferon-beta Human genes 0.000 description 1
• 108010074328 Interferon-gamma Proteins 0.000 description 1
• 108010050904 Interferons Proteins 0.000 description 1
• 102000014150 Interferons Human genes 0.000 description 1
• 108090000177 Interleukin-11 Proteins 0.000 description 1
• 102000003815 Interleukin-11 Human genes 0.000 description 1
• 102000013462 Interleukin-12 Human genes 0.000 description 1
• 108010065805 Interleukin-12 Proteins 0.000 description 1
• 108090000176 Interleukin-13 Proteins 0.000 description 1
• 108090000172 Interleukin-15 Proteins 0.000 description 1
• 102100039879 Interleukin-19 Human genes 0.000 description 1
• 108050009288 Interleukin-19 Proteins 0.000 description 1
• 108010002350 Interleukin-2 Proteins 0.000 description 1
• 102000000588 Interleukin-2 Human genes 0.000 description 1
• 102000013264 Interleukin-23 Human genes 0.000 description 1
• 108010065637 Interleukin-23 Proteins 0.000 description 1
• 108010002386 Interleukin-3 Proteins 0.000 description 1
• 108090000978 Interleukin-4 Proteins 0.000 description 1
• 108010002616 Interleukin-5 Proteins 0.000 description 1
• 102000004889 Interleukin-6 Human genes 0.000 description 1
• 108090001005 Interleukin-6 Proteins 0.000 description 1
• 102000010781 Interleukin-6 Receptors Human genes 0.000 description 1
• 108010038501 Interleukin-6 Receptors Proteins 0.000 description 1
• 108010002586 Interleukin-7 Proteins 0.000 description 1
• 102000002791 Interleukin-8B Receptors Human genes 0.000 description 1
• 108010018951 Interleukin-8B Receptors Proteins 0.000 description 1
• 108010002335 Interleukin-9 Proteins 0.000 description 1
• 206010022941 Iridocyclitis Diseases 0.000 description 1
• LPHGQDQBBGAPDZ-UHFFFAOYSA-N Isocaffeine Natural products CN1C(=O)N(C)C(=O)C2=C1N(C)C=N2 LPHGQDQBBGAPDZ-UHFFFAOYSA-N 0.000 description 1
• 102000008986 Janus Human genes 0.000 description 1
• 108050000950 Janus Proteins 0.000 description 1
• 206010059176 Juvenile idiopathic arthritis Diseases 0.000 description 1
• 208000007766 Kaposi sarcoma Diseases 0.000 description 1
• 208000008839 Kidney Neoplasms Diseases 0.000 description 1
• 108010093008 Kinins Proteins 0.000 description 1
• 102000002397 Kinins Human genes 0.000 description 1
• WTDRDQBEARUVNC-LURJTMIESA-N L-DOPA Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-LURJTMIESA-N 0.000 description 1
• WTDRDQBEARUVNC-UHFFFAOYSA-N L-Dopa Natural products OC(=O)C(N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-UHFFFAOYSA-N 0.000 description 1
• ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
• CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
• WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
• KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 1
• SNDPXSYFESPGGJ-UHFFFAOYSA-N L-norVal-OH Natural products CCCC(N)C(O)=O SNDPXSYFESPGGJ-UHFFFAOYSA-N 0.000 description 1
• ULSSJYNJIZWPSB-CVRXJBIPSA-N LY-411575 Chemical compound C1([C@H](O)C(=O)N[C@@H](C)C(=O)N[C@@H]2C(N(C)C3=CC=CC=C3C3=CC=CC=C32)=O)=CC(F)=CC(F)=C1 ULSSJYNJIZWPSB-CVRXJBIPSA-N 0.000 description 1
• JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 1
• 108010092277 Leptin Proteins 0.000 description 1
• 102000016267 Leptin Human genes 0.000 description 1
• 102100032352 Leukemia inhibitory factor Human genes 0.000 description 1
• 108090000581 Leukemia inhibitory factor Proteins 0.000 description 1
• 239000012448 Lithium borohydride Substances 0.000 description 1
• 206010058467 Lung neoplasm malignant Diseases 0.000 description 1
• 206010025323 Lymphomas Diseases 0.000 description 1
• KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
• 239000004472 Lysine Substances 0.000 description 1
• 241000282553 Macaca Species 0.000 description 1
• 241000282567 Macaca fascicularis Species 0.000 description 1
• 241000282560 Macaca mulatta Species 0.000 description 1
• 108010046938 Macrophage Colony-Stimulating Factor Proteins 0.000 description 1
• 102000007651 Macrophage Colony-Stimulating Factor Human genes 0.000 description 1
• 102100027998 Macrophage metalloelastase Human genes 0.000 description 1
• 101710187853 Macrophage metalloelastase Proteins 0.000 description 1
• FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
• OFOBLEOULBTSOW-UHFFFAOYSA-L Malonate Chemical compound [O-]C(=O)CC([O-])=O OFOBLEOULBTSOW-UHFFFAOYSA-L 0.000 description 1
• 206010026749 Mania Diseases 0.000 description 1
• 102100030412 Matrix metalloproteinase-9 Human genes 0.000 description 1
• 108010015302 Matrix metalloproteinase-9 Proteins 0.000 description 1
• 201000009906 Meningitis Diseases 0.000 description 1
• 102000005741 Metalloproteases Human genes 0.000 description 1
• 108010006035 Metalloproteases Proteins 0.000 description 1
• 206010027480 Metastatic malignant melanoma Diseases 0.000 description 1
• 102100025695 Meteorin Human genes 0.000 description 1
• 101710204352 Meteorin Proteins 0.000 description 1
• AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 1
• WJAJPNHVVFWKKL-UHFFFAOYSA-N Methoxamine Chemical compound COC1=CC=C(OC)C(C(O)C(C)N)=C1 WJAJPNHVVFWKKL-UHFFFAOYSA-N 0.000 description 1
• 206010049567 Miller Fisher syndrome Diseases 0.000 description 1
• UCHDWCPVSPXUMX-TZIWLTJVSA-N Montelukast Chemical compound CC(C)(O)C1=CC=CC=C1CC[C@H](C=1C=C(\C=C\C=2N=C3C=C(Cl)C=CC3=CC=2)C=CC=1)SCC1(CC(O)=O)CC1 UCHDWCPVSPXUMX-TZIWLTJVSA-N 0.000 description 1
• 241000699670 Mus sp. Species 0.000 description 1
• 102000014415 Muscarinic acetylcholine receptor Human genes 0.000 description 1
• 108050003473 Muscarinic acetylcholine receptor Proteins 0.000 description 1
• 208000002231 Muscle Neoplasms Diseases 0.000 description 1
• 241000282339 Mustela Species 0.000 description 1
• 208000003926 Myelitis Diseases 0.000 description 1
• 208000033761 Myelogenous Chronic BCR-ABL Positive Leukemia Diseases 0.000 description 1
• 206010028570 Myelopathy Diseases 0.000 description 1
• 208000014767 Myeloproliferative disease Diseases 0.000 description 1
• RQLXKQUZTLVUQY-IYBDPMFKSA-N N([C@H]1C[C@H](C1)N(C)C=1C=2C=CN(C=2N=CN=1)S(=O)(=O)C=1C=CC(C)=CC=1)S(=O)(=O)C1CNC1 Chemical compound N([C@H]1C[C@H](C1)N(C)C=1C=2C=CN(C=2N=CN=1)S(=O)(=O)C=1C=CC(C)=CC=1)S(=O)(=O)C1CNC1 RQLXKQUZTLVUQY-IYBDPMFKSA-N 0.000 description 1
• MBBZMMPHUWSWHV-BDVNFPICSA-N N-methylglucamine Chemical compound CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO MBBZMMPHUWSWHV-BDVNFPICSA-N 0.000 description 1
• KULAQFFRSWFJPY-GASCZTMLSA-N N=1C=NC=2N(S(=O)(=O)C=3C=CC(C)=CC=3)C=CC=2C=1N(C)[C@@H]1C[C@H](CS(O)(=O)=O)C1 Chemical compound N=1C=NC=2N(S(=O)(=O)C=3C=CC(C)=CC=3)C=CC=2C=1N(C)[C@@H]1C[C@H](CS(O)(=O)=O)C1 KULAQFFRSWFJPY-GASCZTMLSA-N 0.000 description 1
• 229910002651 NO3 Inorganic materials 0.000 description 1
• CMWTZPSULFXXJA-UHFFFAOYSA-N Naproxen Natural products C1=C(C(C)C(O)=O)C=CC2=CC(OC)=CC=C21 CMWTZPSULFXXJA-UHFFFAOYSA-N 0.000 description 1
• JAUOIFJMECXRGI-UHFFFAOYSA-N Neoclaritin Chemical compound C=1C(Cl)=CC=C2C=1CCC1=CC=CN=C1C2=C1CCNCC1 JAUOIFJMECXRGI-UHFFFAOYSA-N 0.000 description 1
• 206010029113 Neovascularisation Diseases 0.000 description 1
• 206010029350 Neurotoxicity Diseases 0.000 description 1
• 229940123925 Nicotinic receptor agonist Drugs 0.000 description 1
• NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 description 1
• 102100023050 Nuclear factor NF-kappa-B p105 subunit Human genes 0.000 description 1
• 108090000630 Oncostatin M Proteins 0.000 description 1
• 102100031942 Oncostatin-M Human genes 0.000 description 1
• 206010073938 Ophthalmic herpes simplex Diseases 0.000 description 1
• 206010033128 Ovarian cancer Diseases 0.000 description 1
• 206010061535 Ovarian neoplasm Diseases 0.000 description 1
• 241000283903 Ovis aries Species 0.000 description 1
• MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 1
• 102100028045 P2Y purinoceptor 2 Human genes 0.000 description 1
• 101710096700 P2Y purinoceptor 2 Proteins 0.000 description 1
• 229940076380 PDE9 inhibitor Drugs 0.000 description 1
• 229910019142 PO4 Inorganic materials 0.000 description 1
• 208000002193 Pain Diseases 0.000 description 1
• 241000282579 Pan Species 0.000 description 1
• 102000016387 Pancreatic elastase Human genes 0.000 description 1
• 108010067372 Pancreatic elastase Proteins 0.000 description 1
• 241001494479 Pecora Species 0.000 description 1
• 206010034277 Pemphigoid Diseases 0.000 description 1
• 229920001774 Perfluoroether Polymers 0.000 description 1
• 208000031845 Pernicious anaemia Diseases 0.000 description 1
• 241000286209 Phasianidae Species 0.000 description 1
• NBIIXXVUZAFLBC-UHFFFAOYSA-L Phosphate ion(2-) Chemical compound OP([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-L 0.000 description 1
• 229940121836 Phosphodiesterase 1 inhibitor Drugs 0.000 description 1
• 229940121828 Phosphodiesterase 2 inhibitor Drugs 0.000 description 1
• 229940123263 Phosphodiesterase 3 inhibitor Drugs 0.000 description 1
• 208000024571 Pick disease Diseases 0.000 description 1
• 208000012654 Primary biliary cholangitis Diseases 0.000 description 1
• 241000288906 Primates Species 0.000 description 1
• 206010036774 Proctitis Diseases 0.000 description 1
• KNAHARQHSZJURB-UHFFFAOYSA-N Propylthiouracile Chemical compound CCCC1=CC(=O)NC(=S)N1 KNAHARQHSZJURB-UHFFFAOYSA-N 0.000 description 1
• 108050000258 Prostaglandin D receptors Proteins 0.000 description 1
• 102100024218 Prostaglandin D2 receptor 2 Human genes 0.000 description 1
• 108030003866 Prostaglandin-D synthases Proteins 0.000 description 1
• 102100033279 Prostaglandin-H2 D-isomerase Human genes 0.000 description 1
• 102000004005 Prostaglandin-endoperoxide synthases Human genes 0.000 description 1
• 108090000459 Prostaglandin-endoperoxide synthases Proteins 0.000 description 1
• 206010060862 Prostate cancer Diseases 0.000 description 1
• 208000000236 Prostatic Neoplasms Diseases 0.000 description 1
• 208000020410 Psoriasis-related juvenile idiopathic arthritis Diseases 0.000 description 1
• 206010071141 Rasmussen encephalitis Diseases 0.000 description 1
• 208000004160 Rasmussen subacute encephalitis Diseases 0.000 description 1
• 241000700159 Rattus Species 0.000 description 1
• 208000033464 Reiter syndrome Diseases 0.000 description 1
• 206010038389 Renal cancer Diseases 0.000 description 1
• 206010063897 Renal ischaemia Diseases 0.000 description 1
• 206010063837 Reperfusion injury Diseases 0.000 description 1
• 241000282849 Ruminantia Species 0.000 description 1
• 241000288961 Saguinus imperator Species 0.000 description 1
• 206010039705 Scleritis Diseases 0.000 description 1
• 229940124639 Selective inhibitor Drugs 0.000 description 1
• GIIZNNXWQWCKIB-UHFFFAOYSA-N Serevent Chemical compound C1=C(O)C(CO)=CC(C(O)CNCCCCCCOCCCCC=2C=CC=CC=2)=C1 GIIZNNXWQWCKIB-UHFFFAOYSA-N 0.000 description 1
• 102100028904 Serine/threonine-protein kinase MARK2 Human genes 0.000 description 1
• 208000000453 Skin Neoplasms Diseases 0.000 description 1
• UIIMBOGNXHQVGW-DEQYMQKBSA-M Sodium bicarbonate-14C Chemical compound [Na+].O[14C]([O-])=O UIIMBOGNXHQVGW-DEQYMQKBSA-M 0.000 description 1
• 201000009594 Systemic Scleroderma Diseases 0.000 description 1
• 206010042953 Systemic sclerosis Diseases 0.000 description 1
• 210000001744 T-lymphocyte Anatomy 0.000 description 1
• 102000003141 Tachykinin Human genes 0.000 description 1
• QJJXYPPXXYFBGM-LFZNUXCKSA-N Tacrolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1\C=C(/C)[C@@H]1[C@H](C)[C@@H](O)CC(=O)[C@H](CC=C)/C=C(C)/C[C@H](C)C[C@H](OC)[C@H]([C@H](C[C@H]2C)OC)O[C@@]2(O)C(=O)C(=O)N2CCCC[C@H]2C(=O)O1 QJJXYPPXXYFBGM-LFZNUXCKSA-N 0.000 description 1
• 208000031981 Thrombocytopenic Idiopathic Purpura Diseases 0.000 description 1
• 102000036693 Thrombopoietin Human genes 0.000 description 1
• 108010041111 Thrombopoietin Proteins 0.000 description 1
• 102100031294 Thymic stromal lymphopoietin Human genes 0.000 description 1
• 102100039360 Toll-like receptor 4 Human genes 0.000 description 1
• 206010044221 Toxic encephalopathy Diseases 0.000 description 1
• 108091023040 Transcription factor Proteins 0.000 description 1
• 102000040945 Transcription factor Human genes 0.000 description 1
• DTQVDTLACAAQTR-UHFFFAOYSA-M Trifluoroacetate Chemical compound [O-]C(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-M 0.000 description 1
• OKJPEAGHQZHRQV-UHFFFAOYSA-N Triiodomethane Natural products IC(I)I OKJPEAGHQZHRQV-UHFFFAOYSA-N 0.000 description 1
• 208000025865 Ulcer Diseases 0.000 description 1
• 208000007097 Urinary Bladder Neoplasms Diseases 0.000 description 1
• SECKRCOLJRRGGV-UHFFFAOYSA-N Vardenafil Chemical compound CCCC1=NC(C)=C(C(N=2)=O)N1NC=2C(C(=CC=1)OCC)=CC=1S(=O)(=O)N1CCN(CC)CC1 SECKRCOLJRRGGV-UHFFFAOYSA-N 0.000 description 1
• DDNCQMVWWZOMLN-IRLDBZIGSA-N Vinpocetine Chemical compound C1=CC=C2C(CCN3CCC4)=C5[C@@H]3[C@]4(CC)C=C(C(=O)OCC)N5C2=C1 DDNCQMVWWZOMLN-IRLDBZIGSA-N 0.000 description 1
• 241000700605 Viruses Species 0.000 description 1
• YEEZWCHGZNKEEK-UHFFFAOYSA-N Zafirlukast Chemical compound COC1=CC(C(=O)NS(=O)(=O)C=2C(=CC=CC=2)C)=CC=C1CC(C1=C2)=CN(C)C1=CC=C2NC(=O)OC1CCCC1 YEEZWCHGZNKEEK-UHFFFAOYSA-N 0.000 description 1
• ZIGIADNCAWZUAB-CTNGQTDRSA-N [(3ar,8bs)-8b-methyl-2,3,3a,4-tetrahydro-1h-pyrrolo[2,3-b]indol-7-yl] n-(4-propan-2-ylphenyl)carbamate Chemical compound C1=CC(C(C)C)=CC=C1NC(=O)OC1=CC=C(N[C@@H]2[C@@]3(C)CCN2)C3=C1 ZIGIADNCAWZUAB-CTNGQTDRSA-N 0.000 description 1
• VADGYMAIAMJJLP-UHFFFAOYSA-N [3-(cyanomethyl)-3-methylcyclobutyl] 4-methylbenzenesulfonate Chemical compound C1=CC(C)=CC=C1S(=O)(=O)OC1CC(C)(CC#N)C1 VADGYMAIAMJJLP-UHFFFAOYSA-N 0.000 description 1
• FCGMOGXHPQIDAB-UHFFFAOYSA-N [3-(cyanomethyl)oxetan-3-yl]methyl thiocyanate Chemical compound N#CSCC1(CC#N)COC1 FCGMOGXHPQIDAB-UHFFFAOYSA-N 0.000 description 1
• WERSQRBKCXZBBA-UHFFFAOYSA-N [3-[methyl-[7-(4-methylphenyl)sulfonylpyrrolo[2,3-d]pyrimidin-4-yl]amino]cyclobutyl]methanesulfonyl chloride Chemical compound N=1C=NC=2N(S(=O)(=O)C=3C=CC(C)=CC=3)C=CC=2C=1N(C)C1CC(CS(Cl)(=O)=O)C1 WERSQRBKCXZBBA-UHFFFAOYSA-N 0.000 description 1
• 238000009825 accumulation Methods 0.000 description 1
• FHEAIOHRHQGZPC-KIWGSFCNSA-N acetic acid;(2s)-2-amino-3-(4-hydroxyphenyl)propanoic acid;(2s)-2-aminopentanedioic acid;(2s)-2-aminopropanoic acid;(2s)-2,6-diaminohexanoic acid Chemical compound CC(O)=O.C[C@H](N)C(O)=O.NCCCC[C@H](N)C(O)=O.OC(=O)[C@@H](N)CCC(O)=O.OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 FHEAIOHRHQGZPC-KIWGSFCNSA-N 0.000 description 1
• MNZMECMQTYGSOI-UHFFFAOYSA-N acetic acid;hydron;bromide Chemical compound Br.CC(O)=O MNZMECMQTYGSOI-UHFFFAOYSA-N 0.000 description 1
• PBCJIPOGFJYBJE-UHFFFAOYSA-N acetonitrile;hydrate Chemical compound O.CC#N PBCJIPOGFJYBJE-UHFFFAOYSA-N 0.000 description 1
• WETWJCDKMRHUPV-UHFFFAOYSA-N acetyl chloride Chemical compound CC(Cl)=O WETWJCDKMRHUPV-UHFFFAOYSA-N 0.000 description 1
• 239000012346 acetyl chloride Substances 0.000 description 1
• 230000002378 acidificating effect Effects 0.000 description 1
• 150000007513 acids Chemical class 0.000 description 1
• 230000003213 activating effect Effects 0.000 description 1
• 239000013543 active substance Substances 0.000 description 1
• 208000002552 acute disseminated encephalomyelitis Diseases 0.000 description 1
• 125000002015 acyclic group Chemical group 0.000 description 1
• 229960002964 adalimumab Drugs 0.000 description 1
• 239000003449 adenosine A2 receptor antagonist Substances 0.000 description 1
• 239000002465 adenosine A2a receptor agonist Substances 0.000 description 1
• 239000002467 adenosine A2a receptor antagonist Substances 0.000 description 1
• WNLRTRBMVRJNCN-UHFFFAOYSA-L adipate(2-) Chemical compound [O-]C(=O)CCCCC([O-])=O WNLRTRBMVRJNCN-UHFFFAOYSA-L 0.000 description 1
• 239000000048 adrenergic agonist Substances 0.000 description 1
• 239000000695 adrenergic alpha-agonist Substances 0.000 description 1
• 229940126157 adrenergic receptor agonist Drugs 0.000 description 1
• 230000002411 adverse Effects 0.000 description 1
• 206010064930 age-related macular degeneration Diseases 0.000 description 1
• 150000001299 aldehydes Chemical class 0.000 description 1
• 239000013566 allergen Substances 0.000 description 1
• 201000009961 allergic asthma Diseases 0.000 description 1
• 208000002205 allergic conjunctivitis Diseases 0.000 description 1
• 231100000360 alopecia Toxicity 0.000 description 1
• 102000030619 alpha-1 Adrenergic Receptor Human genes 0.000 description 1
• 108020004102 alpha-1 Adrenergic Receptor Proteins 0.000 description 1
• 102000030484 alpha-2 Adrenergic Receptor Human genes 0.000 description 1
• 108020004101 alpha-2 Adrenergic Receptor Proteins 0.000 description 1
• BAZMYXGARXYAEQ-UHFFFAOYSA-N alpha-ethyl valeric acid Chemical compound CCCC(CC)C(O)=O BAZMYXGARXYAEQ-UHFFFAOYSA-N 0.000 description 1
• XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
• 229910052782 aluminium Inorganic materials 0.000 description 1
• 125000003277 amino group Chemical group 0.000 description 1
• 125000006598 aminocarbonylamino group Chemical group 0.000 description 1
• 229960000836 amitriptyline Drugs 0.000 description 1
• 239000002269 analeptic agent Substances 0.000 description 1
• 230000033115 angiogenesis Effects 0.000 description 1
• 201000004612 anterior uveitis Diseases 0.000 description 1
• 239000003242 anti bacterial agent Substances 0.000 description 1
• 230000001078 anti-cholinergic effect Effects 0.000 description 1
• 229940121363 anti-inflammatory agent Drugs 0.000 description 1
• 239000002260 anti-inflammatory agent Substances 0.000 description 1
• 230000000840 anti-viral effect Effects 0.000 description 1
• 229940088710 antibiotic agent Drugs 0.000 description 1
• 229940125681 anticonvulsant agent Drugs 0.000 description 1
• 239000001961 anticonvulsive agent Substances 0.000 description 1
• 229940125715 antihistaminic agent Drugs 0.000 description 1
• 239000000739 antihistaminic agent Substances 0.000 description 1
• 239000000164 antipsychotic agent Substances 0.000 description 1
• 229940005529 antipsychotics Drugs 0.000 description 1
• 239000003443 antiviral agent Substances 0.000 description 1
• 229940070343 apokyn Drugs 0.000 description 1
• 229960004046 apomorphine Drugs 0.000 description 1
• 230000006907 apoptotic process Effects 0.000 description 1
• 239000003125 aqueous solvent Substances 0.000 description 1
• 238000010936 aqueous wash Methods 0.000 description 1
• 210000000576 arachnoid Anatomy 0.000 description 1
• ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
• 229940039856 aricept Drugs 0.000 description 1
• 208000011775 arteriosclerosis disease Diseases 0.000 description 1
• 229940009098 aspartate Drugs 0.000 description 1
• 229940092117 atgam Drugs 0.000 description 1
• 229960002430 atomoxetine Drugs 0.000 description 1
• 208000024998 atopic conjunctivitis Diseases 0.000 description 1
• 201000000448 autoimmune hemolytic anemia Diseases 0.000 description 1
• 229940003504 avonex Drugs 0.000 description 1
• 229960002170 azathioprine Drugs 0.000 description 1
• 125000003725 azepanyl group Chemical group 0.000 description 1
• KVVMXWRFYAGASO-UHFFFAOYSA-N azetidine-1-carboxylic acid Chemical compound OC(=O)N1CCC1 KVVMXWRFYAGASO-UHFFFAOYSA-N 0.000 description 1
• HWZXQNQIPMKXJY-UHFFFAOYSA-N azetidine-3-sulfonamide Chemical compound N1CC(C1)S(=O)(=O)N HWZXQNQIPMKXJY-UHFFFAOYSA-N 0.000 description 1
• 125000002393 azetidinyl group Chemical group 0.000 description 1
• 125000004069 aziridinyl group Chemical group 0.000 description 1
• 229960000794 baclofen Drugs 0.000 description 1
• 229950001863 bapineuzumab Drugs 0.000 description 1
• 230000004888 barrier function Effects 0.000 description 1
• 230000008901 benefit Effects 0.000 description 1
• JUHORIMYRDESRB-UHFFFAOYSA-N benzathine Chemical compound C=1C=CC=CC=1CNCCNCC1=CC=CC=C1 JUHORIMYRDESRB-UHFFFAOYSA-N 0.000 description 1
• SRSXLGNVWSONIS-UHFFFAOYSA-M benzenesulfonate Chemical compound [O-]S(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-M 0.000 description 1
• GTRLQRHWPXEBLF-UHFFFAOYSA-N benzyl carbamimidothioate Chemical compound NC(=N)SCC1=CC=CC=C1 GTRLQRHWPXEBLF-UHFFFAOYSA-N 0.000 description 1
• PSAMWNBBHLUISE-UHFFFAOYSA-N benzyl n-(3-oxocyclobutyl)carbamate Chemical compound C=1C=CC=CC=1COC(=O)NC1CC(=O)C1 PSAMWNBBHLUISE-UHFFFAOYSA-N 0.000 description 1
• UENWRTRMUIOCKN-UHFFFAOYSA-N benzyl thiol Chemical compound SCC1=CC=CC=C1 UENWRTRMUIOCKN-UHFFFAOYSA-N 0.000 description 1
• 229940124748 beta 2 agonist Drugs 0.000 description 1
• 102000012740 beta Adrenergic Receptors Human genes 0.000 description 1
• 108010079452 beta Adrenergic Receptors Proteins 0.000 description 1
• 239000002876 beta blocker Substances 0.000 description 1
• 229940097320 beta blocking agent Drugs 0.000 description 1
• 239000002439 beta secretase inhibitor Substances 0.000 description 1
• 229940021459 betaseron Drugs 0.000 description 1
• 229960002123 bethanechol chloride Drugs 0.000 description 1
• 229960000397 bevacizumab Drugs 0.000 description 1
• 230000033228 biological regulation Effects 0.000 description 1
• 125000005620 boronic acid group Chemical class 0.000 description 1
• 210000004556 brain Anatomy 0.000 description 1
• 208000025698 brain inflammatory disease Diseases 0.000 description 1
• 210000000133 brain stem Anatomy 0.000 description 1
• 229940077737 brain-derived neurotrophic factor Drugs 0.000 description 1
• OZVBMTJYIDMWIL-AYFBDAFISA-N bromocriptine Chemical compound C1=CC(C=2[C@H](N(C)C[C@@H](C=2)C(=O)N[C@]2(C(=O)N3[C@H](C(N4CCC[C@H]4[C@]3(O)O2)=O)CC(C)C)C(C)C)C2)=C3C2=C(Br)NC3=C1 OZVBMTJYIDMWIL-AYFBDAFISA-N 0.000 description 1
• 229960002802 bromocriptine Drugs 0.000 description 1
• 206010006451 bronchitis Diseases 0.000 description 1
• 229960004436 budesonide Drugs 0.000 description 1
• 208000000594 bullous pemphigoid Diseases 0.000 description 1
• 102100036377 cAMP and cAMP-inhibited cGMP 3',5'-cyclic phosphodiesterase 10A Human genes 0.000 description 1
• 229960001948 caffeine Drugs 0.000 description 1
• VJEONQKOZGKCAK-UHFFFAOYSA-N caffeine Natural products CN1C(=O)N(C)C(=O)C2=C1C=CN2C VJEONQKOZGKCAK-UHFFFAOYSA-N 0.000 description 1
• 239000011575 calcium Substances 0.000 description 1
• 229910052791 calcium Inorganic materials 0.000 description 1
• 239000000480 calcium channel blocker Substances 0.000 description 1
• 159000000007 calcium salts Chemical class 0.000 description 1
• MIOPJNTWMNEORI-UHFFFAOYSA-N camphorsulfonic acid Chemical compound C1CC2(CS(O)(=O)=O)C(=O)CC1C2(C)C MIOPJNTWMNEORI-UHFFFAOYSA-N 0.000 description 1
• 229960000623 carbamazepine Drugs 0.000 description 1
• 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 description 1
• 229940057922 carbatrol Drugs 0.000 description 1
• QTAOMKOIBXZKND-PPHPATTJSA-N carbidopa Chemical compound O.NN[C@@](C(O)=O)(C)CC1=CC=C(O)C(O)=C1 QTAOMKOIBXZKND-PPHPATTJSA-N 0.000 description 1
• 229960004205 carbidopa Drugs 0.000 description 1
• 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 1
• LWAFSWPYPHEXKX-UHFFFAOYSA-N carteolol Chemical compound N1C(=O)CCC2=C1C=CC=C2OCC(O)CNC(C)(C)C LWAFSWPYPHEXKX-UHFFFAOYSA-N 0.000 description 1
• 229960001222 carteolol Drugs 0.000 description 1
• 210000000845 cartilage Anatomy 0.000 description 1
• 229940063628 catapres Drugs 0.000 description 1
• RZEKVGVHFLEQIL-UHFFFAOYSA-N celecoxib Chemical compound C1=CC(C)=CC=C1C1=CC(C(F)(F)F)=NN1C1=CC=C(S(N)(=O)=O)C=C1 RZEKVGVHFLEQIL-UHFFFAOYSA-N 0.000 description 1
• 229960000590 celecoxib Drugs 0.000 description 1
• 229940047493 celexa Drugs 0.000 description 1
• 230000024245 cell differentiation Effects 0.000 description 1
• 230000010261 cell growth Effects 0.000 description 1
• 230000009087 cell motility Effects 0.000 description 1
• 229940107810 cellcept Drugs 0.000 description 1
• 230000001413 cellular effect Effects 0.000 description 1
• 230000036755 cellular response Effects 0.000 description 1
• 206010008118 cerebral infarction Diseases 0.000 description 1
• 229960001803 cetirizine Drugs 0.000 description 1
• 238000007385 chemical modification Methods 0.000 description 1
• 239000003638 chemical reducing agent Substances 0.000 description 1
• 235000013330 chicken meat Nutrition 0.000 description 1
• 229910052801 chlorine Inorganic materials 0.000 description 1
• 229960001231 choline Drugs 0.000 description 1
• OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 description 1
• 239000000544 cholinesterase inhibitor Substances 0.000 description 1
• 208000016644 chronic atrophic gastritis Diseases 0.000 description 1
• 201000005795 chronic inflammatory demyelinating polyneuritis Diseases 0.000 description 1
• 229960003728 ciclesonide Drugs 0.000 description 1
• LOUPRKONTZGTKE-UHFFFAOYSA-N cinchonine Natural products C1C(C(C2)C=C)CCN2C1C(O)C1=CC=NC2=CC=C(OC)C=C21 LOUPRKONTZGTKE-UHFFFAOYSA-N 0.000 description 1
• 229960001653 citalopram Drugs 0.000 description 1
• 229960002896 clonidine Drugs 0.000 description 1
• 208000029742 colonic neoplasm Diseases 0.000 description 1
• 108010002212 colostrinine Proteins 0.000 description 1
• 238000010276 construction Methods 0.000 description 1
• 238000013270 controlled release Methods 0.000 description 1
• 238000007796 conventional method Methods 0.000 description 1
• 238000001816 cooling Methods 0.000 description 1
• 229940038717 copaxone Drugs 0.000 description 1
• 229920001577 copolymer Polymers 0.000 description 1
• 229910052802 copper Inorganic materials 0.000 description 1
• 239000010949 copper Substances 0.000 description 1
• YNYHGRUPNQLZHB-UHFFFAOYSA-M copper(1+);trifluoromethanesulfonate Chemical compound [Cu+].[O-]S(=O)(=O)C(F)(F)F YNYHGRUPNQLZHB-UHFFFAOYSA-M 0.000 description 1
• 210000004087 cornea Anatomy 0.000 description 1
• 239000006184 cosolvent Substances 0.000 description 1
• 229940109248 cromoglycate Drugs 0.000 description 1
• IMZMKUWMOSJXDT-UHFFFAOYSA-N cromoglycic acid Chemical compound O1C(C(O)=O)=CC(=O)C2=C1C=CC=C2OCC(O)COC1=CC=CC2=C1C(=O)C=C(C(O)=O)O2 IMZMKUWMOSJXDT-UHFFFAOYSA-N 0.000 description 1
• 238000009109 curative therapy Methods 0.000 description 1
• MAEBCGDGGATMSC-OSHGGGOQSA-N cyclamine Chemical compound O([C@H]1CO[C@H]([C@@H]([C@H]1O[C@@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O[C@@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)O[C@H]1CC[C@]2(C)[C@H]3CCC45OCC6([C@@H](C[C@@]4(C)[C@]3(C)CCC2C1(C)C)O)CC[C@@](C[C@@H]65)(C)C=O)[C@@H]1OC[C@@H](O)[C@H](O)[C@H]1O MAEBCGDGGATMSC-OSHGGGOQSA-N 0.000 description 1
• 125000000582 cycloheptyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
• 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
• 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
• 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 1
• ACQBHJXEAYTHCY-UHFFFAOYSA-N cyclopropyl-[4-[3-(1H-imidazol-5-yl)propoxy]phenyl]methanone Chemical compound C=1C=C(OCCCC=2NC=NC=2)C=CC=1C(=O)C1CC1 ACQBHJXEAYTHCY-UHFFFAOYSA-N 0.000 description 1
• 230000010250 cytokine signaling pathway Effects 0.000 description 1
• 229960002806 daclizumab Drugs 0.000 description 1
• 230000007812 deficiency Effects 0.000 description 1
• 230000006735 deficit Effects 0.000 description 1
• 230000003111 delayed effect Effects 0.000 description 1
• 229940027008 deltasone Drugs 0.000 description 1
• 230000003831 deregulation Effects 0.000 description 1
• 201000001981 dermatomyositis Diseases 0.000 description 1
• NKLCNNUWBJBICK-UHFFFAOYSA-N dess–martin periodinane Chemical compound C1=CC=C2I(OC(=O)C)(OC(C)=O)(OC(C)=O)OC(=O)C2=C1 NKLCNNUWBJBICK-UHFFFAOYSA-N 0.000 description 1
• 125000002576 diazepinyl group Chemical group N1N=C(C=CC=C1)* 0.000 description 1
• 235000005911 diet Nutrition 0.000 description 1
• 230000000378 dietary effect Effects 0.000 description 1
• ZBCBWPMODOFKDW-UHFFFAOYSA-N diethanolamine Chemical compound OCCNCCO ZBCBWPMODOFKDW-UHFFFAOYSA-N 0.000 description 1
• HPNMFZURTQLUMO-UHFFFAOYSA-N diethylamine Chemical compound CCNCC HPNMFZURTQLUMO-UHFFFAOYSA-N 0.000 description 1
• NBIIXXVUZAFLBC-UHFFFAOYSA-M dihydrogenphosphate Chemical compound OP(O)([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-M 0.000 description 1
• 229940043279 diisopropylamine Drugs 0.000 description 1
• 229910001873 dinitrogen Inorganic materials 0.000 description 1
• 229950010286 diolamine Drugs 0.000 description 1
• 229940042399 direct acting antivirals protease inhibitors Drugs 0.000 description 1
• 231100000676 disease causative agent Toxicity 0.000 description 1
• 238000004090 dissolution Methods 0.000 description 1
• 238000004821 distillation Methods 0.000 description 1
• ADEBPBSSDYVVLD-UHFFFAOYSA-N donepezil Natural products O=C1C=2C=C(OC)C(OC)=CC=2CC1CC(CC1)CCN1CC1=CC=CC=C1 ADEBPBSSDYVVLD-UHFFFAOYSA-N 0.000 description 1
• 229960003135 donepezil hydrochloride Drugs 0.000 description 1
• 239000000534 dopa decarboxylase inhibitor Substances 0.000 description 1
• 239000003210 dopamine receptor blocking agent Substances 0.000 description 1
• 239000000221 dopamine uptake inhibitor Substances 0.000 description 1
• 230000009977 dual effect Effects 0.000 description 1
• 229940011681 elavil Drugs 0.000 description 1
• 239000003480 eluent Substances 0.000 description 1
• 229940071670 emsam Drugs 0.000 description 1
• 238000004945 emulsification Methods 0.000 description 1
• 230000002124 endocrine Effects 0.000 description 1
• 201000001564 eosinophilic gastroenteritis Diseases 0.000 description 1
• NLPRAJRHRHZCQQ-IVZWLZJFSA-N epibatidine Chemical compound C1=NC(Cl)=CC=C1[C@@H]1[C@H](N2)CC[C@H]2C1 NLPRAJRHRHZCQQ-IVZWLZJFSA-N 0.000 description 1
• 229960003367 ersofermin Drugs 0.000 description 1
• 150000002148 esters Chemical class 0.000 description 1
• 229960000403 etanercept Drugs 0.000 description 1
• CCIVGXIOQKPBKL-UHFFFAOYSA-M ethanesulfonate Chemical compound CCS([O-])(=O)=O CCIVGXIOQKPBKL-UHFFFAOYSA-M 0.000 description 1
• DQYBDCGIPTYXML-UHFFFAOYSA-N ethoxyethane;hydrate Chemical compound O.CCOCC DQYBDCGIPTYXML-UHFFFAOYSA-N 0.000 description 1
• GRBYBXPLQQKADW-UHFFFAOYSA-N ethyl 1-methyl-3-methylidenecyclobutane-1-carboxylate Chemical compound CCOC(=O)C1(C)CC(=C)C1 GRBYBXPLQQKADW-UHFFFAOYSA-N 0.000 description 1
• XKHOHMXSBJQHCV-UHFFFAOYSA-N ethyl 3-[(2-methylpropan-2-yl)oxycarbonylamino]cyclobutane-1-carboxylate Chemical compound CCOC(=O)C1CC(NC(=O)OC(C)(C)C)C1 XKHOHMXSBJQHCV-UHFFFAOYSA-N 0.000 description 1
• 125000004494 ethyl ester group Chemical group 0.000 description 1
• 239000003172 expectorant agent Substances 0.000 description 1
• 238000000605 extraction Methods 0.000 description 1
• 210000003414 extremity Anatomy 0.000 description 1
• 208000024711 extrinsic asthma Diseases 0.000 description 1
• 229960001022 fenoterol Drugs 0.000 description 1
• RWTNPBWLLIMQHL-UHFFFAOYSA-N fexofenadine Chemical compound C1=CC(C(C)(C(O)=O)C)=CC=C1C(O)CCCN1CCC(C(O)(C=2C=CC=CC=2)C=2C=CC=CC=2)CC1 RWTNPBWLLIMQHL-UHFFFAOYSA-N 0.000 description 1
• 229960003592 fexofenadine Drugs 0.000 description 1
• 239000000835 fiber Substances 0.000 description 1
• 230000004761 fibrosis Effects 0.000 description 1
• 238000003818 flash chromatography Methods 0.000 description 1
• 125000001153 fluoro group Chemical group F* 0.000 description 1
• MGNNYOODZCAHBA-GQKYHHCASA-N fluticasone Chemical compound C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@]1(F)[C@@H]2[C@@H]2C[C@@H](C)[C@@](C(=O)SCF)(O)[C@@]2(C)C[C@@H]1O MGNNYOODZCAHBA-GQKYHHCASA-N 0.000 description 1
• 229960002714 fluticasone Drugs 0.000 description 1
• 239000006260 foam Substances 0.000 description 1
• 235000013305 food Nutrition 0.000 description 1
• 229940044170 formate Drugs 0.000 description 1
• 229960002848 formoterol Drugs 0.000 description 1
• BPZSYCZIITTYBL-UHFFFAOYSA-N formoterol Chemical compound C1=CC(OC)=CC=C1CC(C)NCC(O)C1=CC=C(O)C(NC=O)=C1 BPZSYCZIITTYBL-UHFFFAOYSA-N 0.000 description 1
• 238000001640 fractional crystallisation Methods 0.000 description 1
• 239000012458 free base Substances 0.000 description 1
• 238000004108 freeze drying Methods 0.000 description 1
• 229940050411 fumarate Drugs 0.000 description 1
• 125000002541 furyl group Chemical group 0.000 description 1
• 239000003540 gamma secretase inhibitor Substances 0.000 description 1
• 239000007789 gas Substances 0.000 description 1
• 230000002496 gastric effect Effects 0.000 description 1
• 230000014509 gene expression Effects 0.000 description 1
• 238000007429 general method Methods 0.000 description 1
• 229960003776 glatiramer acetate Drugs 0.000 description 1
• 229940097042 glucuronate Drugs 0.000 description 1
• 229930195712 glutamate Natural products 0.000 description 1
• 229960002449 glycine Drugs 0.000 description 1
• 208000024908 graft versus host disease Diseases 0.000 description 1
• 238000005469 granulation Methods 0.000 description 1
• 230000003179 granulation Effects 0.000 description 1
• 238000000227 grinding Methods 0.000 description 1
• 239000003102 growth factor Substances 0.000 description 1
• 230000003394 haemopoietic effect Effects 0.000 description 1
• 210000002216 heart Anatomy 0.000 description 1
• 208000006454 hepatitis Diseases 0.000 description 1
• 231100000283 hepatitis Toxicity 0.000 description 1
• 201000010884 herpes simplex virus keratitis Diseases 0.000 description 1
• 125000000592 heterocycloalkyl group Chemical group 0.000 description 1
• IPCSVZSSVZVIGE-UHFFFAOYSA-M hexadecanoate Chemical compound CCCCCCCCCCCCCCCC([O-])=O IPCSVZSSVZVIGE-UHFFFAOYSA-M 0.000 description 1
• AILKHAQXUAOOFU-UHFFFAOYSA-N hexanenitrile Chemical compound CCCCCC#N AILKHAQXUAOOFU-UHFFFAOYSA-N 0.000 description 1
• 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
• 125000003707 hexyloxy group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])O* 0.000 description 1
• 229950000177 hibenzate Drugs 0.000 description 1
• 229940121372 histone deacetylase inhibitor Drugs 0.000 description 1
• 239000003276 histone deacetylase inhibitor Substances 0.000 description 1
• 230000013632 homeostatic process Effects 0.000 description 1
• 102000057041 human TNF Human genes 0.000 description 1
• 150000004677 hydrates Chemical class 0.000 description 1
• 229930195733 hydrocarbon Natural products 0.000 description 1
• 229910000042 hydrogen bromide Inorganic materials 0.000 description 1
• XLYOFNOQVPJJNP-UHFFFAOYSA-M hydroxide Chemical compound [OH-] XLYOFNOQVPJJNP-UHFFFAOYSA-M 0.000 description 1
• 229960002491 ibudilast Drugs 0.000 description 1
• 125000002883 imidazolyl group Chemical group 0.000 description 1
• 230000002519 immonomodulatory effect Effects 0.000 description 1
• 230000005965 immune activity Effects 0.000 description 1
• 230000036737 immune function Effects 0.000 description 1
• 210000000987 immune system Anatomy 0.000 description 1
• 230000034435 immune system development Effects 0.000 description 1
• 208000026278 immune system disease Diseases 0.000 description 1
• 239000002955 immunomodulating agent Substances 0.000 description 1
• 229940121354 immunomodulator Drugs 0.000 description 1
• 230000001506 immunosuppresive effect Effects 0.000 description 1
• 229940073062 imuran Drugs 0.000 description 1
• 238000011065 in-situ storage Methods 0.000 description 1
• 230000004968 inflammatory condition Effects 0.000 description 1
• 208000027866 inflammatory disease Diseases 0.000 description 1
• 229960000598 infliximab Drugs 0.000 description 1
• 208000030603 inherited susceptibility to asthma Diseases 0.000 description 1
• 108010044426 integrins Proteins 0.000 description 1
• 102000006495 integrins Human genes 0.000 description 1
• 229960004461 interferon beta-1a Drugs 0.000 description 1
• 229960003161 interferon beta-1b Drugs 0.000 description 1
• 229960001388 interferon-beta Drugs 0.000 description 1
• 229940047124 interferons Drugs 0.000 description 1
• 108090000681 interleukin 20 Proteins 0.000 description 1
• 102000004114 interleukin 20 Human genes 0.000 description 1
• 108010074108 interleukin-21 Proteins 0.000 description 1
• 108010074109 interleukin-22 Proteins 0.000 description 1
• 201000010659 intrinsic asthma Diseases 0.000 description 1
• JMAHZWXTTITJER-UHFFFAOYSA-N iodoboronic acid Chemical class IB(O)O JMAHZWXTTITJER-UHFFFAOYSA-N 0.000 description 1
• INQOMBQAUSQDDS-UHFFFAOYSA-N iodomethane Chemical compound IC INQOMBQAUSQDDS-UHFFFAOYSA-N 0.000 description 1
• 238000005342 ion exchange Methods 0.000 description 1
• OEXHQOGQTVQTAT-JRNQLAHRSA-N ipratropium Chemical compound O([C@H]1C[C@H]2CC[C@@H](C1)[N@@+]2(C)C(C)C)C(=O)C(CO)C1=CC=CC=C1 OEXHQOGQTVQTAT-JRNQLAHRSA-N 0.000 description 1
• 229960001888 ipratropium Drugs 0.000 description 1
• 208000028867 ischemia Diseases 0.000 description 1
• SUMDYPCJJOFFON-UHFFFAOYSA-N isethionic acid Chemical compound OCCS(O)(=O)=O SUMDYPCJJOFFON-UHFFFAOYSA-N 0.000 description 1
• 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
• 125000001972 isopentyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])C([H])([H])* 0.000 description 1
• 125000001786 isothiazolyl group Chemical group 0.000 description 1
• 125000000842 isoxazolyl group Chemical group 0.000 description 1
• 230000000366 juvenile effect Effects 0.000 description 1
• 229940102367 kemstro Drugs 0.000 description 1
• 150000002576 ketones Chemical class 0.000 description 1
• 210000003734 kidney Anatomy 0.000 description 1
• 201000010982 kidney cancer Diseases 0.000 description 1
• 150000003951 lactams Chemical class 0.000 description 1
• 150000002596 lactones Chemical class 0.000 description 1
• VHOGYURTWQBHIL-UHFFFAOYSA-N leflunomide Chemical compound O1N=CC(C(=O)NC=2C=CC(=CC=2)C(F)(F)F)=C1C VHOGYURTWQBHIL-UHFFFAOYSA-N 0.000 description 1
• 229960000681 leflunomide Drugs 0.000 description 1
• NRYBAZVQPHGZNS-ZSOCWYAHSA-N leptin Chemical compound O=C([C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](N)CC(C)C)CCSC)N1CCC[C@H]1C(=O)NCC(=O)N[C@@H](CS)C(O)=O NRYBAZVQPHGZNS-ZSOCWYAHSA-N 0.000 description 1
• 229940039781 leptin Drugs 0.000 description 1
• 229960001508 levocetirizine Drugs 0.000 description 1
• 229960004502 levodopa Drugs 0.000 description 1
• 239000003446 ligand Substances 0.000 description 1
• 210000003715 limbic system Anatomy 0.000 description 1
• 108010052322 limitin Proteins 0.000 description 1
• 229940063721 lioresal Drugs 0.000 description 1
• 238000004811 liquid chromatography Methods 0.000 description 1
• XTCODXIBYUDBPQ-UHFFFAOYSA-N lithium bis(dimethylsilyl)azanide Chemical compound [Li+].C[SiH](C)[N-][SiH](C)C XTCODXIBYUDBPQ-UHFFFAOYSA-N 0.000 description 1
• 210000004185 liver Anatomy 0.000 description 1
• 201000007270 liver cancer Diseases 0.000 description 1
• 208000014018 liver neoplasm Diseases 0.000 description 1
• 229940127212 long-acting beta 2 agonist Drugs 0.000 description 1
• JCCNYMKQOSZNPW-UHFFFAOYSA-N loratadine Chemical compound C1CN(C(=O)OCC)CCC1=C1C2=NC=CC=C2CCC2=CC(Cl)=CC=C21 JCCNYMKQOSZNPW-UHFFFAOYSA-N 0.000 description 1
• 229960003088 loratadine Drugs 0.000 description 1
• 210000004072 lung Anatomy 0.000 description 1
• 201000005202 lung cancer Diseases 0.000 description 1
• 208000020816 lung neoplasm Diseases 0.000 description 1
• 229960001432 lurasidone Drugs 0.000 description 1
• PQXKDMSYBGKCJA-CVTJIBDQSA-N lurasidone Chemical compound C1=CC=C2C(N3CCN(CC3)C[C@@H]3CCCC[C@H]3CN3C(=O)[C@@H]4[C@H]5CC[C@H](C5)[C@@H]4C3=O)=NSC2=C1 PQXKDMSYBGKCJA-CVTJIBDQSA-N 0.000 description 1
• 229960003646 lysine Drugs 0.000 description 1
• 208000002780 macular degeneration Diseases 0.000 description 1
• 239000011777 magnesium Substances 0.000 description 1
• 229910052749 magnesium Inorganic materials 0.000 description 1
• 229940091250 magnesium supplement Drugs 0.000 description 1
• 229940049920 malate Drugs 0.000 description 1
• VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
• BJEPYKJPYRNKOW-UHFFFAOYSA-N malic acid Chemical compound OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
• 241001515942 marmosets Species 0.000 description 1
• 238000004949 mass spectrometry Methods 0.000 description 1
• 201000006512 mast cell neoplasm Diseases 0.000 description 1
• 208000008585 mastocytosis Diseases 0.000 description 1
• 239000011159 matrix material Substances 0.000 description 1
• 229960003194 meglumine Drugs 0.000 description 1
• 201000001441 melanoma Diseases 0.000 description 1
• 201000008350 membranous glomerulonephritis Diseases 0.000 description 1
• 208000030159 metabolic disease Diseases 0.000 description 1
• 208000021039 metastatic melanoma Diseases 0.000 description 1
• 229960000485 methotrexate Drugs 0.000 description 1
• 229960005192 methoxamine Drugs 0.000 description 1
• SQIBNKUEUWGZBH-UHFFFAOYSA-N methyl 3-chlorosulfonylbenzoate Chemical compound COC(=O)C1=CC=CC(S(Cl)(=O)=O)=C1 SQIBNKUEUWGZBH-UHFFFAOYSA-N 0.000 description 1
• JZMJDSHXVKJFKW-UHFFFAOYSA-M methyl sulfate(1-) Chemical compound COS([O-])(=O)=O JZMJDSHXVKJFKW-UHFFFAOYSA-M 0.000 description 1
• 125000000250 methylamino group Chemical group [H]N(*)C([H])([H])[H] 0.000 description 1
• 229960003955 mianserin Drugs 0.000 description 1
• 239000002480 mineral oil Substances 0.000 description 1
• 235000010446 mineral oil Nutrition 0.000 description 1
• 238000002156 mixing Methods 0.000 description 1
• 238000003032 molecular docking Methods 0.000 description 1
• 229960001664 mometasone Drugs 0.000 description 1
• QLIIKPVHVRXHRI-CXSFZGCWSA-N mometasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(Cl)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CCl)(O)[C@@]1(C)C[C@@H]2O QLIIKPVHVRXHRI-CXSFZGCWSA-N 0.000 description 1
• 229960005127 montelukast Drugs 0.000 description 1
• 125000002757 morpholinyl group Chemical group 0.000 description 1
• 239000012452 mother liquor Substances 0.000 description 1
• 208000005264 motor neuron disease Diseases 0.000 description 1
• 210000003205 muscle Anatomy 0.000 description 1
• 201000002077 muscle cancer Diseases 0.000 description 1
• 230000035772 mutation Effects 0.000 description 1
• 206010028417 myasthenia gravis Diseases 0.000 description 1
• 229940014456 mycophenolate Drugs 0.000 description 1
• HPNSFSBZBAHARI-RUDMXATFSA-N mycophenolic acid Chemical compound OC1=C(C\C=C(/C)CCC(O)=O)C(OC)=C(C)C2=C1C(=O)OC2 HPNSFSBZBAHARI-RUDMXATFSA-N 0.000 description 1
• 201000000050 myeloid neoplasm Diseases 0.000 description 1
• 210000003098 myoblast Anatomy 0.000 description 1
• 208000010125 myocardial infarction Diseases 0.000 description 1
• 208000031225 myocardial ischemia Diseases 0.000 description 1
• KVKFRMCSXWQSNT-UHFFFAOYSA-N n,n'-dimethylethane-1,2-diamine Chemical compound CNCCNC KVKFRMCSXWQSNT-UHFFFAOYSA-N 0.000 description 1
• OKDQKPLMQBXTNH-UHFFFAOYSA-N n,n-dimethyl-2h-pyridin-1-amine Chemical compound CN(C)N1CC=CC=C1 OKDQKPLMQBXTNH-UHFFFAOYSA-N 0.000 description 1
• PSHKMPUSSFXUIA-UHFFFAOYSA-N n,n-dimethylpyridin-2-amine Chemical compound CN(C)C1=CC=CC=N1 PSHKMPUSSFXUIA-UHFFFAOYSA-N 0.000 description 1
• WYUGOKOOOAHPMP-UHFFFAOYSA-N n-(1,2,4,9-tetrahydrocarbazol-3-ylidene)hydroxylamine Chemical compound N1C2=CC=CC=C2C2=C1CCC(=NO)C2 WYUGOKOOOAHPMP-UHFFFAOYSA-N 0.000 description 1
• 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
• OHDXDNUPVVYWOV-UHFFFAOYSA-N n-methyl-1-(2-naphthalen-1-ylsulfanylphenyl)methanamine Chemical compound CNCC1=CC=CC=C1SC1=CC=CC2=CC=CC=C12 OHDXDNUPVVYWOV-UHFFFAOYSA-N 0.000 description 1
• 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
• 229940033872 namenda Drugs 0.000 description 1
• 125000005487 naphthalate group Chemical group 0.000 description 1
• 125000001624 naphthyl group Chemical group 0.000 description 1
• 229960002009 naproxen Drugs 0.000 description 1
• CMWTZPSULFXXJA-VIFPVBQESA-M naproxen(1-) Chemical compound C1=C([C@H](C)C([O-])=O)C=CC2=CC(OC)=CC=C21 CMWTZPSULFXXJA-VIFPVBQESA-M 0.000 description 1
• 229960005027 natalizumab Drugs 0.000 description 1
• 229960002259 nedocromil sodium Drugs 0.000 description 1
• 239000004090 neuroprotective agent Substances 0.000 description 1
• 230000007135 neurotoxicity Effects 0.000 description 1
• 231100000228 neurotoxicity Toxicity 0.000 description 1
• 229960003512 nicotinic acid Drugs 0.000 description 1
• 239000000181 nicotinic agonist Substances 0.000 description 1
• 239000012299 nitrogen atmosphere Substances 0.000 description 1
• 229960001073 nomifensine Drugs 0.000 description 1
• 229960002498 nomifensine maleate Drugs 0.000 description 1
• 239000012740 non-selective inhibitor Substances 0.000 description 1
• 239000002773 nucleotide Substances 0.000 description 1
• 125000003729 nucleotide group Chemical group 0.000 description 1
• QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
• 229960000470 omalizumab Drugs 0.000 description 1
• 201000005737 orchitis Diseases 0.000 description 1
• 239000003960 organic solvent Substances 0.000 description 1
• PXQPEWDEAKTCGB-UHFFFAOYSA-N orotic acid Chemical compound OC(=O)C1=CC(=O)NC(=O)N1 PXQPEWDEAKTCGB-UHFFFAOYSA-N 0.000 description 1
• 230000002018 overexpression Effects 0.000 description 1
• 238000012261 overproduction Methods 0.000 description 1
• 125000001715 oxadiazolyl group Chemical group 0.000 description 1
• 125000005961 oxazepanyl group Chemical group 0.000 description 1
• 125000002971 oxazolyl group Chemical group 0.000 description 1
• 125000003551 oxepanyl group Chemical group 0.000 description 1
• 125000003566 oxetanyl group Chemical group 0.000 description 1
• 125000000466 oxiranyl group Chemical group 0.000 description 1
• YWWARDMVSMPOLR-UHFFFAOYSA-M oxolane;tetrabutylazanium;fluoride Chemical compound [F-].C1CCOC1.CCCC[N+](CCCC)(CCCC)CCCC YWWARDMVSMPOLR-UHFFFAOYSA-M 0.000 description 1
• 125000004430 oxygen atom Chemical group O* 0.000 description 1
• 229960001528 oxymetazoline Drugs 0.000 description 1
• 229910052763 palladium Inorganic materials 0.000 description 1
• 210000000496 pancreas Anatomy 0.000 description 1
• 229960001789 papaverine Drugs 0.000 description 1
• QNGNSVIICDLXHT-UHFFFAOYSA-N para-ethylbenzaldehyde Natural products CCC1=CC=C(C=O)C=C1 QNGNSVIICDLXHT-UHFFFAOYSA-N 0.000 description 1
• 229960005489 paracetamol Drugs 0.000 description 1
• 208000012111 paraneoplastic syndrome Diseases 0.000 description 1
• 229940026768 parcopa Drugs 0.000 description 1
• 238000007911 parenteral administration Methods 0.000 description 1
• 235000019371 penicillin G benzathine Nutrition 0.000 description 1
• 125000001147 pentyl group Chemical group C(CCCC)* 0.000 description 1
• 239000000137 peptide hydrolase inhibitor Substances 0.000 description 1
• 230000002093 peripheral effect Effects 0.000 description 1
• 208000015385 phacoanaphylactic uveitis Diseases 0.000 description 1
• 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 1
• 229960001802 phenylephrine Drugs 0.000 description 1
• SONNWYBIRXJNDC-VIFPVBQESA-N phenylephrine Chemical compound CNC[C@H](O)C1=CC=CC(O)=C1 SONNWYBIRXJNDC-VIFPVBQESA-N 0.000 description 1
• NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
• 239000010452 phosphate Substances 0.000 description 1
• 239000002570 phosphodiesterase III inhibitor Substances 0.000 description 1
• 230000026731 phosphorylation Effects 0.000 description 1
• 238000006366 phosphorylation reaction Methods 0.000 description 1
• 125000004193 piperazinyl group Chemical group 0.000 description 1
• 125000003386 piperidinyl group Chemical group 0.000 description 1
• QYSPLQLAKJAUJT-UHFFFAOYSA-N piroxicam Chemical compound OC=1C2=CC=CC=C2S(=O)(=O)N(C)C=1C(=O)NC1=CC=CC=N1 QYSPLQLAKJAUJT-UHFFFAOYSA-N 0.000 description 1
• 229960002702 piroxicam Drugs 0.000 description 1
• 230000036470 plasma concentration Effects 0.000 description 1
• 239000002797 plasminogen activator inhibitor Substances 0.000 description 1
• 235000011056 potassium acetate Nutrition 0.000 description 1
• NNFCIKHAZHQZJG-UHFFFAOYSA-N potassium cyanide Chemical compound [K+].N#[C-] NNFCIKHAZHQZJG-UHFFFAOYSA-N 0.000 description 1
• LPNYRYFBWFDTMA-UHFFFAOYSA-N potassium tert-butoxide Chemical compound [K+].CC(C)(C)[O-] LPNYRYFBWFDTMA-UHFFFAOYSA-N 0.000 description 1
• ZNNZYHKDIALBAK-UHFFFAOYSA-M potassium thiocyanate Chemical compound [K+].[S-]C#N ZNNZYHKDIALBAK-UHFFFAOYSA-M 0.000 description 1
• 229940116357 potassium thiocyanate Drugs 0.000 description 1
• 244000144977 poultry Species 0.000 description 1
• 235000013594 poultry meat Nutrition 0.000 description 1
• 229960004618 prednisone Drugs 0.000 description 1
• DTYWJKSSUANMHD-UHFFFAOYSA-N preladenant Chemical compound C1=CC(OCCOC)=CC=C1N1CCN(CCN2C3=C(C4=NC(=NN4C(N)=N3)C=3OC=CC=3)C=N2)CC1 DTYWJKSSUANMHD-UHFFFAOYSA-N 0.000 description 1
• 210000005238 principal cell Anatomy 0.000 description 1
• 238000012545 processing Methods 0.000 description 1
• 201000007914 proliferative diabetic retinopathy Diseases 0.000 description 1
• 238000011321 prophylaxis Methods 0.000 description 1
• 239000003223 protective agent Substances 0.000 description 1
• 102000004169 proteins and genes Human genes 0.000 description 1
• 239000003586 protic polar solvent Substances 0.000 description 1
• SCHKZZSVELPJKU-UHFFFAOYSA-N prx-03140 Chemical compound O=C1N(C(C)C)C=2SC=CC=2C(O)=C1C(=O)NCCCN1CCCCC1 SCHKZZSVELPJKU-UHFFFAOYSA-N 0.000 description 1
• 238000010926 purge Methods 0.000 description 1
• KOUKXHPPRFNWPP-UHFFFAOYSA-N pyrazine-2,5-dicarboxylic acid;hydrate Chemical compound O.OC(=O)C1=CN=C(C(O)=O)C=N1 KOUKXHPPRFNWPP-UHFFFAOYSA-N 0.000 description 1
• 125000003373 pyrazinyl group Chemical group 0.000 description 1
• 125000003226 pyrazolyl group Chemical group 0.000 description 1
• 125000002098 pyridazinyl group Chemical group 0.000 description 1
• GPHQHTOMRSGBNZ-UHFFFAOYSA-N pyridine-4-carbonitrile Chemical compound N#CC1=CC=NC=C1 GPHQHTOMRSGBNZ-UHFFFAOYSA-N 0.000 description 1
• 125000004076 pyridyl group Chemical group 0.000 description 1
• 125000000714 pyrimidinyl group Chemical group 0.000 description 1
• 229940043131 pyroglutamate Drugs 0.000 description 1
• DATJETPTDKFEEF-UHFFFAOYSA-N pyrrolidine-3-carbonitrile Chemical compound N#CC1CCNC1 DATJETPTDKFEEF-UHFFFAOYSA-N 0.000 description 1
• LMBZZTJQNYGICT-UHFFFAOYSA-N pyrrolidine-3-carbonitrile;hydrochloride Chemical compound Cl.N#CC1CCNC1 LMBZZTJQNYGICT-UHFFFAOYSA-N 0.000 description 1
• 125000000719 pyrrolidinyl group Chemical group 0.000 description 1
• 125000000168 pyrrolyl group Chemical group 0.000 description 1
• 230000000171 quenching effect Effects 0.000 description 1
• 229960004431 quetiapine Drugs 0.000 description 1
• URKOMYMAXPYINW-UHFFFAOYSA-N quetiapine Chemical compound C1CN(CCOCCO)CCN1C1=NC2=CC=CC=C2SC2=CC=CC=C12 URKOMYMAXPYINW-UHFFFAOYSA-N 0.000 description 1
• 229960000948 quinine Drugs 0.000 description 1
• 150000003254 radicals Chemical class 0.000 description 1
• 229960003876 ranibizumab Drugs 0.000 description 1
• ZAHRKKWIAAJSAO-UHFFFAOYSA-N rapamycin Natural products COCC(O)C(=C/C(C)C(=O)CC(OC(=O)C1CCCCN1C(=O)C(=O)C2(O)OC(CC(OC)C(=CC=CC=CC(C)CC(C)C(=O)C)C)CCC2C)C(C)CC3CCC(O)C(C3)OC)C ZAHRKKWIAAJSAO-UHFFFAOYSA-N 0.000 description 1
• 208000002574 reactive arthritis Diseases 0.000 description 1
• 230000000384 rearing effect Effects 0.000 description 1
• 229940038850 rebif Drugs 0.000 description 1
• 102000027426 receptor tyrosine kinases Human genes 0.000 description 1
• 108091008598 receptor tyrosine kinases Proteins 0.000 description 1
• 238000011084 recovery Methods 0.000 description 1
• 230000009467 reduction Effects 0.000 description 1
• 230000022983 regulation of cell cycle Effects 0.000 description 1
• 230000004043 responsiveness Effects 0.000 description 1
• 229940039245 revatio Drugs 0.000 description 1
• 230000002441 reversible effect Effects 0.000 description 1
• 229940061969 rheumatrex Drugs 0.000 description 1
• 102000000568 rho-Associated Kinases Human genes 0.000 description 1
• 229960002586 roflumilast Drugs 0.000 description 1
• MNDBXUUTURYVHR-UHFFFAOYSA-N roflumilast Chemical compound FC(F)OC1=CC=C(C(=O)NC=2C(=CN=CC=2Cl)Cl)C=C1OCC1CC1 MNDBXUUTURYVHR-UHFFFAOYSA-N 0.000 description 1
• HJORMJIFDVBMOB-UHFFFAOYSA-N rolipram Chemical compound COC1=CC=C(C2CC(=O)NC2)C=C1OC1CCCC1 HJORMJIFDVBMOB-UHFFFAOYSA-N 0.000 description 1
• 229950005741 rolipram Drugs 0.000 description 1
• UHSKFQJFRQCDBE-UHFFFAOYSA-N ropinirole Chemical compound CCCN(CCC)CCC1=CC=CC2=C1CC(=O)N2 UHSKFQJFRQCDBE-UHFFFAOYSA-N 0.000 description 1
• 229960001879 ropinirole Drugs 0.000 description 1
• 238000002390 rotary evaporation Methods 0.000 description 1
• 229960004017 salmeterol Drugs 0.000 description 1
• 229940063122 sandimmune Drugs 0.000 description 1
• 201000000306 sarcoidosis Diseases 0.000 description 1
• 238000007423 screening assay Methods 0.000 description 1
• 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
• 150000003333 secondary alcohols Chemical class 0.000 description 1
• 229960003946 selegiline Drugs 0.000 description 1
• 230000019491 signal transduction Effects 0.000 description 1
• 229940001089 sinemet Drugs 0.000 description 1
• 238000009097 single-agent therapy Methods 0.000 description 1
• QFJCIRLUMZQUOT-HPLJOQBZSA-N sirolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 QFJCIRLUMZQUOT-HPLJOQBZSA-N 0.000 description 1
• 229960002930 sirolimus Drugs 0.000 description 1
• 201000000849 skin cancer Diseases 0.000 description 1
• 208000017520 skin disease Diseases 0.000 description 1
• 210000000813 small intestine Anatomy 0.000 description 1
• LPOHISIOJHPMJN-UHFFFAOYSA-N sodium bis(dimethylsilyl)azanide Chemical compound [Na+].C[SiH](C)[N-][SiH](C)C LPOHISIOJHPMJN-UHFFFAOYSA-N 0.000 description 1
• WRIKHQLVHPKCJU-UHFFFAOYSA-N sodium bis(trimethylsilyl)amide Chemical compound C[Si](C)(C)N([Na])[Si](C)(C)C WRIKHQLVHPKCJU-UHFFFAOYSA-N 0.000 description 1
• WBHQBSYUUJJSRZ-UHFFFAOYSA-M sodium bisulfate Chemical compound [Na+].OS([O-])(=O)=O WBHQBSYUUJJSRZ-UHFFFAOYSA-M 0.000 description 1
• 229910000342 sodium bisulfate Inorganic materials 0.000 description 1
• BEOOHQFXGBMRKU-UHFFFAOYSA-N sodium cyanoborohydride Chemical compound [Na+].[B-]C#N BEOOHQFXGBMRKU-UHFFFAOYSA-N 0.000 description 1
• 229940079827 sodium hydrogen sulfite Drugs 0.000 description 1
• 235000010265 sodium sulphite Nutrition 0.000 description 1
• 239000012321 sodium triacetoxyborohydride Substances 0.000 description 1
• 238000000638 solvent extraction Methods 0.000 description 1
• DKGZKTPJOSAWFA-UHFFFAOYSA-N spiperone Chemical compound C1=CC(F)=CC=C1C(=O)CCCN1CCC2(C(NCN2C=2C=CC=CC=2)=O)CC1 DKGZKTPJOSAWFA-UHFFFAOYSA-N 0.000 description 1
• 229950001675 spiperone Drugs 0.000 description 1
• 208000010110 spontaneous platelet aggregation Diseases 0.000 description 1
• 238000005507 spraying Methods 0.000 description 1
• 206010041823 squamous cell carcinoma Diseases 0.000 description 1
• 239000007858 starting material Substances 0.000 description 1
• 239000012258 stirred mixture Substances 0.000 description 1
• 229940012488 strattera Drugs 0.000 description 1
• 125000003107 substituted aryl group Chemical group 0.000 description 1
• 238000006467 substitution reaction Methods 0.000 description 1
• 239000000758 substrate Substances 0.000 description 1
• KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 1
• 238000009495 sugar coating Methods 0.000 description 1
• 239000000829 suppository Substances 0.000 description 1
• 238000013268 sustained release Methods 0.000 description 1
• 239000012730 sustained-release form Substances 0.000 description 1
• 238000002636 symptomatic treatment Methods 0.000 description 1
• 230000002194 synthesizing effect Effects 0.000 description 1
• 201000000596 systemic lupus erythematosus Diseases 0.000 description 1
• 108060008037 tachykinin Proteins 0.000 description 1
• 229960000835 tadalafil Drugs 0.000 description 1
• IEHKWSGCTWLXFU-IIBYNOLFSA-N tadalafil Chemical compound C1=C2OCOC2=CC([C@@H]2C3=C([C]4C=CC=CC4=N3)C[C@H]3N2C(=O)CN(C3=O)C)=C1 IEHKWSGCTWLXFU-IIBYNOLFSA-N 0.000 description 1
• 229950008160 tanezumab Drugs 0.000 description 1
• LRBQNJMCXXYXIU-NRMVVENXSA-N tannic acid Chemical class OC1=C(O)C(O)=CC(C(=O)OC=2C(=C(O)C=C(C=2)C(=O)OC[C@@H]2[C@H]([C@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)O2)OC(=O)C=2C=C(OC(=O)C=3C=C(O)C(O)=C(O)C=3)C(O)=C(O)C=2)O)=C1 LRBQNJMCXXYXIU-NRMVVENXSA-N 0.000 description 1
• 230000008685 targeting Effects 0.000 description 1
• 229940000238 tasmar Drugs 0.000 description 1
• 229940090016 tegretol Drugs 0.000 description 1
• IIBBSDGELCSBTF-UHFFFAOYSA-N tert-butyl 1-(hydroxyiminomethyl)-3-azabicyclo[3.1.0]hexane-3-carboxylate Chemical compound C1N(C(=O)OC(C)(C)C)CC2CC21C=NO IIBBSDGELCSBTF-UHFFFAOYSA-N 0.000 description 1
• BTWDGFQQIGGAPU-UHFFFAOYSA-N tert-butyl 1-(hydroxymethyl)-3-azabicyclo[3.1.0]hexane-3-carboxylate Chemical compound C1N(C(=O)OC(C)(C)C)CC2CC21CO BTWDGFQQIGGAPU-UHFFFAOYSA-N 0.000 description 1
• AZNUWDVFBPYWSU-UHFFFAOYSA-N tert-butyl 3-chlorosulfonylazetidine-1-carboxylate Chemical compound CC(C)(C)OC(=O)N1CC(S(Cl)(=O)=O)C1 AZNUWDVFBPYWSU-UHFFFAOYSA-N 0.000 description 1
• QZVCJLUVFPPQLX-UHFFFAOYSA-N tert-butyl 3-sulfanylpyrrolidine-1-carboxylate Chemical compound CC(C)(C)OC(=O)N1CCC(S)C1 QZVCJLUVFPPQLX-UHFFFAOYSA-N 0.000 description 1
• NXZIGGBPLGAPTI-UHFFFAOYSA-N tert-butyl 6-oxa-3-azabicyclo[3.1.0]hexane-3-carboxylate Chemical compound C1N(C(=O)OC(C)(C)C)CC2OC21 NXZIGGBPLGAPTI-UHFFFAOYSA-N 0.000 description 1
• 150000003509 tertiary alcohols Chemical class 0.000 description 1
• 229960005333 tetrabenazine Drugs 0.000 description 1
• 125000003718 tetrahydrofuranyl group Chemical group 0.000 description 1
• 125000001412 tetrahydropyranyl group Chemical group 0.000 description 1
• 125000003831 tetrazolyl group Chemical group 0.000 description 1
• 229960000278 theophylline Drugs 0.000 description 1
• 125000001113 thiadiazolyl group Chemical group 0.000 description 1
• 125000000335 thiazolyl group Chemical group 0.000 description 1
• 125000001544 thienyl group Chemical group 0.000 description 1
• DUYAAUVXQSMXQP-UHFFFAOYSA-M thioacetate Chemical compound CC([S-])=O DUYAAUVXQSMXQP-UHFFFAOYSA-M 0.000 description 1
• RZWIIPASKMUIAC-VQTJNVASSA-N thromboxane Chemical compound CCCCCCCC[C@H]1OCCC[C@@H]1CCCCCCC RZWIIPASKMUIAC-VQTJNVASSA-N 0.000 description 1
• 206010043778 thyroiditis Diseases 0.000 description 1
• LERNTVKEWCAPOY-DZZGSBJMSA-N tiotropium Chemical compound O([C@H]1C[C@@H]2[N+]([C@H](C1)[C@@H]1[C@H]2O1)(C)C)C(=O)C(O)(C=1SC=CC=1)C1=CC=CS1 LERNTVKEWCAPOY-DZZGSBJMSA-N 0.000 description 1
• 229940110309 tiotropium Drugs 0.000 description 1
• 229960004603 tolcapone Drugs 0.000 description 1
• 125000005147 toluenesulfonyl group Chemical group C=1(C(=CC=CC1)S(=O)(=O)*)C 0.000 description 1
• 125000005425 toluyl group Chemical group 0.000 description 1
• 230000000699 topical effect Effects 0.000 description 1
• 125000005490 tosylate group Chemical group 0.000 description 1
• 210000003437 trachea Anatomy 0.000 description 1
• 230000037317 transdermal delivery Effects 0.000 description 1
• 208000009174 transverse myelitis Diseases 0.000 description 1
• 230000008736 traumatic injury Effects 0.000 description 1
• 229940111528 trexall Drugs 0.000 description 1
• 125000001425 triazolyl group Chemical group 0.000 description 1
• 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 description 1
• 230000001960 triggered effect Effects 0.000 description 1
• 239000005051 trimethylchlorosilane Substances 0.000 description 1
• LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
• 229960000281 trometamol Drugs 0.000 description 1
• 231100000397 ulcer Toxicity 0.000 description 1
• JABYJIQOLGWMQW-UHFFFAOYSA-N undec-4-ene Chemical compound CCCCCCC=CCCC JABYJIQOLGWMQW-UHFFFAOYSA-N 0.000 description 1
• 229940045137 urecholine Drugs 0.000 description 1
• 201000005112 urinary bladder cancer Diseases 0.000 description 1
• 108010084171 vanutide cridificar Proteins 0.000 description 1
• 229960002381 vardenafil Drugs 0.000 description 1
• 230000002792 vascular Effects 0.000 description 1
• 208000018464 vernal keratoconjunctivitis Diseases 0.000 description 1
• 229940094720 viagra Drugs 0.000 description 1
• 229960000744 vinpocetine Drugs 0.000 description 1
• 229940025158 xenazine Drugs 0.000 description 1
• 238000002689 xenotransplantation Methods 0.000 description 1
• 125000005023 xylyl group Chemical group 0.000 description 1
• 229960004764 zafirlukast Drugs 0.000 description 1
• MWLSOWXNZPKENC-SSDOTTSWSA-N zileuton Chemical compound C1=CC=C2SC([C@H](N(O)C(N)=O)C)=CC2=C1 MWLSOWXNZPKENC-SSDOTTSWSA-N 0.000 description 1
• 229960005332 zileuton Drugs 0.000 description 1
• 150000003751 zinc Chemical class 0.000 description 1
• 229910052725 zinc Inorganic materials 0.000 description 1